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Abstract 
Bill B. Chen, PhD 
 
Ubiquitin E3 Ligases in Lung Disease 
 
Travis Bradley Lear, PhD 
 
University of Pittsburgh, 2020 
 
 
Abstract 
 
Diseases of the lung form the one of the largest causes of death globally. Inflammatory 
diseases such as Acute Respiratory Distress Syndrome, and fibrosis such as interstitial lung 
disease, in particular have high mortality rates with limited therapy. Thus, there is an unmet public 
health need for new avenues of intervention. Inflammatory, fibrotic, and nutrient lung diseases are 
driven by cellular signaling pathways, leading to pathological cell responses. Effector lung cells 
naturally dampen these deleterious signaling pathways; dysfunction of these dampening 
mechanisms play causal roles in lung disease, notably through excessive destruction of critical 
signal transduction proteins. Modulation of signal transduction protein degradation may have 
therapeutic effect by controlling deleterious signaling. The ubiquitin-proteasome system is the 
major cellular mechanism controlling protein degradation. Ubiquitin E3 ligase proteins are a 
critical part of ubiquitination, specifically targeting substrates for degradation. Research shows the 
importance of protein degradation in lung disease, however the potential to identify and inhibit 
specific E3-ligase-substrate interactions remains unexplored. Through both candidate-based and 
unbiased high-throughput screening techniques, we probed the importance of E3 ligases in lung 
disease through their targeted degradation of signal transduction proteins, and the therapeutic 
potential of E3 ligase inhibition. We investigated three aspects of lung disease – 1) inflammation 
and innate immunity, 2) fibrosis and interstitial lung disease, and 3) regulation of nutrient sensing 
mechanisms. Here we report multiple E3 ligase-substrate axes, including those associated with 
 v 
fibrosis: FIEL1-PIAS4; KLHL42-PPP2R5e, with innate immunity: PPP1R11-TLR2, RNF113A-
CXCR4, KIAA0317-SOCS2, RNFT2-IL3Ra, and with nutrient sensing: RNF186-SESN2. We 
observed that E3 ligases potently control inflammatory signaling through control of cytokine 
receptors and signal modulators during acute inflammation and bacterial infection. We uncovered 
that E3 ligases are significantly associated with fibrotic signaling in interstitial lung fibrosis, and 
can be targeted by small molecules. Finally, we detected new mechanisms of nutrient sensor 
control leading to manipulation of anabolism. These results show the criticality of ubiquitin e3 
ligases in the biology of lung inflammation, fibrosis, and nutrient sensing. Further, these studies 
validate ubiquitin E3 ligases as potential targets for therapeutic intervention to provide new tools 
to combat lung diseases. 
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1 
1.0 Introduction 
The human lung system is the critical organ system for respiratory function. Separated into 
two multi-lobed segments, the lungs are part of the lower respiratory system tasked with gas 
exchange to the circulatory system. Connecting to the upper-respiratory system at the trachea, the 
architecture of the lung becomes increasing complex deeper into the airway. The lungs are 
connected to the trachea and the upper respiratory system through large airways known as bronchi. 
Bronchi branch into smaller and more numerous sub-airways, decreasing in diameter and 
increasing in total surface area. The lung terminates in collections of hollow cavities termed 
alveoli. Pulmonary alveoli are coated with capillary vasculature, and their proximity to the alveolar 
epithelial cells allow for gas exchange of oxygen and carbon dioxide, which is used to maintain 
homeostasis in the systemic vascular system. 
1.1 Diseases of Lung 
Lung respiratory efficacy is reliant on the integrity and health of the alveolar spaces and 
surrounding and supporting interstitial tissue. As outside air is processed for gas exchange, the 
lung is exposed to environmental and occupational exposures, several of which may cause damage 
or disease.  
2 
1.1.1 Global Public Health Significance of Lung Disease 
Diseases of the lung collectively account for the majority of global human hospitalization 
and mortality (1, 2). The World Health Organization has identified five major disease types that 
account for the largest proportion of lung diseases, chronic obstructive pulmonary disease 
(COPD), tuberculosis, lung cancer, asthma, and lower respiratory infections (2). Lower respiratory 
infections are particularly of public health concern due to little change in mortality despite decades 
of research and therapy (3). Lower respiratory infections can arise from bacterial, viral, or 
sometimes fungal causes, leading to acute immune responses, pneumonia, sepsis, and in many 
cases, respiratory failure (4, 5). Inflammation in the lung, and particularly the alveolar spaces is an 
important determinant of disease course during respiratory infection, as a balance needs to be 
struck between enough immune response to clear infection, while restraining the response from 
causing damage to the lung and host (5). In addition to the predominant lung diseases, numerous 
other pathologies arise in the lung, including interstitial lung disease (fibrosis), pulmonary arterial 
hypertension, and cystic fibrosis. Further, many of these diseases show an increase prevalence and 
mortality among aged patients, an area for concern as the global human population grows older in 
the coming decades.    
In these dissertation projects, we sought to investigate new protein-protein relationships in 
cellular signaling that are biologically relevant in lung disease, and the potential to chemically 
intervene to improve the underlying disease. As a proof of principle, we focused on three types of 
lung disease: 1) pulmonary fibrosis, 2) lung inflammation related to infection and acute lung 
injury, and 3) mechanisms of aging through pilot studies into nutrient sensing. We believe these 
research efforts have highlighted new mechanisms of disease-related signaling and new avenues 
for therapeutic intervention and targeting. 
3 
1.1.2 Fibrosis in the Lung 
Interstitial lung disease is a collection of pathologies characterized by the hardening of the 
interstitial space in the lung and between the alveolar cavities (6). During normal injury repair 
processes, fibrosis response is a healthy mechanism to repair damaged tissue, and restore normal 
function (7). However, aberrant and pathological fibrosis results in runaway fibrotic deposition of 
collagenous material with an increase in inflammatory signaling. Interstitial lung disease can arise 
from environmental or occupational exposures such as silica or asbestos or an underlying medical 
condition such as sarcoidosis or systemic auto-immune diseases such as Scleroderma/Systemic 
sclerosis (8, 9). However, one type, idiopathic pulmonary fibrosis, has no understood cause (10). 
 Idiopathic Pulmonary Fibrosis 
Adapted from: Lear and Chen, Therapeutic targets in fibrotic pathways, Cytokine. 2016 
Dec;88:193-195. doi: 10.1016/j.cyto.2016.09.008. Epub 2016 Sep 19. (11) 
 
Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease with no 
cure and a grim median survival time of 3 years. This disease afflicts over 50 people per 100,000; 
and disproportionately affects the elderly: up to 0.2% of those over 75 years of age (12). Excessive 
fibrous deposition in the alveolar space results in pulmonary failure. Interestingly, there is 
profound heterogeneity in disease course and severity among patients, necessitating research into 
the molecular mechanisms of pathogenicity. Despite years of research, the sub-cellular molecular 
etiology of pulmonary fibrosis remains unclear. Several groups have sought to clarify the 
pathogenesis of pulmonary fibrosis. 
4 
 Determinants of IPF Pathology 
Both genetic and environmental insults show association with the development of IPF. 
Research from the Armanios lab has implicated telomere distress as a causal agent in a subset of 
cases, as part of generational genetic anticipation (13). Additionally, research has shown several 
genetic hotspots, such as the MUC5B promoter, associate with a worsened phenotype (14). Extra-
cellular matrix proteins such as integrins and matricellular proteins have been associated with 
fibrosis (15, 16). Most saliently important is the cytokine Transforming Growth Factor β (TGF-β), 
which is well accepted as a driver of cellular fibrosis (16, 17). TGF-β is sequestered in the 
extracellular matrix of cells in a latent form prior to cleavage and activation. Reed and colleagues 
demonstrated the importance of integrin-mediated latent-TGF-β activation in the context of liver 
and pulmonary fibrosis, as well as the potential for therapeutic targeting (18). Active TGF-β is a 
ligand for the TGF-β receptor, which initiates the SMAD signaling cascade (19). TGF-β signaling 
transduces through SMAD proteins, which dimerize prior to nuclear translocation and regulation 
of gene expression (20). Gao and colleagues demonstrated Ubiquitin E3 ligases directly regulate 
SMAD signal transduction, and Imoto and colleagues observed direct SUMOylation of SMADs 
leading to signaling suppression (21-23).  
 Therapeutic Options for IPF 
Until recently, IPF had few therapeutic options and was an orphan drug disease. 
Researchers halted triple treatment of immuno-suppressants and N-acetylcysteine due to concerns 
of increased mortality among study patients (24). However, in 2014, the FDA approved two 
therapeutics for IPF treatment. Several groups developed Nintedanib as a small-molecule 
treatment for idiopathic pulmonary fibrosis, culminating in the INPULSIS trials and FDA approval 
(25). Nintedanib inhibits multiple tyrosine kinases, such as vascular endothelial growth factor 
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(VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). This therapy 
shows efficacy in critical metrics of pulmonary function. Concurrently, several research groups 
developed Pirfenidone, culminating in the ASCEND Study trial (26). The discreet targets of 
Pirfenidone still remain unclear, yet it shows efficacy in delaying disease progression (27).  Due 
to the heterogeneity of this disease, multiple targets in the fibrotic pathway lay open for potential 
intervention (28) (Figure 1).  
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Figure 1 Therapeutic Targets in Fibrotic Pathways  
Membrane proteins such as integrins and secreted proteins in the extracellular matrix (ECM) such as CCN1 interact 
and facilitate the conversion of latent, ECM-sequestered TGFβ to its active form. Active TGFβ is ligand to the 
TGFβ receptor on epithelia, fibroblasts, and immune cells. Receptor stimulation causes a signaling cascade via 
SMAD proteins, leading to the nuclear translocation of a SMAD complex and the transcriptional activation of pro-
fibrotic genes. Ubiquitin-E3 ligases, such as NEDD4L, regulate SMAD signaling through proteasome-mediated 
degradation. Additionally, SUMO-E3 ligases, such as PIAS4, regulate SMAD signaling by forcing its nuclear 
export. Direct regulators of SMAD signaling are themselves regulated, as FIEL1 catalyzes the degradation of 
PIAS4. In addition to transcriptional regulation of pro-fibrotic genes and gene products such as collagens, smooth 
muscle action and fibronectin, genetic abnormalities associate with fibrosis. Mutation within the MUC5B promoter 
and shortened telomeres caused by telomerase mutations both associate with worsened fibrosis. The current 
therapeutics Nintedanib and Pirfenidone target growth receptors, ECM formation, and TGFβ. Novel compound BC-
1485 targets downstream profibrotic protein FIEL1, which may serve as a new therapeutic approach for the future 
IPF therapy. 
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1.1.3 Inflammation in the Lung 
The inflammatory response in the lung is a critical deterrent to infection such as acute lower 
respiratory infections, and in maintaining pulmonary homeostasis. Inflammation induces cytokine 
signaling leading to immune responses to respiratory infections. Sentinel cells, including 
pulmonary epithelia, detect pathogens, and initiate innate inflammatory responses via cytokine 
signaling cascades (29). Cytokine signaling pathways rely on receptor protein complexes that 
detect extracellular signals or patterns to initiate signaling. Two common classes of cellular 
signaling species are Pathogen Associated Molecular Patterns (PAMPs) and Damage Associated 
Molecular Patterns (DAMPs). PAMPs are molecular patterns distinct to invading pathogens, often 
part of their structural make-up. Lipopolysaccharide is a classic PAMP from Gram-negative 
bacteria such as E. coli or P. aeruginosa (30). Peptidoglycan species are Gram-positive PAMPs 
from S. aureus (31). DAMPs are often released as a product of ongoing stress and damage to the 
host and include proteins like HMGB1 and free nuclei acids (32). PAMPs are key to innate 
immunity, as they are recognized by pattern-recognition receptors, such as Toll-Like Receptors, 
on sentinel pulmonary cells which then initiate cytokine signaling cascades. Pro-inflammatory 
cytokine signaling leads to gene expression programs and the generation of immune recruitment 
markers such as cytokines to activate the systemic immune response. Research has shown 
pulmonary epithelial cell models that closely mimic effector cells in the alveolar compartment are 
able release pro-inflammatory cytokines upon stimulation with PAMPs, suggesting that alveolar 
epithelial cells are important initiators of pulmonary inflammation (33, 34). The increase in 
cytokine secretion also has paracrine and autocrine effect on the alveolar epithelial cells, as 
cytokines such as chemokines and interleukins modulate signaling. Indeed several studies have 
suggested lung sensitization or a “double-hit” where a combination of cytokine and PAMP 
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exacerbates the inflammatory response (35-37). This cytokine release facilitates the activation of 
resident alveolar macrophages and the recruitment of leukocytes from the vasculature to the 
afflicted area (38).  
This innate immunological response is critical to containing and clearing a respiratory 
infection. However, the inflammatory response induces changes to the pulmonary landscape (39). 
Dysregulated or pulmonary inflammation leads to capillary damage, disruption of pulmonary 
barrier function, and alveolar damage caused by leukocytes (40). These cells cause lung injury 
through the release of toxic species such as proteases and reactive oxygen species that affect the 
integrity of epithelial cells and their intercellular junctions, leading to edema formation and 
reduced gas exchange across the alveolus (41). This disruption of the alveolar architecture and 
functional is termed Diffuse Alveolar Damage: a classic hallmark of pulmonary distress resulting 
from excessive inflammatory response (5, 42, 43). This uncontrolled pulmonary inflammation is 
the characteristic and causal of several acute pathologies, such as acute respiratory distress 
syndrome (ARDS), pneumonia, and exacerbations of chronic diseases (44). For example, ARDS 
affects almost 0.25 million patients annually, whom suffer over 40% mortality (45, 46).  
One pathway, nuclear factor-kappa B (NF-κB), potently stimulates the release of 
inflammatory cytokines such as IL-1, IL-6, and TNF (47). These and other chemotactic cytokines 
promote endothelial activation, in which the pulmonary vasculature loosens and allows the 
migration of immune cells into the alveolar space (48). Subsequent research has shown that NF-
κB signaling promotes the transcription of cytokines involved in ARDS pathogenesis (49-52). 
Indeed, isolated alveolar macrophages from ARDS patients show more activated NF-κB than 
control (49). NF-κB signaling has been implicated with pulmonary inflammation leading to 
cardiovascular distress (53, 54). Cytokine signaling pathways utilize signal modulating proteins to 
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accelerate or dampen the signaling process depending on the cellular context (55, 56). Signal-
suppressing proteins, such as SOCS, work to repress cytokine signaling (57). Previous studies by 
the Mallampalli and Chen Labs have shown that key proteins that modulate inflammatory 
responses in the lung are dysregulated during inflammatory disease and injury  (58-62). We sought 
to investigate novel E3 ligase-substrates relationships in lung inflammation, and if the E3 ligases 
were druggable. 
1.1.4 Nutrient Sensing in the Lung 
Nutrient sensing is a critical molecular process driving cellular responses during 
homeostasis, anabolism, and catabolism (63-65). The major mechanism of sensing amino acids 
and nutrients is the mechanistic target of rapamycin (mTOR) network (66, 67). Activated 
mTORC1 promotes cellular processes such as protein translation, glucose metabolism, and fatty 
acid synthesis, while suppressing autophagy (68-70). Dysfunctional nutrient sensing is 
characteristic of cancer, metabolic disorders, immune dysregulation, and is considered a major 
hallmark of aging itself (68, 71). Inhibition of mTORC1 has shown clinical promise, specifically 
for use in immunosuppression and in treating mTOR-sensitive tumors, however mTORC1 
inhibitors suffer from adverse side effects (72-75), illustrating the need for new therapies. Further, 
mTORC1 inhibition is one of the sole mechanisms for extended longevity in multiple experimental 
systems(76), raising the question as to alternative approaches of intervention.  Researchers have 
uncovered an intricate network of over 30 proteins that directly control mTORC1 (70, 77, 78). 
mTORC1 regulators are critically important in activating or inhibiting mTORC1, as loss-of-
function and mutational studies of individual regulator result in impaired mTORC1 function. For 
example, depletion of the mTORC1-inhbitor nutrient sensor Sestrin-2, led to constitutive 
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activation of mTORC1, even during nutrient deprivation when mTORC1 is inactive (77, 79). 
mTORC1 regulator mutation and dysfunction occurs in numerous pathologies including metabolic 
diseases, neurological disorders, and neoplasia, leading to disruption of mTORC1 homeostasis 
(80-84). However, the role of mTORC1 regulator protein stability and their mechanisms of 
degradation remain poorly characterized. The mechanisms underlying mTORC1 regulator control 
could represent a new area for selective therapeutic inhibition to modulate mTORC1 activity. 
Previous research has suggested some mTORC1 regulators are controlled by ubiquitination (81); 
however, a systematic analysis of the protein stability of the mTORC1 regulator landscape has not 
been conducted.  
1.2 Protein Degradation 
1.2.1 Protein Lifespan 
Cellular proteins are dynamically regulated in time and space through numerous post-
translational modifications. Key to these modifications is the observation that cellular proteins tend 
to exhibit differential permanence over time, likely due to differences in individual protein 
stabilities. These seemingly intrinsic proteins of specific proteins have been termed protein 
lifespan or “half-life”, signifying an estimation before degradation of the protein. Differential 
protein half-life occurs due to functional differences in the underlying proteins ranging from 
sensitive transcription factors to long-lived structure proteins. Overall, the scope of cellular 
proteins have been estimated to have half-lives ranging from minutes to many hours (85-87). 
Protein half-life is also modulated due to context specific cellular needs, such as changes in cell 
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production due to cell proliferation, growth, metabolism, or immune response (88). For example, 
researchers observed cell-cycle specific changes in protein degradation rates, as proteins become 
more stable around the moment of cytokinesis (89). Protein stability has consequences in disease, 
as infection can manipulate endogenous cellular protein stability processes to favor the pre-mature 
degradation of otherwise anti-viral proteins, such as the hijacking of ubiquitination activity by HIV 
to preserve infectivity (90-92). These observations utilized the hijacking of a cell’s E3 ligase, 
which is part of the ubiquitin proteasome system, an integral regulator of protein stability. 
Moreover, inhibition of the process of protein degradation has been an effective avenue of disease 
therapy, as inhibition of the proteasome has shown efficacy in combating cancers such as multiple 
myeloma (93). 
1.2.2 The Ubiquitin Proteasome System 
The Ubiquitin Proteasome System is the major cellular mechanism for protein degradation 
and recycling (94). This system utilizes the 76 amino-acid protein Ubiquitin as a molecular tag for 
substrate proteins through post-translational modification. The C-terminus of ubiquitin is 
covalently bound to target residues of the substrate protein, usually the ε-amino group of a 
substrate lysine (Lys) residue. Ubiquitin has the interesting ability to be itself ubiquitinated, with 
a second ubiquitin forming peptide bonds to Lys residues within the initial ubiquitin. From this, 
substrates can become poly-ubiquitinated, with long chains of linked ubiquitin moieties (95). Poly-
ubiquitination offers an additional level of coding, as ubiquitin has seven Lys sites that can be 
substrate sites for ubiquitination (Lys-6, 11, 27, 29, 33, 48, 63). In addition, ubiquitin can form 
linear assemblages through methionine-1 (Met-1) serving as the substrate site for subsequent 
ubiquitination (96). Research has shown that specific poly-ubiquitin chain linkage types can signal 
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for specific fates of the ubiquitinated substrate (97, 98). For example, Lys-63 linked poly-ubiquitin 
chains are implicated directed substrates for degradation in the lysosome rather than the 
proteasome (99). Met-1 linear ubiquitination plays a key role in controlling NF-κB signaling (100). 
Lys-48 specific poly-ubiquitination is the canonical signal for degradation in the proteasome, a 
massive protein structure that recycles proteins to their amino acids (101). The fate of ubiquitin 
itself during proteasomal substrate degradation is an developing topic of research, recent studies 
have suggested that the proximal ubiquitin attached the substrate is degraded along with the 
substrate protein, while the distal poly-ubiquitin chains are cleaved of their isopeptide bonds by 
de-ubiquitinases, and recycled to the intracellular space (102). 
The conjugation of ubiquitin to target substrates is accomplished in an enzymatic cascade. 
First, using ATP, the catalytically active cysteine (Cys) residue of the E1-activating enzyme forms 
a high energy thioester bond to the C-terminal glycine of ubiquitin (Ub). Then, using another ATP, 
the E1 enzyme transfers ubiquitin to the active center Cys of the E2 Ub conjugating enzyme 
(Ubc)(103). Finally, ubiquitin is covalently attached to target substrates through the aid of 
ubiquitin E3 ligases. Within this enzymatic cascade, E3 ligases play the critical role in identifying 
and binding the substrate protein fated for ubiquitination. 
1.2.3 Ubiquitin E3 Ligases  
The third enzyme class in the ubiquitination pathway cascade is the Ubiquitin E3 Ligase. 
E3 ligases play the critical role in targeting and binding substrates fated for ubiquitination. 
Substrates are then ubiquitinated either through E3 ligase steric orientation that allows the E2 
conjugating enzyme to be in close proximity to the substrate, or through intrinsic E3 ligase 
enzymatic activity. Research has identified over 800 unique E3 ligase proteins, which quite 
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numerous compared to the 20 E2 enzymes and single E1 activating enzyme complex (19, 20). 
Ubiquitin E3 ligases can be classified into several distinct families, including Cullin-RING-Ligase 
(CRL) complexes, Really Interesting New Gene (RING) Domain, U-box, and E6-AP Carboxyl 
Terminus (HECT) domain (Figure 2) (103-106). Distinct E3 ligase families demonstrate different 
mechanistic and functional attributes, for example, HECT E3 ligases possess a unique feature in 
which they accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester 
bond and directly transfer the ubiquitin to the substrate. An active site within the C-terminal of the 
HECT domain containing a cysteine residue is required for ubiquitin-thioester formation (107). In 
contrast, F-box E3 ligases, which serve as the substrate receptor subunit of the Cullin-RING-
Ligase 1 (CRL1) E3 ligase complex, function to bind substrate proteins, which are then 
ubiquitinated by the accompanying E2 enzyme (108-112). RING finger E3 ligases contain a 
unique RING (Really Interesting New Gene) finger domain that consists of two zinc finger type 
domains (113-115). RING domains facilitate the coordination of ubiquitin E2 domains, but some 
RING E3 ligases exhibit ligase activity independent of a scaffolding framework of a CRL complex 
(116, 117). Of these E3 ligase families, HECT-domain and RING-domain E3 ligases remain 
poorly characterized (118). There are about 30 HECT E3 ligases in mammalian cells, and 
functional data is only available for a select few including E6AP, Smurf, HECTD2 and NEDD4 
(118, 119). Functional data are available for only about a dozen of the over 300 predicted RING 
E3 ligases , such as MDM2 and several RNF and TRIM proteins (120-123). 
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Figure 2 Ubiquitin E3 ligase Sub-Families  
Schematic of different Ubiquitin E3 ligase sub-families and diagrams of their mechanisms of action for 
ubiquitination and substrate engagement. RING and Cullin-RING E3 ligase complexes rely on E2 ubiquitin 
conjugating enzymes to faciliate substrate ubiquitiantion, while HECT E3 ligases have instrinsic ligase activity to 
directly ubiqutinate substrate proteins. 
 Ubiquitin E3 Ligases in disease 
Dysfunction of E3 ligases lay at the heart of many diseases, as aberrant E3 ligase activity 
disrupts substrate homeostasis. The RING E3 ligase Mdm2 is a classic example of E3 ligase 
dysfunction in disease. Mdm2 is a RING-family E3 ligase and has been described to negatively 
regulate the ubiquitination and stability of the tumor suppressor p53 (124). Genetic mutations or 
amplification of Mdm2 has been described in numerous oncological cases, as Mdm2 hyperactivity 
leads to reduced p53, and increased tumorigenesis (124-126). Indeed, Mdm2 has been the target 
for therapeutic development to combat cancer, with inhibitors and antagonists such as Nutlin-series 
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compounds undergoing clinical trials (124, 127, 128). The genes BReast-CAncer susceptibility 
gene (BRCA) 1 and 2, encode proteins with RING-domains and ubiquitin E3 ligase activity. 
Research suggests BRCA1/2 function in DNA damage repair; disease-associated mutations impair 
their activity, thus leading to increased risk of cancer. (129) (130). Clinical studies have shown 
that mutations in BRCA1/2 confer around 70% cumulative risk for breast cancer and reduced but 
significant risk for ovarian cancer (131). BRCA1/2 mutations are of such clinical risk that 
prophylactic risk-reducing mastectomy has become an increasingly used therapy; evaluations of 
its efficacy are ongoing (132). The ligase Parkin, belonging to the smaller RING-between-RING 
E3 ligase family, is named for its associations with Parkinson’s’ Disease. Mutations with Parkin 
have been associated with hereditary early onset Parkinson’s Disease (133). Subsequent 
mechanistic research has uncovered that Parkin plays a critical role in the selective autophagy of 
mitochondria, termed mitophagy (134). During mitophagy, Parkin is recruited to the outer-
mitochondrial membrane of damaged mitochondria and catalyzes the ubiquitination of numerous 
surface proteins. These ubiquitinated proteins signal the autophagy machinery to initiate 
mitophagy of the damaged mitochondria (135). The Von Hippel–Lindau tumor suppressor gene 
(VHL) encodes the VHL ubiquitin ligase that functions as part of the cullin-2-ring ligase complex 
(CRL2) (136). The VHL-CRL2 complex mediates the ubiquitination and degradation of Hypoxia-
Inducible Factor (HIF) proteins, with numerous downstream consequences in oxygen sensing, 
tumorigenesis, and innate immune activation, including in the lung (137-139) . VHL was originally 
uncovered as a genetic determinant for the rare neurological disease, Von Hippel-Laud disorder; 
nicely reviewed by Gossage et al. (140). These observations demonstrate the ubiquitin e3 ligases 
are both causal and potentially targetable in human diseases. From this, we hypothesize that 
additional substrate-E3 ligase interactions are yet to be uncovered in lung diseases.  
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1.3 Specific Aims 
Increasingly, research has shown that Ubiquitin E3 ligases are biologically relevant in lung 
diseases. Concomitantly, there is un-tapped therapeutic potential in the selective targeting and 
inhibition of specific disease related E3 ligases to ameliorate lung diseases. These dissertation 
studies have focused on novel ubiquitin E3 ligase-substrate interactions and their effects on 
downstream signaling pathways with the goal of understanding if 1.) ubiquitin E3 ligases-substrate 
interactions biologically important for lung diseases, and 2.) Can we target E3 ligase for inhibition 
and therapeutically intervene in lung disease?  
To test these concepts, we approached in three specific aims, which have resulted in peer-
reviewed publications: 
Aim 1: To determine the role of Ubiquitin E3 ligases in regulating lung fibrosis mechanisms 
Sub-aim 1.1: Ubiquitin E3 Ligase FIEL1 Regulates Fibrotic Lung Injury through SUMO-
E3 Ligase PIAS4 
Sub-aim 1.2: Kelch-like Protein 42 is a Pro-Fibrotic Ubiquitin E3 Ligase in Systemic 
Sclerosis 
Aim 2: Innate immunity and inflammatory signaling can be manipulated by E3 ligase 
targeting  
Sub-aim 2.1: RING Finger E3 Ligase PPP1R11 Regulates TLR2 Signaling and Innate 
Immunity 
Sub-aim 2.2: 3.2 KIAA0317 Regulates Pulmonary Inflammation Through SOCS2 
Degradation 
Sub-aim 2.3: The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity 
Sub-aim 2.4: RNF113A Regulates CXCR4 stability and signaling 
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Aim 3: Nutrient sensing mechanisms are controlled by E3 ligase-mediated ubiquitination 
Sub-aim 3.1: The RING-type E3 ligase RNF186 ubiquitinates Sestrin-2 and thereby 
controls nutrient sensing 
These studies utilized both candidate-based and unbiased methods to determine 
biologically relevant substrates. E3 ligases for specific substrates were determined through narrow, 
targeted screens, or larger high-throughput RNAi-based screens. Finally, the biologic effects of 
the E3 ligase-substrate axis were investigated in biochemical, molecular, cellular, animal and 
translational manners. 
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2.0 Ubiquitination in Fibrosis 
In our first aim, we investigated the role of ubiquitin e3 ligases in fibrosis through their 
targeted degradation of anti-fibrotic proteins. This research focused on mediators of the TGFβ 
signaling pathway in idiopathic pulmonary fibrosis, and in the lung manifestation of systemic 
sclerosis. These studies also investigated the therapeutic potential in designing inhibitors of 
Ubiquitin E3 ligase activity to prevent degradation of anti-fibrotic substrates, and to intervene in 
fibrotic signaling and disease. 
2.1 Ubiquitin E3 Ligase FIEL1 Regulates Fibrotic Lung Injury through SUMO-E3 Ligase 
PIAS4  
Adapted from: Lear et al, Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-
E3 ligase PIAS4. J Exp Med 30 May 2016; 213 (6): 1029–1046. doi: 
https://doi.org/10.1084/jem.20151229, (141) 
2.1.1 Study Overview 
The E3 SUMO-protein ligase PIAS4 is a pivotal protein in regulating the TGFβ pathway. 
Here we discovered a new protein isoform encoded by KIAA0317, termed FIEL1 (Fibrosis 
Inducing E3 Ligase 1), which potently stimulates the TGFβ signaling pathway through the site-
specific ubiquitination of PIAS4. FIEL1 targets PIAS4 using a “double locking” mechanism which 
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is facilitated by the kinases PKCζ and GSK3. Specifically, PKCζ phosphorylation of PIAS4 and 
GSK3 phosphorylation of FIEL1 are both essential for the degradation of PIAS4. FIEL1 protein 
is highly expressed in lung tissues from patients with Idiopathic Pulmonary Fibrosis (IPF), whereas 
PIAS4 protein levels are significantly reduced. FIEL1 overexpression significantly increases 
fibrosis in bleomycin murine model, while FIEL1 knockdown attenuates fibrotic conditions. 
Further, we developed a first-in-class small molecule inhibitor towards FIEL1 that is highly 
effective in ameliorating fibrosis in mice. This study provides a basis for IPF therapeutic 
intervention by modulating PIAS4 protein abundance. 
2.1.2 Introduction 
Idiopathic Pulmonary Fibrosis (IPF) is a fibrotic disease of unknown etiology, but it is 
characterized by deposition of extracellular matrix into the interstitium and destruction of alveolar 
architecture resulting in progressive impairment in gas exchange and ultimately death (142-145). 
IPF is the most common form of interstitial lung disease with a prevalence of 50 per 100,000 cases, 
and it almost exclusively affects patients older than 50 (146). Despite its unknown etiology, the 
downstream effectors of IPF are well-characterized. Samples from IPF patients show increased 
levels of transforming growth factor beta (TGFβ) across all three isoforms (147). TGFβ promotes 
several IPF-relevant phenotypes: the differentiation of fibroblasts to myofibroblasts, the activation 
of epithelial to mesenchymal transition, and the promotion of lung epithelial cell apoptosis (148-
151). TGFβ transduces downstream signaling in part through the mothers against decapentaplegic 
homolog (SMAD) protein family. SMAD proteins regulate a variety of cellular processes, such as 
differentiation, proliferation, tumorigenesis, and immune responses (152-154). The SMAD family 
is comprised of receptor-SMADs (R-SMAD), inhibitor SMADs (I-SMAD), and the common 
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mediator SMAD (co-SMAD) (155). TGFβ signal transduction commences with the 
phosphorylation of R-SMADs, often SMAD2 or SMAD3, which form a trimeric structure with 
the co-SMAD, SMAD4, and translocate to the nucleus. In the nucleus, the trimer binds to the 
SMAD binding element (SBE) in the JunB promoter to activate the transcription of pro-fibrotic 
genes (156). Therefore, TGFβ is a major pro-fibrotic growth factor through the downstream 
SMAD signaling pathway (157, 158).  
 PIAS proteins and SMAD signaling 
PIAS (protein inhibitor of activated STAT) proteins are a family of proteins that are known 
to negatively control and regulate gene transcription and inflammatory pathways in cells (159). 
There are four characterized PIAS family members, PIAS1, PIASx (PIAS2), PIAS3, and PIASy 
(PIAS4), each with specificity toward different pathways (160). Specifically, PIAS4 has been 
shown to suppress TGFβ signaling by several mechanisms (23, 161). First, TGFβ promotes the 
interaction of PIAS4 with SMAD3 and SMAD4 to form a ternary complex (161). PIAS4 is known 
to possess small ubiquitin-like modifier (SUMO) E3 ligase activity within its RING-type domain 
(162). It promotes the sumoylation of SMAD3, in turn stimulating its nuclear export and inhibiting 
SMAD3/4-driven pro-fibrotic transcription (22, 163). Furthermore, PIAS4 directly recruits and 
interacts with histone deacetylase 1 (HDAC1) to repress SMAD3-driven transcriptional activation 
(161). In all, PIAS4 is an important negative regulator of TGFβ signaling. 
In this study, we discovered a new protein isoform encoded by KIAA0317, termed FIEL1 
(Fibrosis Inducing E3 Ligase 1). We also revealed a new molecular pathway in which FIEL1 
regulates TGFβ signaling through the ubiquitin-mediated degradation of PIAS4. Under TGFβ 
stimulation, two kinases, PKCζ and GSK3, phosphorylate PIAS4 and FIEL1 respectively. 
Phosphorylated FIEL1 targets phosphorylated PIAS4 and mediates its ubiquitination and 
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degradation, thereby exaggerating TGFβ signaling. These studies provide a new molecular model 
of fibrotic lung injury and lead to the development of a small molecule antagonist that exerts potent 
anti-fibrotic activity by regulating the abundance of PIAS4. 
2.1.3 FIEL1-PIAS4 pathway in pulmonary fibrosis 
PIAS4 degradation occurs in a ubiquitin-dependent manner through the proteasome 
(Figure 3A-B). We next screened our E3 ligase library and determined that the HECT domain E3 
ligase KIAA0317 regulates PIAS4 protein stability (data not shown). KIAA0317 encodes two 
major isoforms, of lengths 823 and 789 residues. The longer isoform has been previously 
characterized as AREL1 and contains an additional 34 residues in the C-terminal HECT-domain 
(164). However, we found that the shorter isoform (789 residues, termed FIEL1, Fibrosis Inducing 
E3 Ligase 1) behaves distinctly in cells. First, only FIEL1 overexpression significantly decreased 
PIAS4 protein levels (Figure 3C). Compared to AREL1, solely FIEL1 interacted with PIAS4 
protein via co-immunoprecipitation (Figure 3D). Moreover, overexpressed FIEL1 in murine lung 
epithelial (MLE), HeLa, and 293T cells co-migrated with the endogenous protein upon FIEL1 
immunoblotting, which suggested that FIEL1 is the predominant KIAA0317 isoform in all of these 
cell lines (data not shown). FIEL1 is sufficient for PIAS4 ubiquitination in vitro (Figure 3E). 
FIEL1 expression selectively decreased PIAS4, compared to other PIAS family members in MLE 
cells (Figure 3F). A randomly selected HECT E3 ligase, UBE3B, was also tested as a negative 
control (Figure 3F). FIEL1 expression in HeLa and 293T cells also decreased PIAS4 protein levels 
(data not shown). Conditional expression of FIEL1 in MLE cells using a doxycycline-inducible 
plasmid resulted in PIAS4 protein degradation (data not shown). Further, FIEL1 expression 
significantly decreased PIAS4 protein levels, whereas FIEL1 knockdown using shRNA stabilized 
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PIAS4 by extending its half-life (Figure 3G-H). FIEL1 also regulates PIAS4 protein levels in 
human fetal lung primary fibroblast MRC5 cells. As shown in Figure 3I and J, expression of FIEL1 
reduced PIAS4 protein levels in a dose dependent manner, whereas other proteins such as 
TGFR1, TGFR2, SMURF1, and SMAD7 levels were unchanged. Moreover, FIEL1 expression 
did not reduce PIAS4 mRNA levels (Figure 3K). TGF treatment increased FIEL1 protein and 
decreased PIAS4 protein in MRC5 cells while also increased the association of PIAS4 and FIEL1 
(Figure 3L). Last, TGF treatment drastically increased FIEL1 mRNA levels (data not shown). 
We also determined that K31 is the ubiquitin acceptor site within PIAS4 (Figure 4A-C). We 
measured FIEL1 and PIAS4 protein levels in lung tissues from five control subjects and five 
subjects with IPF. Subjects with IPF had significantly less PIAS4 protein and more 
immunoreactive FIEL1 protein in their lungs versus control subjects (Figure 3M). We also tested 
this pathway in bleomycin-induced murine lung fibrosis (165, 166). Bleomycin challenge 
significantly increased FIEL1 protein level and decreased PIAS4 protein level in mice lungs with 
a maximum effect at day 14 (Figure 3N). These results suggest that the FIEL1-PIAS4 pathway is 
functional and important in individuals with IPF. 
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Figure 3 FIEL1–PIAS4 pathway in pulmonary fibrosis  
(A) PIAS4 protein half-life determination in MLE cells transfected with empty plasmid or ubiquitin plasmid (n = 2). 
(B) PIAS4 protein half-life determination with MG132 or leupeptin treatment (n = 3). (C) Immunoblots (top) showing 
levels of PIAS4 protein and V5 after KIAA0317 (823 aa, AREL1) and (789 aa, FIEL1) plasmid expression. PIAS4 
protein quantification was normalized and graphed (bottom). Data represent mean values ± SEM (n = 3 independent 
experiments; *, P < 0.05 compared with 0 μg plasmid, Student’s t test). (D) PIAS4 protein was immunoprecipitated 
from cell lysate using a PIAS4 antibody and coupled to protein A/G beads. PIAS4 beads were then incubated with in 
vitro–synthesized products expressing HIS-V5-FIEL1 (789 aa) or HIS-V5-AREL1 (823 aa). After washing, proteins 
were eluted and processed for V5 immunoblotting (n = 2). (E) In vitro ubiquitination assay. Purified E1 and E2 
components were incubated with V5-PIAS4 and FIEL1. The full complement of ubiquitination reaction components 
(second lane) showed polyubiquitinated PIAS4 proteins (n = 3). (F) Immunoblots showing levels of PIAS proteins 
and V5 after ectopic FIEL1 or UBE3B expression. (G and H) PIAS4protein half-life determination in MLE cells with 
empty plasmid or FIEL1 expression (G); PIAS4 protein half-life determination with CON shRNA or FIEL1 shRNA 
expression (H). Data represent mean values ± SEM (n = 3 independent experiments; *, P < 0.05 compared with Empty 
or to Control, Student’s t test). (I–J) Immunoblots (I) showing levels of PIAS4, TGFBR1, TGFBR2, SMAD7, Smurf1, 
and V5 after FIEL1 expression. Protein quantification was graphed (J). Data represent mean values ± SEM (n = 3 
independent experiments; *, P < 0.05 compared with 0 μg FIEL1, Student’s t test). (K) mRNA levels of PIAS4 upon 
FIEL1 expression was measured using two sets of PIAS4 RT-PCR primers. Data represent mean values ± SEM (n = 
3 independent experiments). (L) MRC5 cells were treated with TGFβ in a time- or dose-dependent manner; cells were 
collected and immunoblotted for FIEL1 and PIAS4. Endogenous FIEL1 was also immunoprecipitated and 
immunoblotted for PIAS4 (n = 3). (M) PIAS4 and FIEL1 immunoblotting from lung tissues samples from five control 
and five IPF patients. PIAS4 and both the shorter and longer forms of KIAA0317 were quantified using ImageJ and 
graphed. Data represent mean values (n = 5 patients; NS, not significant *, P < 0.05 compared with CON, Student’s t 
test). (N) C57BL/6J mice were treated i.t. with bleomycin (0.02 U) for up to 21 d. Mice were then euthanized, and 
lungs were isolated and assayed for PIAS4 and FIEL1 immunoblotting. Bands corresponding to each protein on 
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immunoblots were quantified using ImageJ software, and the results are displayed graphically. Data represent mean 
values ± SEM (n = 4–5 mice per group; *, P < 0.05 compared with day 0, Student’s t test). 
 
 
Figure 4 Mapping Study of FIEL1 and PIAS4 interaction   
A. Several point mutants of PIAS4 were designed and cloned into a pcDNA3.1D/V5-HIS vector. B. Half-life study 
of WT, K31R, K35R, and K114R PIAS4 in MLE cells.  C. MLE cells were co-transfected with WT or PIAS4 lysine 
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mutants with or without HA-Ubiquitin. Cells were then collected and immunoblotted. PIAS4 protein levels were 
quantified and graphed. Data represent mean values ± SEM (n=3 independent experiments; NS, not significant, *, 
p<0.05 compared to without HA-Ubiquitin, Student’s t-test). D. Several deletional mutants of PIAS4 were designed 
and cloned into a pcDNA3.1D/V5-HIS vector.  E-F. FIEL1 protein was immunoprecipitated from cell lysates using a 
FIEL1 antibody and coupled to protein A/G beads. FIEL1 beads were then incubated with in vitro synthesized products 
expressing HIS-V5-PIAS4 mutants. After washing, proteins were eluted and processed for V5-PIAS4 
immunoblotting.  G. Half-life study of WT, Q21A, S14A, S18A, S18A/Q21A, and S14A/S18A PIAS4 in MLE cells.  
H. MLE cells were co-transfected with WT or PIAS4 mutants with or without FIEL1. Cells were then collected and 
immunoblotted. I. Several deletional mutants of FIEL1 were designed and cloned into a pcDNA3.1D/V5-HIS vector.  
J-N, P. PIAS4 protein was immunoprecipitated from cell lysate using a PIAS4 antibody and coupled to protein A/G 
beads. PIAS4 beads were then incubated with in vitro synthesized products expressing HIS-V5-FIEL1 mutants. After 
washing, proteins were eluted and processed for V5-FIEL1 immunoblotting.  O. MLE cells were transfected with WT 
or FIEL1 mutants. Cells were then collected and immunoblotted for PIAS4 protein.  Q. The cartoon illustrates the 
“double locking” molecular interplay between PIAS4 and FIEL1. Specifically, both the P779 and GSK3β 
phosphorylated T783 residues within FIEL1 are required for PIAS4 binding; both the Q21 and PKCζ phosphorylated 
S18 residues within PIAS4 are required for FIEL1 binding.  R. PIAS4 suppresses the TGFβ pathway, in part, by 
sumoylating SMAD3 and causing SMAD3 nuclear exportation. FIEL1 serves as a bona-fide E3 ligase and triggers 
the site-directed ubiquitination of PIAS4. TGFβ hijacks FIEL1 protein to ubiquitinate PIAS4 and promote fibrosis. 
PKCζ phosphorylates PIAS4 and regulates its stability. Moreover, GSK3β serves as another regulator of PIAS4 
protein stability through the phosphorylation of FIEL1. A small-molecule FIEL1 inhibitor, BC-1485, lowers tissue 
fibrosis by antagonizing the actions of FIEL1 on PIAS4-TGFβ signaling. 
2.1.4 FIEL1 promotes TGF signaling 
Using a SMAD reporter assay (Qiagen), we determined that FIEL1 overexpression 
increased SMAD promoter driven luciferase activity upon TGF stimulation (Figure 5A). By 
decreasing PIAS4 protein, expression of FIEL1 also decreased SMAD3 sumoylation (Figure 5B) 
as previously described (22, 163) and further promoted SMAD3 nuclear concentration (Figure 
5C). FIEL1 ectopic expression did not change SMAD3 phosphorylation. FIEL1 expression 
increased the expression of fibrotic proteins Fibronectin (FN) and alpha smooth muscle actin (-
SMA) in MRC5 cells (Figure 5 FIEL1 promotes TGFβ signalingFigure 5D). When we knock down 
FIEL1 using several shRNAs, we observed a significantly reduced SMAD driven luciferase 
activity, with shRNA 3 serving as a negative control (Figure 5E). FIEL1 knockdown increased 
PIAS4 protein, increased SMAD3 sumoylation (Figure 5F), and further decreased SMAD3 nuclear 
concentration (Figure 5G). FIEL1 knockdown also decreased the expression of fibrotic proteins 
Fibronectin (FN) and alpha smooth muscle actin (-SMA) in MRC5 cells (Figure 5H). To 
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complement the biochemistry approach, we also performed immunostaining on MRC5 cells, and 
we observed that FIEL1 knockdown also reduced nuclear localization of SMAD3 upon TGF 
treatment (Figure 5I). 
 
Figure 5 FIEL1 promotes TGFβ signaling  
 
(A and E) SMAD reporter assays. 293T cells were cotransfected with Cignal SMAD dual luciferase reporter plasmids 
along with empty, FIEL1, Con shRNA, or FIEL1 shRNA. 24 h later, cells were treated with TGFβ for 2–16 h. Cells 
were collected and assayed for luciferase activity to evaluate SMAD promoter activity. Data represent mean values ± 
SEM (n = 3; *, P < 0.05 compared with empty, Student’s t test). (B and F) 293T cells were transfected with empty, 
FIEL1, CON shRNA, or FIEL1 shRNA for 48 h before TGFβ treatment (0–2 ng/ml) for 1 h. Cells were then collected 
and immunoblotted. Cell lysates were immunoprecipitated using SUMO antibody before SMAD2, 3, and 4 
immunoblotting (n = 2). (C and G) 293T cells were transfected with empty, FIEL1, CON shRNA, or FIEL1 shRNA 
for 48 h before TGFβ treatment (2 ng/ml) for up to 1 h. Cells were then collected and nuclear/ cytosol fractions were 
isolated prior to immunoblotting. (D and H) MRC5 cells were transfected with empty, FIEL1, CON shRNA, or FIEL1 
shRNA for 48 h before TGFβ dose course treatment for an additional 18 h. Cells were then collected and 
immunoblotted (n = 2). (I) MRC5 cells were seeded in 35-mm glass bottom dishes before being transfected with CON 
shRNA or FIEL1 shRNA for 48 h before TGFβ treatment for an additional 30 min. Cells were then fixed and 
immunostained with α-SMAD3.The nucleus was counterstained with DAPI and F-actin was counterstained with 
phalloidin (n = 3). Bar, 10 μm. 
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2.1.5 PIAS4 phosphorylation by PKCζ is required for FIEL1 binding 
We next investigated the FIEL1 binding site within PIAS4. We determined that PIAS4 S18 
and Q21 are both important for FIEL1 interaction (Figure 4D-F). We performed a kinase screen 
and determined that PKCζ interacts with PIAS4 via Co-IP (Figure 6A). PKCζ expression also 
decreased PIAS4 protein level, whereas JNK1 expression was unable to achieve such an effect 
(Figure 6B). Moreover, PKCζ knockdown using shRNA drastically stabilized PIAS4 protein in a 
t1/2 study (Figure 6C), whereas PKCζ expression decreased PIAS4 t1/2 to about 2h (Figure 6D). 
TGF stimulation also drastically increased PIAS4 serine phosphorylation and PKCζ association, 
but not PKC association (Figure 6E-F). PKCζ directly phosphorylated PIAS4 in a kinase assay 
(Figure 6G). PKCζ knockdown also protected PIAS4 from phosphorylation and degradation 
during TGF treatment (Figure 6H). Compared to WT PIAS4, S18A and S14/S18A double mutant 
exhibited a dramatic decrease in phosphorylation and offered resistance to degradation during 
TGF treatment (Figure 6I). PIAS4 S18A, Q21A, and S18/Q21A double mutants also exhibited 
much longer half-lives (Figure 4G) and resisted degradation from FIEL1 co-expression (Figure 
4H). Last, we performed a peptide binding experiment (Figure 6J). The peptide with S18 
phosphorylation (P2) showed the strongest binding to FIEL1; the peptide with both S18 
phosphorylation and Q21 mutation (P3) offered drastically decreased FIEL1 interaction. These 
experiments suggested that PKCζ is an authentic regulator of PIAS4 protein stability; Q21 and 
phosphorylated S18 of PIAS4 are both required for FIEL1 interaction.  
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Figure 6 PIAS4 phosphorylation by PKCζ is required for FIEL1 binding 
 
(A) Endogenous PIAS4 was immunoprecipitated and immunoblotted for Erk1, PKCα, and PKCζ (n = 2). (B) MLE 
cells were transfected with increasing amounts of PKCζ or JNK1 plasmids for 18 h before PIAS4 immunoblotting (n 
= 2). (C) PIAS4 protein half-life determination with CON shRNA or PKCζ shRNA expression (n = 3). (D) PIAS4 
protein half-life determination with Empty or PKCζ plasmid overexpression (n = 3). (E and F) MRC5 cells were 
treated with TGFβ in a time or dose-dependent manner; cells were collected and immunoblotted for FIEL1, PIAS4, 
PKCζ, and p-PKCζ (Thr410). Endogenous PIAS4 was also immunoprecipitated and followed by PKCζ, PKCα, 
phosphoserine, and phosphothreonine immunoblotting (n = 2). (G) In vitro PKCζ kinase assay. Recombinant PKCζ 
(Enzo) was used as the kinase, and V5-tagged PIAS4 was synthesized via TnT in vitro kits (Promega), purified by 
HIS pulldown, and used as the substrate. The kinase reactions were incubated at 37°C for 2 h, and products were 
resolved by SDS-PAGE and processed for autoradiography either by using Personal Molecular Imager (Bio-Rad 
Laboratories) or immunoblotting for V5 to visualize the substrate input. *, heat inactivated PKCζ (n = 2). (H) 
Immunoblots showing levels of FIEL1, PKCζ, p-PKCζ (Thr410), and PIAS4 protein in 293T cells transfected with 
either CON shRNA or PKCζ shRNA, followed by a TGFβ dose treatment. Endogenous PIAS4 was also 
immunoprecipitated and followed by PKCζ, phosphoserine, and phosphothreonine immunoblotting. (I) 293T cells 
were transfected with WT, S14A, S18A, or S14/18A PIAS4 before being treated with a dose course of TGFβ. Cells 
were then collected and assayed for V5-PIAS4 immunoblotting. Overexpressed V5-PIAS4 was also 
immunoprecipitated using a V5 antibody and followed by phosphoserine immunoblotting (n = 2). (J) Four biotin-
labeled PIAS4 peptides were bound to streptavidin and served as the bait for FIEL1 binding. After washing, proteins 
were eluted and immunoblotted for FIEL1-V5 (n = 2). 
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2.1.6 GSK3 phosphorylation of FIEL1 is required for PIAS4 targeting 
We next investigated the PIAS4 binding site within FIEL1. A mapping study was 
conducted similarly to Figure 4D and we determined that both P779 and T783 are important for 
PIAS4 interaction (Figure 4I-N). Compared with WT FIEL1, neither P779A nor T783A mutant 
expression decreased PIAS4 protein levels (Figure 4O). We also determined that C770 is a 
potential active site of FIEL1 as the C770S mutant also failed to decrease PIAS4 protein level 
(Figure 4O).  SNP database analysis indicated a naturally occurring polymorphism (rs371610162) 
within FIEL1 (P779L). We further tested this mutation in a binding assay and showed that T783A, 
P779L, and P779L/T783A double mutants all lost interaction with PIAS4 (Figure 4P). We 
performed a kinase screen and determined that GSK3 interacts with FIEL1 via Co-IP (Figure 
7A). WT GSK3 overexpression decreased PIAS4 protein levels in a dose dependent manner, and 
PIAS4 protein levels decreased more dramatically when we transfected cells with a constitutively 
activated GSK3 hyper mutant plasmid (Figure 7B). Moreover, a CHX t1/2 study suggested that 
WT GSK3 ectopic expression decreased PIAS4 t1/2 to about 4h, whereas the more potent GSK3 
hyper mutant further decreased PIAS4 t1/2 to about 2 h (Figure 7C). TGF stimulation drastically 
increased FIEL1 threonine phosphorylation (Figure 7D), and GSK3 knockdown drastically 
stabilized PIAS4 in a t1/2 study (Figure 7E). Moreover, GSK3 knockdown also prevented FIEL1 
threonine phosphorylation and protected PIAS4 from degradation with TGF treatment (Figure 
7F).  
Using the lung lysates from Figure 3M, we performed a Co-IP experiment and observed a 
positive and significant association between PIAS4 and phospho-threonine signal, which 
suggested that FIEL1 threonine phosphorylation is essential for PIAS4 binding (Figure 7G). We 
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further studied the role of FIEL1 T783 in regulating PIAS4 protein stability. FIEL1 T783A mutant 
overexpression completely failed to decrease PIAS4 protein level. However, in phosphorylation 
mimic T783D mutant, FIEL1 expression decreased PIAS4 protein level more dramatically 
compared to WT FIEL1 expression (Figure 8A). Moreover, a t1/2 study suggested that WT FIEL1 
expression decreased PIAS4 t1/2 to about 4h, whereas the more potent phosphorylation mimic 
T783D further decreased PIAS4 t1/2 to about 2 h (Figure 8B). The FIEL1 T783A mutant was 
resistant to GSK3 phosphorylation in vitro (Figure 8C) and in cells (Figure 8D). We also 
performed a peptide binding experiment (Figure 8E). Peptide with phosphorylation at T783 (P2) 
showed the strongest binding to PIAS4; peptide with no phosphorylation (P1) or T783A mutant 
(P4) offered drastically decreased PIAS4 interaction. FIEL1 T783A and P779L expression both 
failed to decrease PIAS4 protein level (Figure 8F) or half-lives (Figure 8G). FIEL1 T783A/P779L 
double mutant expression showed a dominant negative phenotype by increasing PIAS4 protein 
levels (Figure 8F). We further used PIAS4 peptide 2 with S18 phosphorylation (Figure 6J) as bait 
and determined that both P779L and T783A FIEL1 drastically lost binding with PIAS4 (Figure 
8H), which is similar to Figure 4P. Similarly, FIEL1 Peptide 2 with phosphorylation at T783 (P2) 
(Figure 8E) was used to reconfirm the importance of S18 phosphorylation and Q21 within PIAS4 
for FIEL1 interaction (Figure 8I), which is similar to Figure 4F. Last, FIEL1 T783A/P779L 
dominant negative mutant overexpression protected PIAS4 from TGF treatment (Figure 8J). 
These experiments suggested that GSK3 phosphorylation of FIEL1 is required for PIAS4 
targeting, and FIEL1 residues P779 and phosphorylated T783 are both required for PIAS4 
interaction (Figure 4Q).  
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Figure 7 GSK3β regulates PIAS4 protein stability through FIEL1  
(A) Endogenous FIEL1 was immunoprecipitated and followed by JNK2, PKCα, and GSK3β immunoblotting (n = 2). 
(B) MLE cells were transfected with increasing amounts of WT or constitutively activated GSK3β hyper mutant 
plasmids for 18 h before PIAS4 immunoblotting. The arrow indicates the overexpressed GSK3β (n = 2). (C) PIAS4 
protein half-life determination with WT GSK3β or hyperactive GSK3β plasmid overexpression. The arrow indicates 
the overexpressed GSK3β (n = 2). (D) MRC5 cells were treated with TGFβ in a time or dose-dependent manner; cells 
were then collected and immunoblotted for FIEL1 and PIAS4. Endogenous FIEL1 was also immunoprecipitated and 
followed by phosphoserine and phosphothreonine immunoblotting (n = 2). (E) PIAS4 protein half-life determination 
with CON shRNA or GSK3β shRNA expression (n = 2). (F) Immunoblots showing levels of GSK3β, phospho-GSK3β 
(Ser9), PIAS4, and FIEL1 protein in 293T cells transfected with either CON shRNA or GSK3β shRNA followed by 
a TGFβ dose treatment. Endogenous FIEL1 was also immunoprecipitated, followed by phosphoserine and 
phosphothreonine immunoblotting. (G) Lung samples from Figure 3J were subjected to FIEL1 immunoprecipitation, 
followed by PIAS4, phosphothreonine, and phosphoserine immunoblotting. PIAS4 protein abundance was plotted as 
a function of p-Thr protein (n = 5 patients per group; *, P <0.01, Pearson correlation). 
32 
 
Figure 8 GSK3β phosphorylation of FIEL1 is required for PIAS4 targeting  
(A) MLE cells were transfected with increasing amounts of WT, T783A, or T783D mutant FIEL1 plasmids for 18 h 
before PIAS4 immunoblotting (n = 2). (B) PIAS4 protein half-life determination with WT, T783A, or T783D mutant 
FIEL1 (n = 2). (C) In vitro GSK3β kinase assay. Recombinant GSK3β (Enzo) was used as the kinase, and V5-tagged 
FIEL1 were synthesized via TnT in vitro kits (Promega), purified by HIS pulldown, and used as the substrate. The 
kinase reactions were incubated at 37°C for 2 h, and products were resolved by SDS-PAGE and processed for 
autoradiography either by using Personal Molecular Imager (Bio-Rad Laboratories) or immunoblotting for V5 to 
visualize the substrate input. *heat inactivated GSK3β (n = 2). (D) 293T cells were transfected with empty, WT, or 
T783A FIEL1 for 24h. Cells were then collected and immunoblotted for V5-FIEL1 and PIAS4. Overexpressed V5-
FIEL1 was also immunoprecipitated using V5 antibody and followed by phosphothreonine immunoblotting (n = 2). 
(E) Four biotin-labeled FIEL1 peptides were prebound to streptavidin and served as the bait for PIAS4 binding. After 
washing, proteins were eluted and processed for PIAS4 immunoblotting (n = 2). (F) MLE cells were transfected with 
increasing amounts of WT, T783A, P779L, or T783A/P779L double mutant FIEL1 plasmids for 18 h before PIAS4 
immunoblotting. (G) PIAS4 protein half-life determination with WT, T783A, P779L, or T783A/P779L double mutant 
FIEL1 (n = 2). (H) PIAS4 peptide 2 (Biotin-MSF RVS(p)DLQM) was prebound to streptavidin and served as the bait 
for FIEL1 binding. After washing, proteins were eluted and processed for V5-FIEL1 immunoblotting (n = 2). (I) 
FIEL1 peptide 2 (Biotin-QII AAP THST(p)LPTA) was bound to streptavidin and served as the bait for PIAS4 binding. 
After washing, proteins were eluted and processed for V5-PIAS4 immunoblotting (n = 2). (J) 293T cells were 
transfected with WT, T783A, P779L, or T783A/P779L double mutant FIEL1 before being treated with TGFβ. Cells 
were then collected and assayed for PIAS4 immunoblotting. (K) MLE cells were transfected with increasing amounts 
of WT, I514V, or D207V mutant FIEL1 plasmids for 18 h before PIAS4 immunoblotting. (L) PIAS4 protein half-life 
determination with WT, I514V, or D207V mutant FIEL1 expression. 
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2.1.7 Gene transfer of FIEL1 exacerbates bleomycin induced lung injury in vivo 
So far, our in vitro studies suggest that FIEL1 promotes TGF signaling in vitro. As 
exacerbated TGF signaling partakes in fibrotic formation, the results raise the possibility that 
expression of FIEL1 in vivo might alter host inflammatory responses and induce fibrotic lung 
injury. To extend the above observations in vivo, mice were infected with an empty lentivirus or 
lentivirus encoding FIEL1 for 144 h (107 cfu/mouse, intratracheally [i.t.]). Mice were then 
challenged with bleomycin (0.02U i.t.) for an additional 1-21 days (Figure 9A). Mice were 
euthanized to analyze parameters of fibrotic lung injury. Bleomycin injury is one of the most 
widely studied models of pulmonary fibrosis (18, 158, 165, 166). As shown in Figure 9B, the 
increased BAL total protein concentration that occurs after bleomycin injury in control mice was 
significantly higher in mice overexpressing FIEL1. Total inflammatory cells and Chemokine 
CXCL1 levels in BALs were also significantly increased in mice overexpressing FIEL1 (Figure 
9C-D). Specifically, the differential cell counts of the BALs revealed that the total increase in 
inflammatory cells was mostly due to neutrophils and lymphocytes, with the exception of 
macrophages on day 7 (Figure 9E-G). FIEL1 expression in mice also significantly reduced survival 
(Figure 9H). Bleomycin challenge also showed changes consistent with peribronchiolar and 
parenchymal fibrosis in a time-dependent manner (Figure 9I-J). Elevated lung collagen deposition 
visualized by Masson Trichrome staining also suggested that FIEL1 expression exacerbates 
bleomycin-induced lung fibrosis (Figure 9J-K).We observed a marked increase in lung fibrosis in 
mice overexpressing FIEL1 as demonstrated by significantly increased hydroxyproline content 
(Figure 9L). The extent of these changes present in FIEL1 expression mice was substantially 
increased compared to the empty control (Figure 9I-L). Last, we analyzed FIEL1/PIAS4 protein 
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levels in murine lung samples and observed that lentiviral FIEL1 expression completely depleted 
PIAS4 protein in the lung (Figure 9Figure 9M). 
 
 
Figure 9 Gene transfer of FIEL1 exacerbates bleomycin-induced lung injury in vivo 
(A)C57BL/6J mice weretreated i.t. with Lenti-Empty or Lenti-FIEL1 (107 PFU/mouse) for 144 h; mice were then 
treated i.t. with bleomycin (0.02 U). Mice were euthanized over the next 1–21 d, and lungs were lavaged with saline, 
harvested, and then homogenized. (B–D) Lavage protein, total cells, and CXCL1 concentrations were measured. Data 
represent mean values ± SEM (n = 4–6 mice per group, data are from one of the two experiments performed; *, P < 
0.05 compared with empty, Student’s t test). (E–G) Lavage cells were then processed for Wright-Giemsa stain; lavage 
macrophages, neutrophils, and lymphocytes were counted and graphed. Data represent mean values ±SEM (n = 4–6 
mice per group, *, P < 0.05 compared with empty, Student’s t test). (H) Survival studies of mice that were given 
bleomycin. Mice were carefully monitored over time; moribund, preterminal animals were immediately euthanized 
and recorded as deceased. Kaplan-Meier survival curves were generated using SPSS software (n = 9–11 mice per 
group; *, P < 0.05 compared with Empty, Log-rank test). Empty: n = 9, FIEL1: n = 11. (I and J) Hematoxylin and 
eosin (H&E) and Trichrome staining were performed on lung samples. Bars, 100 μm. (K) Collagen percentage 
quantification from Trichrome staining. Data represent mean values ± SEM (n = 4–6 mice per group, *, P < 0.05 
compared with empty, Student’s t test). (L) Hydroxyproline content was measured in lungs from 7, 14, and 21 d after 
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bleomycin challenge. Data represent mean values ± SEM (n = 4–6 mice per group, *, P < 0.05 compared with empty, 
Student’s t test). (M) Mice lungs were isolated and assayed for PIAS4 and FIEL1 immunoblotting. 
2.1.8 FIEL1 knockdown ameliorates bleomycin-induced lung injury in vivo 
To further confirm the role of FIEL1 in lung fibrosis and inflammation, we pursued in vivo 
knockdown studies. Mice were first infected with lentivirus encoding CON shRNA or FIEL1 
shRNA for 144h (107CFU/mouse, i.t) and then challenged with bleomycin (0.05U i.t.) for an 
additional 1-21 days (Figure 10A). FIEL1 knockdown significantly decreased BAL protein 
concentrations, total cell counts, and chemokine CXCL1 levels (Figure 10B-D). Specifically, the 
differential cell counts of BALs revealed that the total decrease in inflammatory cells was mostly 
due to neutrophils and lymphocytes, with the exception of macrophages on day 3 and 21 (Figure 
10E-G). FIEL1 knockdown in mice also significantly improved survival (Figure 10H). 
Peribronchiolar and parenchymal fibrosis were also substantially decreased in FIEL1 knockdown 
mice (Figure 10I-J) suggesting that FIEL1 knockdown ameliorates bleomycin-induced lung injury. 
Elevated lung collagen deposition visualized by Masson Trichrome staining also suggested that 
FIEL1 expression exacerbates bleomycin-induced lung fibrosis (Figure 10J-K). We observed a 
marked decrease in lung fibrosis in FIEL1 knockdown mice as demonstrated by a significant 
decrease in hydroxyproline content (Figure 10L). Last, we analyzed FIEL1 and PIAS4 protein 
levels in murine lung samples and showed that lentiviral FIEL1 knockdown reversed bleomycin 
induced FIEL1 increase and rescued PIAS4 protein levels in the lung (Figure 10M). 
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Figure 10 FIEL1 knockdown ameliorates bleomycin-induced lung injury in vivo 
(A) C57BL/6J mice were treated i.t. with Lenti-CON shRNA or Lenti-FIEL1 shRNA (107 PFU/mouse) for 144 h; 
mice were then treated i.t. with bleomycin (0.05 U). Mice were euthanized over the next 1–21 d, and lungs were 
lavaged with saline, harvested, and then homogenized. (B–D) Lavage protein, total cells, and CXCL1 concentrations 
were measured. Data represent mean values ± SEM (n = 4–6 mice per group, data are from one of the two experiments 
performed; *, P < 0.05 compared with Control, Student’s t test). (E–G) Lavage cells were then processed for Wright-
Giemsa stain; lavage macrophages, neutrophils, and lymphocytes were counted and graphed. Data represent mean 
values ± SEM (n = 4–6 mice per group, *, P < 0.05 compared with Control, Student’s t test). (H) Survival studies of 
mice that were given bleomycin. Mice were carefully monitored over time; moribund, preterminal animals were 
immediately euthanized and recorded as deceased. Kaplan-Meier survival curves were generated using SPSS software 
(n = 8 mice per group; *, P < 0.05 compared with Control, Log-rank test P < 0.05). Empty: n = 8, FIEL1: n = 8. (I and 
J) H&E and Trichrome staining was performed on lung samples. Bar indicates 100 μm. (K) Collagen percentage 
quantification from Trichrome staining. Data represent mean values ± SEM (n = 4–6 mice per group, *, P < 0.05 
compared with Control, Student’s t test). (L) Hydroxyproline content was measured in lungs from 7, 14, and 21 d after 
bleomycin challenge. Data represent mean values ± SEM (n = 4–6 mice per group; *, P < 0.05 compared with Control, 
Student’s t test). (M) Mice lungs were isolated and assayed for PIAS4 and FIEL1 immunoblotting. 
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2.1.9 Anti-fibrotic activity of a FIEL1 small molecule inhibitor  
We first constructed a FIEL1 HECT domain homology model using the NEDD4 HECT 
domain structure (167, 168) (Protein Database 2XBF.pdb) (Figure 11A). We observed a major 
cavity within the C-terminal of the FIEL1 HECT domain that is also required for PIAS4 binding 
(Figure 11A). Through the LibDock program from Discovery Studio 3.5, we were able to screen 
potential ligands for the FIEL1 cavity. We selected BC-1480 as a backbone to further develop new 
small-molecule inhibitors (Figure 11B). BC-1485 was synthesized by reacting alaninamide with 
BC-1480 (data not shown). BC-1485 fits in the FIEL1 cavity fairly well by having several 
electrostatic interactions with GLN 774, HIS 788, ILE 776, and THR 783 (Figure 11C-D) 
 In vitro 
We next sought to investigate the effect of FIEL1 small molecule inhibitors in vitro. 
Compared to BC-1480, BC-1485 exhibited >100 fold activity in disrupting the FIEL1/PIAS4 
interaction (Figure 11E). BC-1485 also exhibited potent activity towards disrupting FIEL1 
directed PIAS4 ubiquitination (Figure 11F). Finally, we tested BC-1485 in cells and observed a 
drastic dose-dependent increase in PIAS4 protein levels (Figure 11G). BC-1485 also decreased the 
expression of -SMA in MRC5 cells (data not shown). BC-1485 also stabilized PIAS4 by 
extending its half-life (Figure 11H) without altering its mRNA level (Figure 11I). 
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Figure 11 Antifibrotic activity of a FIEL1 small molecule inhibitor in vitro 
(A) Structural analysis of the FIEL1 HECT domain revealed a major cavity within the C terminus of the HECT 
domain. (B) Structures of the BC-1480 backbone (4-(2-Oxo-2,3-dihydro-1H-benzoimidazole-5-sulfonylamino)-
benzoic acid) and lead compound BC-1485. (C and D) Docking studies of the lead compound, BC-1485, interacting 
with the FIEL1-HECT domain. (E) FIEL1 protein was HIS-purified from FIEL1 expression in 293T cells using cobalt 
beads. Beads were then extensively washed before exposure to BC-1480 or BC-1485 at different concentrations (10−4 
to 100 μM). Purified PIAS4 protein was then incubated with drug-bound FIEL1 beads overnight. Beads were washed, 
and proteins were eluted and resolved on SDS-PAGE. The relative amounts of PIAS4 detected in the pull-downs was 
normalized to loading and quantified (n =2). (F) In vitro ubiquitination assay. Purified FIEL1, E1, and E2 protein were 
incubated with purified V5-PIAS4, and the full complement of ubiquitination reaction components with increased 
concentrations of BC-1485 showed decreased levels of polyubiquitinated PIAS4 (arrows). (bottom) Levels of 
ubiquitinated PIAS4 as a function of BC-1485 concentration (n = 2). (G) MLE cells were exposed to BC-1480 or BC-
1485 at various concentrations for 18 h. Cells were then collected and immunoblotted (n = 3). (H) PIAS4 protein half-
life determination after BC-1480 or BC-1485 treatment at 5 μM for 18 h. (I) PIAS4 and FIEL1 mRNA analysis after 
BC-1485 treatment for 18 h. Data represent mean values ± SEM (n = 3 independent experiments; NS, not significant 
compared with 0 μM condition, Student’s t test).            
 In vivo 
To further assess the kinetics of the anti-fibrotic activity of BC-1485, we first tested it in 
vivo following bleomycin injury. Briefly, mice were challenged with bleomycin (0.05U i.t.); BC-
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1485 and control compound BC-1480 were given in the drinking water (~5mg/kg/d) for an 
additional 7-21 days (Figure 12A). BC-1485 significantly decreased BAL protein concentrations 
and CXCL1 levels (Figure 12B-C,). BC-1485 also significantly decreased BAL total cell counts, 
specifically neutrophils and lymphocytes (Figure 12D-G), and significantly improved survival 
(Figure 12H). Peribronchiolar and parenchymal fibrosis were also substantially decreased by BC-
1485 (Figure 12I). Decreased lung collagen visualized by Trichrome staining also suggested that 
BC-1485 ameliorates bleomycin-induced lung injury (Figure 12I and K). We observed a marked 
decrease in lung fibrosis in mice treated with the BC-1485 as demonstrated by a significant 
decrease in hydroxyproline content (Figure 12I-J).  We further tested BC-1485 in a dose dependent 
manner using a bleomycin model. This time, mice were challenged with bleomycin (0.05U i.t.) for 
10 days before being treated with BC-1485 (2 and 10mg/kg/d in drinking water) for an additional 
10 days prior to sacrifice (Figure 13A). BC-1485 significantly decreased BAL protein 
concentrations and cell counts compared to vehicles (Figure 13B-C). Specifically, BC-1485 dose-
dependently decreased macrophages, neutrophils, and lymphocytes (Figure 13D) and significantly 
improved survival (Figure 13E). We observed a marked decrease in lung fibrosis in mice treated 
with BC-1485 as demonstrated by a significant decrease in hydroxyproline content (Figure 13F). 
Peribronchiolar and parenchymal fibrosis were also substantially decreased by BC-1485 (Figure 
13G). Decreased lung collagen visualized by Trichrome staining also suggested that BC-1485 
ameliorates bleomycin-induced lung injury (Figure 13G-H). Lastly, BC-1485 rescued PIAS4 
protein levels in bleomycin treated lungs (Figure 13I). Hence, small-molecule targeting of the 
FIEL1/PIAS4 pathway reduced the severity of fibrosis in a preclinical model (Figure 4R). 
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Figure 12 Anti-fibrotic activity of a FIEL1 small molecule inhibitor in vivo  
A. C57BL/6J mice were administered i.t. with bleomycin (0.05U). Compounds BC-1480 and BC-1485 were given to 
mice at the same time through drinking water with an estimated dose of 5mg/kg/d. Mice were euthanized over next 1-
21 days, and lungs were lavaged with saline, harvested, and then homogenized. B-D. Lavage proteins, CXCL1, and 
total cell count were measured. Data represent mean values ± SEM (n=4-8 mice per group, data are from one of two 
experiments performed; *, p<0.05 compared to Vehicle, Student’s t-test).  E-G. Lavage cells were also processed for 
Wright-Giemsa stain; Lavage macrophages, neutrophils, and lymphocytes were counted and graphed. Data represent 
mean values ± SEM (n=4-8 mice per group, *, p<0.05 compared to Vehicle, Student’s t-test).   H. Survival studies of 
mice that were given bleomycin and compound treatments. Mice were carefully monitored over time; moribund, 
preterminal animals were immediately euthanized and recorded as deceased. Kaplan-Meier survival curves were 
generated using SPSS software (n = 12-24 mice per group; *, p<0.05 compared to Vehicle, Log Rank test p<0.05). 
Vehicle: n=24, BC-1480: n=13, BC-1485: n=12.  I. H&E and Trichrome staining was performed on lung samples. 
Original magnification, x20. Bar indicates 100 μm. J. Hydroxyproline content were measured in lungs from 7, 14, and 
21d after bleomycin challenge. Data represent mean values ± SEM (n=4-8 mice per group, *, p<0.05 compared to 
Vehicle, Student’s t-test). K. Collagen percent quantification from Trichrome staining. Data represent mean values ± 
SEM (n=4-8 mice per group, *, p<0.05 compared to Vehicle, Student’s t-test). 
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Figure 13 Anti-fibrotic activity of a FIEL1 small molecule inhibitor in vivo  
A. C57BL/6J mice were administered i.t. with bleomycin (0.05U). 10 days later, compound BC-1485 was given to 
mice through the drinking water with an estimated dose of 2 or 10mg/kg/d. Mice were euthanized an additional 10 
days later, and lungs were lavaged with saline, harvested, and then homogenized.  B-C. Lavage proteins and total cell 
count were measured. Data represent mean values ± SEM (n=6-9 mice per group, *, p<0.05 compared to Vehicle, 
Student’s t-test).  D. Lavage cells were also processed for Wright-Giemsa stain; Lavage macrophages, neutrophils, 
and lymphocytes were counted and graphed. Data represent mean values ± SEM (n=6-9 mice per group, *, p<0.05 
compared to Vehicle, Student’s t-test).  E. Survival studies of mice that were given bleomycin and compound 
treatments. Mice were carefully monitored over time; moribund, pre-terminal animals were immediately euthanized 
and recorded as deceased. Kaplan-Meier survival curves were generated using SPSS software (n = 12-16 mice per 
group; *, p<0.05 compared to Vehicle, Log Rank test p<0.05). Vehicle: n=16, BC-1485 (2mg/kg/d): n=12, BC-1485 
(10mg/kg/d): n=12.  F. Hydroxyproline content were measured in lungs from 10d after bleomycin challenge. Data 
represent mean values ± SEM (n=6-9 mice per group, *, p<0.05 compared to Vehicle, Student’s t-test).  G. H&E and 
Trichrome staining were performed on lung samples from A. Original magnification, x20. Bar indicates 100 μm.  H. 
Collagen percent quantification from Trichrome staining. Data represent mean values ± SEM (n=6-9 mice per group, 
*, p<0.05 compared to Vehicle, Student’s t-test).   I. Mice lungs were isolated and assayed for PIAS4 and FIEL1 
immunoblotting. 
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2.1.10  Discussion 
TGF signaling plays a key role in the pathogenesis of tissue fibrosis (169). PIAS4 
suppresses the TGFβ pathway, in part, by SUMOylating SMAD3 and causing its nuclear export 
(22, 23, 161). Here we show that FIEL1 appears to promote TGF signaling and fibrosis by 
destabilizing PIAS4. Our data not only authenticate FIEL1 as a bona-fide E3 ligase, but also show 
that it triggers the site-directed ubiquitination and degradation of PIAS4 leading to exacerbated 
fibrotic signaling. One evidence to support that FIEL1 regulates PIAS4 protein stability is that 
MRC5 cells ectopically expressing FIEL1 increased PIAS4 mRNA level (Figure 3K). This is a 
common compensatory mechanism used by cells to rescue protein loss. As an E3 ligase, it is quite 
possible that FIEL1 targets many other proteins for ubiquitination and degradation. We measured 
protein abundance of several pro-TGF and anti-TGF proteins such as TGFR1, TGFR2, 
SMAD7, and SMURF1 in cell lysates with ectopically expressing FIEL1 (Figure 3I). However, 
the absence of any difference in their protein levels suggests that it is plausible that FIEL1 regulates 
SMAD signaling through PIAS4. However, we do not rule out the possibility that other proteins 
could also play a role linking FIEL1 to the SMAD pathway, given that all E3 ligases are known to 
target many substrates at the same time. We believe that the FIEL1/PIAS4 pathway is relevant in 
both epithelial cells and fibroblasts as we have tested this pathway in both cell types (Figure 3C, 
I, L, Figure 5B-I), which matches the current understanding that both epithelial cells and 
fibroblasts may be involved in the formation of fibrosis (143, 158, 170, 171). However, future 
studies are needed to identify which cell type is more involved in the FIEL1/PIAS4 pathway.   
We found that PKCζ is a regulator of PIAS4 protein stability and described a mechanism 
of PIAS4 basal protein turnover controlled constitutively by FIEL1. This provides an internal 
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checkpoint for the cell to shut off the anti-fibrotic pathway, a mechanism that TGF hijacks to 
shut down PIAS4 and promote fibrosis. Moreover, we found that GSK3 is another regulator of 
PIAS4 protein stability through the phosphorylation of FIEL1. There appears to be a new “double 
locking” molecular interplay between FIEL1 and PIAS4. Specifically, both the P779 and GSK3 
phosphorylated T783 residues within FIEL1 are required for PIAS4 binding; both the Q21 and 
PKCζ phosphorylated S18 residues within PIAS4 are required for FIEL1 binding. We believe that 
the FIEL1/PIAS4 molecular interplay is based on two pairs of interactions between pT783-Q21 
and P779-pS18 (Figure 4Q-R). In this model, both PKCζ and GSK3 up-regulate TGFβ signaling, 
which correlates well with several previous studies (172-174).  
We observed a naturally occurring amino acid variant in FIEL1 (P779L). This 
hypomorphic polymorphism exhibited a significant decrease in PIAS4 interaction. Thus, its 
expression did not decrease PIAS4 protein levels or half-life. We further characterized a naturally 
occurring amino acid variant (rs113140862) in FIEL1 (I514V). This polymorphism, conversely, 
exhibited hypermorphism as shown by accelerated PIAS4 degradation and shortened protein half-
life (Figure 8K-L). FIEL1P779L may be an important and protective polymorphism in IPF, while 
FIEL1I514V may be a susceptible polymorphism in IPF via exacerbated TGF signaling. Further 
prospective studies in large IPF cohorts are required in order to validate this observation. 
 The FIEL1 HECT domain served as the mechanistic centerpiece and structural basis for 
designing first-in-class FIEL1 inhibitors. We had previously used a similar approach to design the 
inhibitors for the pro-inflammatory protein FBXO3 (175, 176). Since the FIEL1 inhibitor also 
docks at the same region within the HECT domain as the substrate PIAS4, the inhibitor works by 
disrupting the FIEL1/PIAS4 interaction. By adding an alaninamide group to the BC-1480 
backbone we generated BC-1485, which improved its activity >100 fold. BC-1485 optimally 
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interacts with FIEL1, exerts robust anti-fibrotic activity by stabilizing PIAS4, and inhibits TGF 
signaling in both human MRC5 cells and a murine model of pulmonary fibrosis. The effectiveness 
of this inhibitor underscores the physiological importance of the FIEL1/PIAS4 pathway in 
regulating TGF signaling. Currently, there is no cure for IPF, despite extensive research. Many 
failed clinical trials suggest the complexity of TGF signaling and lack of an “authentic” drug 
target (177-180). Our study may be highly clinically relevant because subjects with IPF exhibited 
a significant increase in FIEL1 and decrease in PIAS4 protein. Further, FIEL1 threonine 
phosphorylation is also significantly increased in IPF lung tissue, which is positively associated 
with PIAS4 binding (Figure 7G). Interestingly, only the shorter isoform of KIAA0317 (789aa, 
FIEL1) is significantly increased in IPF lung tissue; our FIEL1 inhibitor design was also based on 
the cavity within FIEL1. The longer form of KIAA0317 lacks the drug binding cavity which 
renders FIEL1 inhibitor ineffective (data not shown). Moreover, in all of the cell lines (MLE, 293T, 
and HeLa) and tissues tested here, we found very little, if any, longer isoform of KIAA0317 protein 
present (Figure 3M, data not shown). Thus, FIEL1 may be physiologically relevant in TGF 
signaling and IPF. Indeed, both FIEL1 knockdown and inhibition significantly ameliorates tissue 
fibrosis coupled with a very dramatic decrease in collagen level in a bleomycin model (Figure 
10K, Figure 12K, Figure 13H). These results suggest that FIEL1 may be a promising new 
therapeutic target for fibrotic diseases such as IPF. 
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2.1.12 Materials and Methods 
 Materials  
Sources of the murine lung epithelial (MLE) and 293T cell lines were described previously 
(181, 182). MRC5 cells were from ATCC.  Purified ubiquitin, E1, E2, MG132, Leupeptin, and 
cyclohexamide (CHX) were purchased from Calbiochem. Mouse monoclonal V5 antibody, the 
pcDNA3.1D cloning kit, E. coli Top10 One Shot competent cells, the pENTR Directional TOPO 
cloning kits, and Gateway mammalian expression system were from Invitrogen. The HECT 
domain E3 ligase cDNA, scramble shRNA, FIEL1, PKCζ, and GSK3 shRNA sets were purchased 
from OpenBiosystems. Nucleofector transfection kits were from Amaxa. The lentiviral packaging 
system and cobalt beads were from Clontech.  Immobilized protein A/G beads were from Pierce. 
In vitro transcription and translation (TnT) kits were from Promega. Cignal SMAD Reporter 
luciferase Kit (CCS-017L) and mRNA isolation kit were from Qiagen. Complete protease 
inhibitors were from Roche. KIAA0317 antibodies were from Sigma, Antibody Verify, and Santa 
Cruz. PIAS and GSK3 antibodies were from Cell Signaling and Santa Cruz. CXCL1 and IL6 
mouse ELISA kits and TGF protein were from R&D Systems. Peptides were custom synthesized 
from CHI Scientific. DNA sequencing was performed at Genewiz. All small molecule compound 
analysis was performed by the University of Pittsburgh Mass Spectrometry and NMR facility. 
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 Human Samples  
This study was approved by the University of Pittsburgh Institutional Review Board. Lung 
tissues were from the University of Pittsburgh lung transplant tissue bank. Lung tissues from IPF 
patients were obtained from excess pathologic tissues after lung transplantation under a protocol 
approved by the University of Pittsburgh Institutional Review Board. Normal lung tissues were 
obtained from donor lungs that were not suitable for patient use and provided by the Center for 
Organ Recovery and Education (CORE). The CORE lungs were only used if there were no 
considerable lung abnormalities based on high resolution CT scan. Multiple small sections of the 
parenchyma were collected and immediately frozen at -80oC for future use. Tissue lysates were 
used for the western blot analysis.  
 Cell culture  
MLE cells were cultured in Dulbecco’s Modified Eagle Medium-F12 (Gibco) 
supplemented with 10% fetal bovine serum (DMEM-F12-10). 293T cells were cultured in 
Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (DMEM-
10). MRC5 cells were cultured in Eagle's Minimum Essential Medium (Gibco) supplemented with 
10% fetal bovine serum (EMEM-10). For protein expression in MLE cells, nucleofection was used 
following Amaxa’s protocol. For protein overexpression in 293T cells, Fugene6HD transfection 
reagents were used following the manufacturer’s protocol. For protein expression in MRC5 cells, 
MRC-5 Cell Avalanche™ Transfection Reagent was used following the manufacturer’s protocol. 
Cells were treated with TGF at 0-2 ng/ml for 0-18h. For FIEL1, PKCζ, or GSK3 knockdown 
studies in cells, scramble shRNA, FIEL1, PKCζ, or GSK3 shRNA were used to transfect cells for 
48h. For drug treatment, compounds were solubilized in DMSO before being added to the cells 
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for up to 18 h. Cell lysates were prepared by brief sonication in 150 mM NaCl, 50 mM Tris, 1.0 
mM EDTA, 2 mM dithiothreitol, 0.025% sodium azide, and 1 mM phenylmethylsulfonyl fluoride 
(Buffer A) at 4°C. For half-life study, MLE cells were exposed to cycloheximide (40g/ml) in a 
time dependent manner for up to 8h. Cells were then collected and immunoblotted. 
 In vitro protein binding assays 
 PIAS4 protein was immunoprecipitated from 1mg cell lysate using PIAS4 antibody (goat) 
and coupled to protein A/G agarose resin. PIAS4 beads were then incubated with in vitro 
synthesized products (50μl) expressing V5-FIEL1 mutants. After washing, the proteins were 
eluted and processed for V5-FIEL1 immunoblotting. Similarly, FIEL1 was immunoprecipitated 
from 1mg cell lysate using FIEL1 antibody (rabbit) and coupled to protein A/G agarose resin. 
FIEL1 beads were then incubated with in vitro synthesized products (50μL) expressing V5-PIAS4 
mutants. After washing, the proteins were eluted and processed for V5-PIAS4 immunoblotting.  
 In vitro peptide binding assays  
Biotin labeled peptides were first coupled to streptavidin agarose beads for 1h. Beads were 
then incubated with in vitro synthesized FIEL1 or PIAS4 for 18h. After washing, proteins were 
eluted and processed for FIEL1 or PIAS4 immunoblotting. 
 In vitro drug binding assays  
FIEL1 protein was HIS-purified from FIEL1 expressed in 293T cells using Talon metal 
affinity resin. Resins were then extensively washed prior to exposure to BC-1480 or BC-1485 at 
different concentrations (10-4 to 100 M). Purified recombinant PIAS4 protein was then incubated 
with drug-bound FIEL1 resins overnight. Resins were washed, and proteins were eluted and 
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resolved on SDS-PAGE. The relative amounts of PIAS4 detected in the pull-downs were 
normalized to loading and quantified. 
 In vitro ubiquitin conjugation assays 
The assay was performed in a volume of 20 l containing 50 mM Tris pH 7.6, 5 mM 
MgCl2, 0.6 mM DTT, 2 mM ATP, 400 μM MG132, 50 nM Ubiquitin activating enzyme, 0.5 μM 
M UbcH5, 0.5 μM UbcH7, 2 μM ubiquitin, and 1 M ubiquitin aldehyde. TnT Coupled 
Reticulocyte in vitro synthesized FIEL1-V5 and PIAS4-V5 proteins were purified via Talon metal 
affinity resin, and reaction products were processed for V5 immunoblotting. 
 In vitro kinase assays 
 The assays were performed by combining 50 mM Tris pH 7.6, 100 mM MgCl2, 25 mM β-
Glycerolphosphate, and 5 mg/mL BSA, bringing them to a total volume of 25 μL using 
combinations of 0.5 mM ATP, 0.2 μCi γ-32P ATP (Perkin Elmer), 500 nM recombinant Aurora 
B (Calbiochem), either 500 nM of recombinant PKCζ (Enzo) or 500 nM of recombinant GSK3β 
(Enzo), and V5-tagged PIAS4 or V5-tagged FIEL1 synthesized via TnT in vitro kits (Promega) 
and purifying them by HIS pulldown. Reaction products were incubated at 37°C for 2 hours, 
resolved by SDS-PAGE, and processed for autoradiography either by using Personal Molecular 
Imager (BioRad) or immunoblotting for V5 to visualize substrate input. 
 Hydroxyproline Assay  
Murine lungs were dried and weighed prior to digestion with HCl. Hydroxyproline 
concentrations were measured using previously described methods (183, 184). Hydroxyproline 
content was normalized to dry lung weight. 
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 SMAD reporter assay 
 Cignal SMAD Reporter luciferase plasmids were co-transfected with Empty, FIEL1, 
PIAS4, CON shRNA, or FIEL1 shRNA for 24-48h before TGF treatment for an additional 2-
18h. Cells were then collected and assayed for firefly and renilla luciferase activity. SMAD 
transcription activity was normalized by a firefly and renilla luciferase activity ratio. 
 Immunostaining 
MRC5 cells were seeded in 35mm MatTek glassbottom dishes before the plasmid 
transfection, inhibitor, and TGF treatment. Cells were washed with PBS and fixed with 4% 
paraformaldehyde for 20 min, then exposed to 2% BSA, 1:500 mouse -SMA, goat FN or SMAD 
antibodies, and 1:1000 Alexa 488 or Alexa 567 labeled goat anti rabbit, chicken anti-mouse or 
donkey anti-goat secondary antibodies sequentially for immunostaining. The nucleus was 
counterstained with DAPI and F-actin was counterstained with Alexa 488-Phalloidin. 
Immunofluorescent cell imaging was performed on a Nikon A1 confocal microscope using 405 
nm, 488 nm, or 567 nm wavelengths. All experiments were done with a 60 x oil differential 
interference contrast objective lens. 
 Molecular docking studies and compound design 
The docking experiments were carried out using software from Discovery Studio 3.5. A 
library containing 500,000 approved or experimental drugs was first used to screen potential 
ligands for FIEL1. FIEL1-HECT domain structural analysis revealed a major drug binding cavity 
within the c-terminal of the HECT domain. The binding cavity was adopted into the LibDock 
algorithm to screen for the optimum inhibitor. Based on the docking and best-fit analysis of 
suitable ligands, BC-1480 was used as the backbone to synthesize other compounds.  
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 BC-1485 synthesis 
A mixture of 4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamido)benzoic acid 
(66 mg, 0.2 mmol), N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (38.3 mg, 
0.2 mmol), and 1-Hydroxybenzotriazole hydrate (30.6 mg, 0.2 mmol) in DMF (3 mL) was stirred 
at room temperature for 10 minutes followed by the addition of 2-amino-N,N-
dimethylpropanamide hydrochloride (37 mg, 0.24 mmol), and triethylamine (24.3 mg, 0.24 
mmol).  The reaction was stirred at room temperature under nitrogen overnight and concentrated 
under vacuum.  The residue was dissolved in dichloromethane (1 mL) and purified by flash 
chromatography (silica gel, toluene/2-propanol/ammonia hydroxide=80/20/1, v/v/v) to obtain a 
sticky white solid.  It was suspended in 2N HCl (2 mL), sonicated for 10 min, and filtered.  The 
wet cake was washed with water several times and then dried by vacuum suction to obtain the 
desired product as a white powder (30 mg, 35% yield)): 1H NMR (400 MHz, DMSO-d6) δ 11.10 
(s, 1H), 10.97 (s, 1H), 10.47 (s, 1H), 8.38 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.41 (d, J 
= 9.2 Hz, 1H),7.28 (s, 1H), 7.12 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.4 Hz, 1H), 4.84 (m, 1H), 3.01 
(s, 3H), 2.81 (s, 3H), 1.22 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 172.30 (C=O), 
165.45 (C = O), 155.66 (C =O), 141.26, 133.95, 131.45, 130.10, 129.26, 129.13, 120.83, 118.62, 
108.74, 107.02, 45.55, 36.89, 35.71, 17.42; HRMS (ESI) calculated for C19H21N5O5S: 431.12634, 
found: 432.13353 [M+H]+.      
 RT–qPCR, cloning, and mutagenesis 
Total RNA was isolated and reverse transcription was performed followed by real-time 
quantitative PCR with SYBR Green qPCR mixture as described (185). All mutant PIAS4 and 
FIEL1 plasmid constructs were generated using PCR-based approaches and appropriate primers 
and subcloned into a pcDNA3.1D/V5-HIS vector. 
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 Lentivirus construction 
To generate lentivirus encoding FIEL1, Lenti-Plvx-FIEL1 plasmid was co-transfected with 
Lenti-X HTX packaging plasmids (Clontech) into 293T cells following the manufacturer’s 
instructions. 72 h later, virus was collected and concentrated using Lenti-X concentrator 
(Clontech). 
 Animal studies 
 All procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. For fibrosis studies, male C57BL/6J mice were deeply anesthetized using a 
ketamine/xylazine mixture, and the larynx was well visualized under a fiber optic light source 
before endotracheal intubation with a 3/400 24-gauge plastic catheter. 107 CFU of lentivirus 
encoding genes for Empty (E), FIEL1,  CON shRNA, or FIEL1 shRNA was given i.t. for 144 h 
before administration of bleomycin (0.02U~0.05U i.t.) for up to 21 days. Animals were euthanized 
and assayed for BAL protein, cell count, cytokines, and lung infiltrates. Survival studies were 
performed on mice that were given bleomycin (0.02U~0.05U i.t.). Mice were carefully monitored 
over time; moribund, preterminal animals were immediately euthanized and recorded as deceased. 
For time course drug studies, mice were deeply anesthetized as above. Bleomycin (0.05U i.t.) was 
given i.t. before BC-1480 or BC-1485 (~5mg/kg/d) was administered to the mice through their 
drinking water. 7-21d later, animals were euthanized and analyzed as above. For dose course drug 
studies, mice were deeply anesthetized as above. Bleomycin (0.05U i.t.) was given i.t. 10 days 
before BC-1485 (~2-10mg/kg/d) was administered to the mice through their drinking water. 
Another 10 days later, animals were euthanized and analyzed as above. 
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 Tissue Staining  
Murine lung samples were fixed in 10% neutral buffered formalin and embedded in 
paraffin and sectioned as previous described (18). Sections were stained with eosin and 
hematoxylin or Masson’s Trichrome. Images were acquired from 20X lens from random fields 
from each section. Fibrotic areas (blue channel) were isolated and determined by pixel area using 
ImageJ. 
 Statistical Analysis  
Statistical comparisons were performed through SPSS (IBM) with p<0.05 indicative of 
significance. Survival curves were generated through SPSS (IBM). 
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2.2 Kelch-like Protein 42 is a Pro-Fibrotic Ubiquitin E3 Ligase in Systemic Sclerosis 
Adapted from: Lear et al, Kelch-like protein 42 is a pro-fibrotic ubiquitin E3 ligase involved in in 
systemic sclerosis J Biol Chem. 2020 Feb 17. pii: jbc.AC119.012066. doi: 
10.1074/jbc.AC119.012066. [Epub ahead of print] PMID: 32071084, (186) 
 
The second part of aim one utilizes high-throughput techniques to screen for ubiquitin E3 
ligases affecting TGF-β signaling in systemic sclerosis. Some E3 ligase sub-families are comprised 
of 20 or fewer members, which makes ectopic over-expression and blotting a feasible screening 
technique (187). However, this method is inherently biased and may fail to capture more 
biologically relevant regulatory relationships from other un-screened E3 ligases. In the goal of 
fully capturing the mechanistic network of protein degradation underlying our disease model, we 
undertook unbiased high throughput screening assays, in which RNAi libraries targeted against 
ubiquitin E3 ligases were transfected to cells and assayed for their effect on the biology. In this 
study we investigated E3 ligases controlling TGF-β-dependent fibrotic signaling in SSc primary 
cells using automated microscopy of SMAD protein translocation as our high throughput 
screening. 
2.2.1 Study Overview 
Systemic scleroderma (SSc) is an autoimmune disease that affects over 2.5 million people 
globally. SSc results in dysfunctional connective tissues with excessive pro-fibrotic signaling, 
affecting skin, cardiovascular, and particularly lung tissue. Over three-quarters of individuals with 
SSc develop pulmonary fibrosis within 5 years, the main cause of SSc mortality. No approved 
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medicines to manage lung SSc currently exist. Recent research suggests that pro-fibrotic signaling 
by transforming growth factor β (TGF-β) is directly tied to SSc. Previous studies have also shown 
that ubiquitin E3 ligases potently control TGF-β signaling through the targeted degradation of key 
regulatory proteins; however, the roles of these ligases in SSc–TGF-β signaling remain unclear. 
Here, we utilized primary SSc patient lung cells for high-throughput screening of TGF-β signaling 
via high-content imaging of nuclear translocation of the pro-fibrotic transcription factor SMAD 
family member 2/3 (SMAD2/3). We screened an RNAi library targeting ubiquitin E3 ligases and 
observed that knockdown of the E3 ligase Kelch-like protein 42 (KLHL42) impairs TGF-β–
dependent pro-fibrotic signaling. KLHL42 knockdown reduced fibrotic tissue production and 
decreased TGF-β–mediated SMAD activation. Using unbiased ubiquitin proteomics, we identified 
phosphatase 2 regulatory subunit B'epsilon (PPP2R5e) as a KLHL42 substrate. Mechanistic 
experiments validated the ubiquitin-mediated control of PPP2R5e stability through KLHL42. 
PPP2R5e knockdown exacerbated TGF-β–mediated pro-fibrotic signaling, indicating a role for 
PPP2R5e in SSc. Our findings indicate that the KLHL42–PPP2R5e axis controls pro-fibrotic 
signaling in SSc lung fibroblasts. We propose that future studies could investigate whether 
chemical inhibition of KLHL42 may ameliorate pro-fibrotic signaling in SSc. 
2.2.2 Introduction 
Pulmonary fibrosis also manifests as a secondary feature of other diseases. Systemic 
sclerosis (SSc) or scleroderma is an auto-immune rheumatic disease affecting numerous tissue and 
organ systems and is characterized by the hardening and fibrosis of connective tissues. SSc 
displays prominently in the skin, through skin thickening or increased inflammation, but afflicts 
numerous organs including the lung, through SSc-associated interstitial lung disease (SSc-ILD) 
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 Scleroderma and Lung Fibrosis  
Due to the resulting pulmonary fibrosis and respiratory failure, SSc-ILD is  the primary 
cause of mortality for SSc patients (188, 189). Over three-quarters of SSc patients develop lung 
fibrosis within five years of diagnosis, with a subset developing progressive fibrotic disease (190). 
SSc-ILD is characterized by decreased respiratory function due to excessive hardening and fibrotic 
scarring due to extra-cellular matrix deposition in the lung. In combination with increased 
inflammatory response, epithelial injury, and cellular fibrotic transition, the fibrous production and 
collagen deposition in the lung interstitium leads to respiratory failure (191, 192). While new 
therapeutics are under evaluation, current treatment options that target the underlying 
pathophysiology are limited (193). Pro-fibrotic cellular signaling pathways are associated with the 
pathological remodeling of the lung leading to SSc-ILD, particularly that of the transforming 
growth factor beta pathway (TGF-β) (191). Research has shown TGF-β cytokine and downstream 
signaling to have stark causal effects on SSc disease models (194). 
 Ubiquitin-based Regulation of TGF-β signaling and a role within SSc-ILD  
TGF-β signaling proceeds through cellular recognition of the TGF-β cytokine by receptor 
complexes, and activation of the SMAD transcription factors (19). In canonical TGF-β/SMAD 
signal transduction, receptor-regulated SMAD2/3 protein is phosphorylated, complexed with co-
SMAD protein SMAD4, and shuttled to the nucleus whereupon pro-fibrotic transcription programs 
are activated (150). Nuclear localization and activating phosphorylation of SMAD transcription 
factors is essential for their signaling transduction, as numerous studies have shown inhibition of 
TGF-β signaling upon SMAD inactivation or nuclear exclusion (195-199). SMAD-dependent 
TGF-β signaling is tightly regulated through a variety of mechanisms, including post-translational 
protein degradation pathways (200, 201). 
56 
Protein degradation is an evolutionarily conserved process for regulating cellular protein 
longevity. Dysfunctional or aberrant protein degradation lay at the heart of many diseases, 
including fibrotic signaling in the lung. Ubiquitination is a crucial mechanism to regulate 
homeostasis in TGF-β signaling, as E3 ligase mediated degradation of the TGF-β receptors, and 
of the SMAD2/3 transcription factors help to dampen signaling (202, 203). However, 
ubiquitination is associated with pathologic fibrotic signaling; we and other groups have observed 
ubiquitination proteins affected multiple facets of fibrotic signaling in the lung, including the TGF-
β pathway (200, 204-206). Further, pro-fibrotic E3 ligases have also shown promise as targets for 
chemical inhibition to reduce deleterious fibrotic signaling (11, 141, 207, 208). To uncover new 
ubiquitin E3 ligases regulators of SSc fibrotic signaling, we utilized a high throughput imaging 
system to screen an RNAi library targeting E3 ligases for their effect on SMAD2/3 translocation 
in SSc lung fibroblasts 
Here we report the development of SSc lung fibroblasts as a screening tool for TGF-β 
activation based on SMAD2/3 nuclear translocation. We identified the ubiquitin E3 ligase 
KLHL42 as a pro-fibrotic mediator of TGF-β-SSc fibrotic signaling. KLHL42 was also shown to 
be a regulator of the stability of the Protein phosphatase 2A regulatory subunit PPP2R5e, and may 
regulate fibrotic signaling through the PP2A pathway. This study provides a new model of E3 
ligase control for fibrotic signaling in SSc lung disease. 
2.2.3 Development of SMAD2/3 translocation ratio screening assay 
The Systemic Sclerosis Center of Research Translation at the University of Pittsburgh 
works with the University of Pittsburgh Medical Center in the collection of tissue and explant 
samples from SSc patients for research. Through this Center, we utilized primary SSc patient lung 
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fibroblasts in culture as the basis for the HCS assay. Previous research demonstrated SSc cell 
cultures have increased TGF-β/SMAD signaling, and exhibit a strongly pro-fibrotic phenotype, 
which would make them ideal for RNAi loss-of-function screening (194, 209, 210). 
We first sought to validate SSc cells as a proper tool for high-content screening in 384-well 
plate format. Immunofluorescent studies of SSc lung fibroblasts (SSc cells) show responsiveness 
to TGF-β1 stimulation, leading to increased SMAD2/3 fluorescent signal in the nucleus (Figure 
14A). As a surrogate for overall fibrotic activity, we calculated a translocation ratio metric based 
on the nuclear SMAD2/3 immunostaining relative to cytoplasmic SMAD2/3. As SMAD 
transcription factors are shuttled to the nucleus for fibrotic signaling, we hypothesized that 
increased translocation ratio represented a more fibrotic response. The translocation ratio metric 
showed robust results through a titration of primary and secondary antibody for both baseline and 
TGF-β1-stimulated treatments (Figure 14B). We calculated a Z’-factor of 0.39 for this assay; this 
signal window proved adequate for screening (Figure 14C) (211). Silencing of an essential protein 
for the TGF-β/SMAD signaling process would result in a decreased translocation ratio (Figure 
14D). We then proceeded to screen for key ubiquitin e3 ligase modulators. 
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Figure 14 Assay development for Scleroderma lung fibroblasts   
(A) Immunofluorescence analysis of SSc lung fibroblasts for SMAD2/3 localization without and with short-term TGF-
β1 stimulation. (B) Optimization of assay conditions. Translocation ratios were calculated for titrations of primary 
and secondary antibody without and with TGF-β1 treatment. (C) Z’-factor calculation of SMAD2/3 translocation ratio 
with vehicle or TGF-β1 treatment (n = 64 wells per treatment). (D) Schematic of high-content assay to measure SMAD 
translocation assay with RNAi screen. SSc cells were treated with siRNA library in 384-well glass plates prior to 
TGF-β1 treatment, fixation and staining for SMAD2/3 and the nucleus. The nucleus was segmented based on nuclear 
counterstain signal, and the cytosolic region was defined through expansion of the nuclear segment to the threshold 
of SMAD2/3 fluorescent signal. The translocation ratio was defined as the ratio of nuclear to cytosolic signal, with 
higher signal suggestive of greater SMAD activation. Translocation Ratios were calculated with either Gen5 software 
(BioTek) or CellProfiler (65). Scale bar = 200µm (A). 
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2.2.4 The E3 ligase KLHL42 affects fibrotic signaling and SMAD activation in SSc 
With the validation of SSc fibroblasts as potential screening tool we sought to screen an 
esiRNA library (Sigma) against ubiquitination proteins for their effect on SMAD2/3 localization. 
Following siRNA knockdown and TGF-β1 stimulation, we collected and immunostained SSc 
fibroblasts for SMAD2/3 protein, conducted automated microscopy, and calculated a translocation 
ratio for each esiRNA (Figure 15A). We observed that most siRNA had little effect on changing 
translocation ratio relative to control esiRNA, but we observed hits whose silencing reduced the 
SMAD2/3 translocation ratio (Figure 15B). Given that knockdown of these targets resulted in a 
reduced translocation ratio (less nuclear SMAD2/3 protein), we hypothesized these ubiquitination 
proteins functioned as pro-fibrotic mediators. Of these hits, we observed the Kelch-like protein 42 
(KLHL42) to be a relatively under-characterized E3 ligase. Previous studies suggest KLHL42 
functioned as part of the Cullin-3 E3 ligase complex, in which KLHL42 functions as the key 
substrate-engaging protein to facilitate substrate ubiquitination (212, 213). However, the effect of 
KLHL42 on fibrotic signaling is unclear. We validated the initial screening data through confocal 
microscopy, as KLHL42 knockdown resulted in decreased SMAD2 activation upon TGF-β1. 
Knockdown of the TGF-βR1 receptor was used as a positive control, as loss of a major membrane 
receptor for TGF-β1 would impede TGF-β1-mediated activation of SMAD signaling (20) (Figure 
15C). KLHL42 knockdown significantly reduced production of fibrotic proteins such as 
fibronectin (Figure 15D-E). Further, we observed through immunoblot assay that KLHL42 
knockdown affects SMAD2 activation (Serine-465/467 phosphorylation), without changing total 
SMAD2 protein level suggesting the effect of KLHL42 occurs upstream in the signaling process 
and not through the degradation of SMAD2 protein (Figure 15F-G). These initial studies suggest 
KLHL42 may be a pro-fibrotic E3 ligase. 
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Figure 15. Depletion of Ubiquitin E3 ligase KLHL42 impairs TGF-β1-mediated fibrotic signaling  
(A) Screening of SSc fibroblasts with an esiRNA library targeted against ubiquitination proteins and E3 ligases by 
their effect on SMAD2/3 translocation ratio. (B) KLHL42 is a top hit from the SSc fibroblast translocation ratio screen. 
(C) qPCR analysis of KLHL42 knockdown by RNAi in SSc cells. Data and means ± SD of 3 independent experiments. 
(D) Knockdown of KLHL42 impairs SMAD2 nuclear translocation upon TGF-β1 treatment. (E) Immunoblot analysis 
of fibrotic products following KLHL42 Knockdown and prolonged TGF-β1 treatment. (F) Quantification of 
Fibronectin signal from (D), data and means ± SD of 3 independent experiments. (G) Immunoblot analysis of SMAD2 
activation following KLHL42 Knockdown and TGF-β1 treatment. (H) Quantification of phosphorylated SMAD2 
(Ser465/467) to total SMAD2 signal from (F), data and means ± SD of 4 independent experiments, *P ＜0.05, **P < 
0.01, ***P < 0.001, relative to controls or as indicated by one-way ANOVA with Tukey’s test of multiple comparisons 
(C) or two-tailed Student’s t-test (F, H). Scale bar = 20µm (D). 
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2.2.5 Unbiased determination of PPP2R5e as a putative KLHL42 substrate 
Ubiquitin E3 ligases primarily exert biologic function through the targeted ubiquitination 
and degradation of substrate proteins. To uncover the putative KLHL42 substrate we conducted 
unbiased ubiquitin proteomics mass spectrometry. We utilized LifeSensors Tandem Ubiquitin 
Binding Entities (TUBE) technology to purify ubiquitinated proteins from Control or KLHL42 
siRNA-treated SSc fibroblasts prior to mass spectrometry(214, 215) (Figure 16A). This technology 
uses multiple ubiquitin binding moieties linked to resin to affinity purify poly-ubiquitinated 
proteins from the lysate. Our hypothesis was that the putative KLHL42 substrate protein would be 
less ubiquitinated in KLHL42 siRNA-treated cells (KLHL42-depleted) relative to control. Less 
ubiquitinated substrate would prevent its precipitation with the TUBE pull-down and thus the 
candidate substrate would be less represented in the proteomics study. The study detected 2486 
total proteins, among which 155 were detected to be directly ubiquitinated (Figure 16B). Among 
the detected proteins, 291 unique proteins were detected in solely the KLHL42 knockdown, 464 
found only in the control sample, and 1731 were found in both samples (Figure 16C). We focused 
our analysis on proteins disproportionately represented on the Control siRNA treatment relative 
to KLHL42 siRNA, (464 proteins) as these proteins may have been less ubiquitinated when 
KLHL42 was silenced.  
We analyzed the sub-set of interest for any gene ontology terms that would be enriched 
relative to the total dataset using Gene Ontology enRIchment anaLysis and visuaLizAtion tool 
(216). We observed that several ontologies terms were significantly enriched in the Control siRNA 
treatment group relative to the total dataset (Figure 16D), including Protein Phosphorylation. This 
suggests that proteins disproportionately represented in the Control siRNA group (and potential 
KLHL42 substrates) may be involved with protein phosphorylation. Next, we investigated the set 
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of proteins detected to be directly ubiquitinated and only found in the Control siRNA treatment 
group for their relevance to the enriched gene ontologies (49 proteins). Of these proteins, the 
Protein phosphatase 2A regulatory subunit epsilon (PPP2R5e) was one of the proteins to be 
detected as directly ubiquitinated and is related to the process of protein phosphorylation. PPP2R5e 
functions as a regulatory subunit for Protein phosphatase 2A (PP2A)(217, 218). Intriguingly, PP2A 
has been implicated in regulation of fibrotic and TGF-β signaling, including SSc patient samples, 
suggesting PPP2R5e might function through this pathway in SSc and be a candidate substrate of 
KLHL42 (219-221). 
 
Figure 16 Ubiquitin Proteomics Screen Uncovers PPP2R5e as a potential KLHL42 substrate  
(A) Schematic of ubiquitin proteomics experiment to find KLHL42 substrates. SSc cells were treated with control or 
KLHL42 siRNA, treated with TGF-β1 prior to lysis and precipitation of ubiquitinated proteins with TUBE technology. 
Precipitated proteins were then subjected to mass spectrometry analysis _more needed. (B) Total proteins detected 
from ubiquitin proteomics. 155 unique proteins were detected to be directly ubiquitinated. (C) Overlap of unique 
proteins detected between control and KLHL42 siRNA treatments. Proteins in the Control KD-only set were 
considered potential substrates of KLHL42. (D) Proteins detected in the Control KD-only set were queried for gene 
ontology (GO) terms significantly enriched relative to the total dataset – several phosphorylation related terms were 
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significantly enriched. The protein phosphatase 2A regulatory subunit PPP2R5e was detected in the Control KD-only 
set and directly detected to be ubiquitinated, and is a candidate substrate of KLHL42. 
 
2.2.6 Detected PPP2R5e ubiquitination on Lysine-84 controls protein stability 
The ubiquitin proteomics assay on SSc fibroblasts detected that PPP2R5e was directly 
ubiquitinated, with the highest probability on lysine 84 (Figure 17A). Given the proximity of two 
other lysine residues to Lys-84, (Lys-86, Lys-89), there was a chance the detected ubiquitination 
was on these Lys site instead of Lys-84. Initial data analysis used a minimum localization 
probability of 0.75 to remove ambiguous sites. Previous proteomic studies have detected PPP2R5e 
to be ubiquitinated, with several other lysines corroborated by multiple studies (Lys-41, -346, -
449, -456)(222) (Figure 17B). To validate PPP2R5e as a ubiquitinated substrate from the 
proteomics assay, and to understand the ubiquitination mechanism on PPP2R5e, we constructed 
Lys to Arg mutants point mutants corresponding to detected ubiquitin conjugation sites and the 
results of our analysis (Lys-84, -86, -89). These constructs were expressed in cells and subjected 
to cycloheximide (CHX) chases to assay PPP2R5e protein stability (Figure 17C-F). We observed 
wild-type (WT) PPP2R5e showed instability by 8 hours of treatment, as did other lysine→arginine 
mutants except for K84R. The persistence of this mutant suggests K84 is a critical ubiquitination 
site for PPP2R5e stability.  
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Figure 17 Lysine 84 is a candidate ubiquitin acceptor site within PPP2R5e  
(A) PPP2R5e peptide identified by ubiquitin proteomics spectrometry, with high probability of ubiquitin remnant on 
Lys-84. (B) Schematic of detected ubiquitin modifications of PPP2R5e from post-translational modifications database 
(Phosphosite). Potentially modified lysine sites from this study (Lys-84, 86, 89) are included. (C) Immunoblot analysis 
of PPP2R5e-V5 protein and Lys-Arg mutants of suspected Lys sites from this study following cycloheximide (CHX) 
time course. Data of 3-5 independent experiments. (D) Immunoblot analysis of PPP2R5e-V5 protein and Lys-Arg 
mutants of Lys sites from other studies following cycloheximide (CHX) time course. Data of 3 independent 
experiments. *P ＜0.05; NS P>0.05, by F-test comparisons of nonlinear regression (one-phase decay), with the null 
hypothesis that rate constant k = 0 (C-D). 
2.2.7 KLHL42 binds PPP2R5e and facilitates in poly-ubiquitination and degradation 
Finally, to validate PPP2R5e as a bona-fide substrate of KLHL42, we investigated the 
mechanism of ubiquitination. Endogenous PPP2R5e immunoprecipitated from KLHL42 siRNA-
treated SSc fibroblasts showed less ubiquitination relative to control (Figure 18A). As an 
orthogonal approach, we ectopically expressed KLHL42-HA with HIS-tagged PPP2R5e prior to 
HIS pull-down and ubiquitin blotting. We observed that KLHL42 co-expression enhanced the 
poly-ubiquitin signal detected upon PPP2R5e precipitation (Figure 18B). As substrate poly-
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ubiquitination often signals for degradation, we probed if KLHL42 depletion affected PPP2R5e 
protein level, and observed KLHL42 knockdown led to significantly increased PPP2R5e signal 
relative to control (Figure 18C-D). We utilized other airway cells, BEAS-2B to ectopically express 
KLHL42, and we observed a significant dose-dependent decrease in PPP2R5e protein level 
(Figure 18E). Further, the critical lysine site PPP2R5e mutant, K84R, proved resistant to co-
expression with KLHL42 (Figure 18F-lane 4), relative to wild-type PPP2R5e (Figure 18F-lane 2), 
suggesting KLHL42 mediates the protein stability of PPP2R5e through Lys-84. These data suggest 
KLHL42 regulates PPP2R5e ubiquitination and protein stability. Finally, we investigated the role 
of PPP2R5e on fibrotic signaling in SSc cells (Figure 18G-I). We observed significantly decreased 
PPP2R5e protein upon siRNA treatment (Figure 18G-I). PPP2R5e KD resulted increased fibrotic 
production upon TGF-β1 treatment as measured by fibronectin protein relative to control siRNA 
(Figure 18G, H). These data suggest a role for the KLHL42-PPP2R5e degradation axis in fibrotic 
SSc signaling, as KLHL42 functions as a pro-fibrotic mediator degrading the PP2A-enhacing 
subunit PPP2R5e and resulting in increased fibrotic signaling (Figure 18G). 
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Figure 18 PPP2R5e is a KLHL42 substrate, and PPP2R5e affects TGF-β signaling in SSc 
(A) Immunoblot validation of ubiquitin proteomics assay; PPP2R5e protein was immunoprecipitated from SSc cells 
with control or KLHL42 siRNA treatments. (B) Immunoblot analysis of in vivo ubiquitination assay in SSc cells, as 
PPP2R5e-V5-HIS protein pull down was subjected to ubiquitin immunoblotting. (C) Immunoblot analysis of 
PPP2R5e level protein following control or KLHL42 siRNA treatments. (D) Densitometry of (C). Data and means ± 
SD of 3 independent experiments. (E) Immunoblot analysis of PPP2R5e protein following dose OE of KLHL42-V5 
plasmid. Data and means ± SD of 4 independent experiments. (F) Wild-type or K84R mutant PPP2R5e-V5 was 
expressed without or with co-expression of KLHL42-HA prior to blotting. (G) SSc cells were treated with PPP2R5e 
siRNA prior to 18hr TGF-β1 treatment and immunoblotting. (H-I) Densitometry of PPP2R5e (H) and Fibronectin (I) 
Protein without and with PPP2R5e knockdown and 18hr TGF-β1 treatment. Data and means ± SD of 3 independent 
experiments. (J) Schematic of proposed model, in which KLHL42 controls the ubiquitination and stability of 
PPP2R5e. PPP2R5e affects PP2A anti-fibrotic activity and downstream fibrotic signaling, leading KLHL42 to be a 
pro-fibrotic regulator in SSc. *P < 0.05, ***P < 0.001, by two-tailed Student’s t-test (D, H, I). **P ＜0.01, by ANOVA, 
with Dunnett’s test for multiple comparisons (E). 
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2.2.8 Discussion 
This study demonstrated SMAD2/3 immunostaining and automated microscopy as a 
screening tool for SSc cells. We calculated a translocation ratio of SMAD signal, as a surrogate 
for TGF-β pathway activity. This assay system is robust and shows good assay parameters with a 
Z-factor of 0.38. We observed that the knockdown of the e3 ligase Kelch-like protein 42 
(KLHL42) acutely affects SMAD localization and affects downstream TGF-β/fibrotic signaling, 
suggesting KLHL42 is a pro-fibrotic E3 ligase. To uncover potential KLHL42 substrates, we 
conducted unbiased mass spectrometry ubiquitin proteomics. Through bioinformatic analysis, the 
Protein phosphatase 2A regulatory subunit epsilon (PPP2R5e) emerged as a putative substrate, and 
we confirmed Lysine 84 as a critical site for PPP2R5e stability through unbiased proteomics and 
mutagenesis assay. Finally, we demonstrated that KLHL42 facilitates the poly-ubiquitination of 
PPP2R5e leading to its degradation, and that knockdown of PPP2R5e increases fibrotic protein 
production, potentially through the PP2A pathway.  
Phosphatase control of TGF-β signaling is a major mechanism in SSc. PP2A has been 
shown to play a direct role in regulating fibrotic signaling in primary SSc disease models. TGF-β 
treatment was observed to affect PP2A modulation of ERK1/2 activation in SSc fibroblast-
autocrine signaling (223). ERK activation has been directly implicated in dysfunction mechanics 
from SSc fibroblasts, and has been observed to be constitutively activated in fibroblasts (224, 225). 
Further, TGF-β treatment to dermal fibroblasts causes PP2A decrease in transcript/protein levels 
(220). The regulatory subunit PPP2R5e belongs to the B56/B’ family and modulates overall PP2A 
activity(217). PPP2R5e expression directly leads to more de-phosphorylation of PP2a substrates, 
suggesting PPP2R5e is an enhancer of PP2a activity (218). This is in line with our functional 
observations, as we observed PPP2R5e knockdown led to increased fibrotic signaling. Most 
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research has emphasized the role of PPP2R5e in neoplasia; this is the first study to suggest a 
function in SSc-ILD fibrotic signaling. More study is needed to characterize the exact molecular 
mechanisms of KLHL42 control of PPP2R5e and PP2A signaling.  
E3 ligases may play an important role in SSc-ILD signaling. Our previous studies have 
shown E3 ligases can potently control fibrotic signaling through the targeted degradation of key 
signal transduction (141). There is evidence that this paradigm can be extended to SSc-ILD fibrotic 
signaling as well (226, 227). Further, therapeutic targeting of ubiquitination may show promise in 
lung fibrotic diseases. Recent studies have shown inhibition of the E3 ligase Skp2 ameliorates 
fibrotic phenotypes in mice (228), and pharmacological inactivation of Cullin-type E3 ligases was 
protective in experimental pulmonary fibrosis models (207). Current therapeutic options in SSc-
ILD are limited, and ubiquitin E3 ligases may prove new targets for intervention. 
In conclusion, we utilized two unbiased approaches (siRNA screen and proteomics) to 
discover the ubiquitin e3 ligase KLHL42 as a mediator of fibrotic signaling in SSc-ILD, through 
the regulation of PPP2R5e ubiquitination and stability.  
2.2.9 Experimental procedures 
 Materials 
PPP2R5e cDNA was from DNASU HsCD00735088 (229). QuikChange II XL Site-
Directed Mutagenesis Kit (200521) was from Agilent. BEAS-2B (CRL-9609) were from ATCC. 
Anti-HA-Tag (6E2) (2367S), -Ubiquitin (P4D1) (3936,), -Phospho-Smad2 (Ser465/467) (138D4) 
(3108), and -Smad2/3 (D7G7) (8685) were from Cell Signaling Technology. 384-well glass 
bottom tissue culture plates (P384-1.5H-N) were from Cellvis. Antibiotic-Antimycotic 
Supplement (15240062), DMEM media (10569044), DMEM-F12 (11330057), FBS (26140079), 
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Pen-Strep (15140122) were from Gibco. Lullaby siRNA transfection reagent (LL7) was from 
OzBiosciences. hTGF-β1 (100-21) was from PeproTech. Anti-PPP2R5e (NBP1-79638,) was from 
Novus. TnT T7 Quick Coupled Transcription/Translation (L1170) was from Promega. Anti-
Fibronectin (EP5) (sc-8422,) and -PPP2R5e (A-11) (sc-376176) were from Santa Cruz. His-Tag 
Dynabeads (10103D) and Hoescht 33342 (H3570) were from Invitrogen. Anti-beta-Actin(AC-
15)(A5441) was from Sigma-Aldrich. Anti-Rabbit IgG, Alexa Fluor 488 (A-11008), anti-V5 Tag 
(R960), Protein A/G Magnetic Beads (88802), pcDNA3.1D TOPO Kit (K490001), were from 
Thermo Fisher. Primers for cloning and dsiRNA were from IDT. Custom siRNA library was from 
SigmaAldrich. Anti-Mouse IgG HRP (18-8817-30) and -Rabbit IgG HRP (18-8816-31) were from 
Rockland Immunochemicals. MG-132 (F1101) was from UBP BIO. Cytation5 was from BioTek. 
 
 Cell Culture  
Primary SSc patient lung fibroblasts were cultured in DMEM (Gibco) according  to 
previous technique (209, 230). Beas-2b cells were from ATCC and cultured in HITES media 
supplemented with 10% FBS. Cells were treated with cycloheximide (100μg/mL). Cells were 
transfected with Nucleofector 2b (Amaxa), XtremeGene HP Plasmid reagent (Roche), 
XtremeGene siRNA reagent (Roche) or Lullaby siRNA reagent (OzBiosciences). TGF-β1 
(Peprotech) was treated at 2ng/mL for indicated times in DMEM without FBS supplement. 
 
 siRNA Transfection 
Cells were seeded to a confluency of 50% before siRNA transfection. siRNA was 
transfected using Lullaby siRNA reagent (OzBiosciences). 1µg of siRNA was mixed with 10uL 
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of Lullaby reagent in 1/10th of final cell volume for 25min and added dropwise to cells. 
Knockdown proceeded for 48-72hr prior to cell collection and analysis. Sequences of dsiRNA 
used:  
KLHL42 siRNA 1:  
5'rCrUrUrArUrCrArGrUrGrUrCrCrUrUrGrArCrArArGrCrATT3'  
5'rArArUrGrCrUrUrGrUrCrArArGrGrArCrArCrUrGrArUrArArGrArA3 
KLHL42 siRNA 2: 
5'rArCrUrCrUrGrArArArUrUrArUrCrUrGrArUrArUrUrUrUGT-3'  
5'rArCrArArArArUrArUrCrArGrArUrArArUrUrUrCrArGrArGrUrGrU-3' 
PPP2R5e siRNA: 
5'rCrArGrCrUrArArUrUrArUrGrGrArUrArUrUrGrUrCrArUCT-3'  
5'rArGrArUrGrArCrArArUrArUrCrCrArUrArArUrUrArGrCrUrGrArC-3' 
TGFBR1 siRNA: 
5'rGrUrUrUrGrArArUrArUrUrCrUrCrArCrArUrCrArArGrCTT-3'  
5'rArArGrCrUrUrGrArUrGrUrGrArGrArArUrArUrUrCrArArArCrArU-3' 
 
 Immunoprecipitation and Immunoblotting  
Cells were lysed in immunoprecipitation (IP) buffer (50 mM Tris HCl pH 7.6, 150 mM 
NaCl, 0.25 % v/v Triton-X-100) for two hours at +4C with 1:100 dilution of immunoprecipitating 
antibody. Antibody was captured with Protein A/G beads (ThermoFisher) for an additional two 
hours. Immunoprecipitate was washed 3 times with IP buffer, and eluted in 1x Laemmli buffer at 
88°C for five minutes prior to immunoblotting analysis. Immunoprecipitated samples were blotted 
with Anti-Mouse or Anti-Rabbit TrueBlot (Rockland).  
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 Cloning 
Recombinant DNA constructs were prepared through PCR cloning techniques and cloned 
into pcDNA3.1D vector (ThermoFisher) unless otherwise noted. Point mutants were generated 
with QuickChange XL 2 site-directed mutagenesis kit (Aglient). All constructs were validated by 
DNA sequencing (Genewiz). 
 
 Ubiquitination siRNA SMAD translocation Screen  
Primary SSc patient lung fibroblast  cells were seeded in 384-well glass-bottom plates 
(Cellvis) (5,000 cells per well) and were transfected with MISSION esiRNA targeting 
ubiquitination proteins (E1, E2, E3 ligases etc.) (Sigma-Aldrich) using XtremeGene siRNA 
transfection reagent (Roche). Knockdown proceeded for 72 hours prior to TGF-β1 (Peprotech) 
(2ng/mL) stimulation for 1 hour. Cells were then fixed (4% paraformaldehyde), permeabilized 
(0.5% Triton-X-100) and stained for endogenous SMAD2/3 (Cell Signaling) followed by Goat 
anti-Rabbit Alexa Fluor 488 or 647 (Invitrogen) and nuclear counterstain with Hoescht 33342 
(Invitrogen). Fluorescent signal was imaged using Cytation5 (BioTek) or Image Express 
(Molecular Devices). SMAD2/3 Translocation Ratio (Nuclear to Cytosolic signal) was calculated 
and analyzed by either cell profiler (231) or Gen5 software (BioTek). 
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 Ubiquitin Proteomics 
Ubiquitin proteomics and TUBE experiment were conducted at LifeSensors (Malvern, 
USA). Experimental and Control samples were analyzed using biological duplicates. Usage of 
biological replicates allowed for better accounting of variability among each step of the mass 
spectrometry workflow (cell culture, sample preparation, analysis).  
Samples were spun down, and duplicate 22 ul volumes of each sample were mixed with 
SDS loading buffer. Samples were heated at 90°C for 5 min, and run on SDS-PAGE prior to 
Coomassie Blue staining. Remaining sample was run on a different gel, resulting in each sample 
being run on a total of 3 gel lanes. The lanes were excised, reduced with TCEP, alkylated with 
iodoacetamide, and digested with trypsin. Tryptic digests were analyzed using a 150 min LC run 
on a Thermo Q Exactive HF mass spectrometer. A 30 min blank was run between samples. 
Ubiquitin proteomics resulted in 4 RAW files, two each for KLHL42 siRNA treatment and 
control siRNA treatment. MaxQuant 1.6.2.3 was used to query MS data against the Uniprot human 
database (2018_10_01); 196,371 entries were specifically searched. First search peptide mass 
tolerance was set at 20ppm; main search peptide tolerance was set at 4.5 ppm. Fragment ion mass 
tolerance was set at 20ppm. Protein, peptide and site false discovery rate was set at 1%.  Full 
trypsin specificity was used to generate peptides, with a maximum of 3 missed cleavages 
permitted. Carabimidomethyl (C) was set as a fixed modification, with Acetyl (Protein N-term), 
Oxidation (M), and GlyGly (K) considered as variable modifications. 
Protein quantification was performed using Razor + unique peptides. Razor peptides are 
shared (non-unique) peptides assigned to the protein group with the most other peptides (Occam's 
razor principle). Quantitation was based on the sum of the peptide MS peak areas for the protein 
(Intensity), due to its increased accuracy compared to MS/MS count. To account that larger 
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proteins will generate more peptides, the intensity values were adjusted by normalizing against the 
number of theoretical peptides for each protein (iBAQ intensity). We then sorted (largest to 
smallest order) on the iBAQ values to determine which proteins are more abundant in a sample. 
Data were then analyzed via Gene Ontology enRIchment anaLysis and visuaLizAtion tool, 
querying the 464 proteins identified solely in the control siRNA treatments (and thus may have 
lost ubiquitination when KLHL42 was knocked-down) for their gene ontologies as previously 
described(216). The set of proteins detected to be directly ubiquitinated and only found in the 
Control siRNA treatment group (49 proteins) were manually inspected based on their relevance to 
the enriched gene ontologies, leading to the uncovering of PPP2R5e. 
 Confocal Microscopy 
SSc cells were seeded in 35-mm MatTek glass bottom dishes before siRNA knockdown 
and TGF-β1 treatment. Cells were washed with 1xPBS prior to fixation with 4% paraformaldehyde 
and permeabilization with 0.5% Triton-x100. Following blocking with 2%BSA in PBS, cells were 
exposed to SMAD2 primary antibody (1:500) overnight, and then 1:1,000 Alexa Fluor 488–
secondary antibodies for immunostaining. The nucleus was counterstained with Hoescht 33342. 
Cells were visualized with a Nikon A1 confocal microscope using 405 nm, 488 nm, or 567 nm 
wavelengths. All experiments were done with a 60× oil differential interference contrast objective 
lens. 
 Statistics 
All statistical tests were calculating using Graphpad Prism 8. P < 0.05 was used to indicate 
significance. Densitometry was calculated using ImageJ (NIH). 
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3.0 Ubiquitination in Innate Immunity and Inflammation 
Innate immunity is a critical mechanism for lung homeostasis and for host defense against 
infection. During respiratory infection, the pathogens are recognized, pro-inflammatory signaling 
is initiated, cytokine and other immune stimulated species are released, and cells extravasate into 
the alveolar space. In some cases, the inflammatory and immunological response is hyperactive, 
causing damage to the alveolar space itself, and often resulting in catastrophic loss of respiratory 
function. In this aim we explored the role of protein degradation along multiple steps of the 
inflammatory process during lung infection, inflammation, and injury, with the goal of identifying 
new molecular mechanism and new potential targets for chemical targeting. 
3.1 RING Finger E3 Ligase PPP1R11 Regulates TLR2 Signaling and Innate Immunity 
Adapted from: McKelvey, Lear, Dunn et al, RING Finger E3 Ligase PPP1R11 Regulates TLR2 
Signaling and Innate Immunity. eLife 2016;5:e18496 DOI: 10.7554/eLife.18496, (232) 
 
In our first sub-aim, we explored the proteolytic regulation of the pattern-recognition 
receptor, Toll-Like Receptor 2 (TLR2). Lower respiratory infection into the alveolar space results 
in the accumulation of pathogen-specific molecular patterns, known as PAMPs. These signatures 
are detected by pulmonary cells through Pattern Recognition Receptors such as TLR2. Receptors 
then initiate pro-inflammatory signaling to spur an immune response in response to the pathogen 
invasion. This project investigated the degradation of TLR2 by the RING E3 ligase PPP1R11, and 
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its effect on the ability to mount an inflammatory response during Gram positive bacterial 
infection. 
3.1.1 Study Overview 
Toll-like receptor 2 (TLR2) is a pattern recognition receptor that recognizes many types of 
PAMPs that originate from gram-positive bacteria. Here we describe a novel mechanism 
regulating TLR2 protein expression and subsequent cytokine release through the ubiquitination 
and degradation of the receptor in response to ligand stimulation.  We show a new mechanism in 
which an uncharacterized RING finger E3 ligase, PPP1R11, directly ubiquitinates TLR2 both in 
vitro and in vivo, which leads to TLR2 degradation and disruption of the signaling 
cascade.  Lentiviral gene transfer or knockdown of PPP1R11 in mouse lungs significantly affects 
lung inflammation and clearance of Staphylococcus aureus. There is a negative correlation 
between PPP1R11 and TLR2 levels in white blood cell samples isolated from patients with 
Staphylococcus aureus infections. These results suggest that PPP1R11 plays an important role in 
regulating innate immunity and gram-positive bacterial clearance by functioning, in part, through 
the ubiquitination and degradation of TLR2. 
3.1.2 Toll-Like Receptors in Innate Immunity 
The human toll-like receptor (TLR) family consists of ten family members (TLR1-
TLR10)(233). TLRs are single transmembrane pattern recognition receptors that recognize 
molecules derived from various pathogens, referred to as pathogen-associated molecular patterns 
(PAMPs)(234-238) . TLRs are highly conserved from invertebrates to mammals, and are essential 
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for mediating innate immunity and the production of cytokines in response to infectious agents 
(239). All TLRs share common structural features, including multiple leucine-rich repeats (LRR), 
a transmembrane domain, and a conserved cytoplasmic Toll−interleukin 1 receptor (IL-1R) 
domain (TIR domain)(233). Specifically, LRR motifs from individual TLRs provide ligand 
binding sites for diverse PAMPs, whereas the TIR domain interacts with several intracellular 
proteins such as MyD88, which is essential for the transduction of downstream signaling (240, 
241).  
 The Biologic Role of TLR2 
Within the TLR family, TLR2 possesses the unique ability to recognize glycolipids, 
lipopeptides, lipoproteins, and lipoteichoic acids from gram-positive bacteria.  Thus, TLR2 is the 
key element of innate immunity that defends against gram-positive bacteria (242). TLR2 is 
expressed not only in immune cells, but is also present in pulmonary alveoli and airway epithelial 
cells, suggesting that it plays a role in mucosal innate immunity and infection-induced lung injury 
(171, 243-245). Interestingly, TLR2 deficient mice are highly susceptible to S. aureus infection 
(246), and in humans, a loss-of-function TLR2 mutation has been linked to susceptibility to 
infectious and inflammatory diseases, faster disease progression, and a more severe course of 
sepsis in critically ill patients (247-250). These studies illustrate the protective role of TLR2 in 
response to inflammatory insults and infectious diseases. Therefore, TLR2 augmentation may be 
a novel therapeutic strategy in the fight against gram-positive infection. 
In this study, we characterize a previously undescribed RING finger E3 ligase family 
member, PPP1R11, and identify its role in regulating cytokine secretion through targeted TLR2 
protein ubiquitination and degradation. These studies describe a new molecular mechanism 
contributing to mucosal innate immunity. 
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3.1.3 TLR2 polyubiquitination is regulated by RING E3 ligase PPP1R11 
We first investigated TLR2 protein degradation using a transformed murine lung epithelial 
(MLE) cell line. MLE cells express high levels of TLR2 protein (Data not shown). Cells were 
stimulated with the TLR2 ligand, Pam3CSK4, and TLR2 protein levels decreased after 4 hours. 
However, co-treatment with the proteasomal inhibitor MG-132 preserved TLR2 protein levels, 
while treatment with the lysosomal inhibitor leupeptin did not. Further, cell lysates from these 
treatments were subjected to TLR2 immunoprecipitation and Ubiquitin immunoblotting. High 
molecular weight ubiquitin signals in TLR2 immunoprecipitate were detected only in cell lysates 
treated with MG-132 (Figure 19A).  Taken together, this suggests that the TLR2 ligand, 
Pam3CSK4, induces the polyubiquitination and subsequent degradation of TLR2 via the 
proteasome. We also investigated the type of ubiquitin linkage on TLR2 using a UbiCRest 
(Ubiquitin Chain Restriction Analysis) assay (114). Polyubiquitinated TLR2 was subjected to 
several deubiquitinating enzymes (DUB) that target specific ubiquitin linkages (Figure 20A). As 
shown in Figure 19, USP2, a DUB that non-specifically targets all ubiquitin linkages, completely 
reduced polyubiquitinated TLR2. We also observed a drastic decrease in TLR2 ubiquitination in 
the OTUB1 treated sample, which suggests that TLR2 ubiquitination is regulated in part through 
K48 ubiquitin linkage. We also observed K48-specific ubiquitin linkage of TLR2 following TLR2 
immunoprecipitation and immunoblotting (Figure 20B). MG-132 dramatically increased the half-
life of TLR2 (Figure 20C) and Ubiquitin overexpression drastically reduced TLR2 protein levels 
and half-life (Figure 20D, Figure 19C). These studies suggest that TLR2 protein degradation 
occurs in a ubiquitin-dependent manner. 
Next, we tested over fifty E3 ligases that might be involved in TLR2 degradation (Data not 
shown) and found that overexpression of PPP1R11 decreased TLR2 levels (Figure 21A). Ectopic 
79 
expression of PPP1R11 triggered TLR2 degradation in a dose dependent manner (Figure 19D) 
without affecting its mRNA levels (Figure 21B). Furthermore, ectopic PPP1R11 expression 
significantly decreased the half-life of TLR2 (Figure 19E), whereas PPP1R11 knockdown 
markedly increased its lifespan (Figure 19F, Figure 21C). Conversely, we observed no effect on 
TLR2 decay with the expression and silencing of fellow RING E3 ligase PCGF1 (Figure 21D-E). 
To confirm PPP1R11 as an authentic TLR2 target, we performed an in vitro ubiquitination assay 
using TLR2 as the substrate and observed polyubiquitination of TLR2 (Figure 19G). 
To investigate the in vivo relevance of the PPP1R11/TLR2 pathway, we assayed white 
blood cell (WBC) pellets for PPP1R11 and TLR2 expression in control and S. aureus-infected 
patients from our Acute Lung Injury Registry and Biospecimen Repository(251). Control patients 
were mechanically ventilated patients intubated for airway protection without clinical evidence of 
or risk factors for ARDS (Acute Respiratory Distress Syndrome), while S. aureus-infected patients 
had evidence of S. aureus in tracheal aspirates, blood, or both, and had evidence of or risk factors 
for ARDS. In control patients, we observed no correlation between PPP1R11 and TLR2 levels, 
but observed a significantly negative PPP1R11/TLR2 correlation in S. aureus-infected 
patients.  We interpret these data to suggest that during S. aureus infection, TLR2 levels may be 
attenuated in part by PPP1R11 expression. This study suggests that the PPP1R11/TLR2 pathway 
may be relevant in the innate immune response to S. aureus infection in patients (Figure 21F).  
RING finger E3 ligases utilize several unique residues, such as cysteine and histidine, to 
interact with zinc and form the two RING finger domains required for E3 ligase activity (252). 
They are characterized by the unique property of auto-ubiquitination (253, 254). We confirmed 
that PPP1R11 is an authentic ring finger E3 ligase by showing its ability to auto-ubiquitinate in 
the presence of ubiquitin, E1, and several different E2 conjugating enzymes (Figure 19H). We also 
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showed that several E2 conjugating enzymes such as UBE2R1 and UBE2D2 preferably interact 
with PPP1R11 in vitro (Figure 19I). Lastly, we showed that PPP1R11 interacts with endogenous 
UBE2D2 through cellular co-immunoprecipitation (Figure 19J).  We also selectively mutated 
several key residues of PPP1R11 putative RING finger (Figure 22A) and showed their loss-of-
function in inducing TLR2 degradation (Figure 22B). H126 was chosen as negative control since 
it is outside of the RING finger domains. The effect of PPP1R11 was specific to TLR2, as ectopic 
expression of PPP1R11 did not alter TLR3, TLR7, TLR8, or TLR9 protein levels (Figure 23). 
These experiments suggest that PPP1R11 is an authentic RING finger E3 ligase that specifically 
induces TLR2 ubiquitination and degradation. 
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Figure 19 TLR2 polyubiquitination is regulated by PPP1R11  
 
A. Murine lung epithelial (MLE) cells were treated with Pam3CSK4 with or without MG-132 or Leupeptin in a time-
dependent manner. Cells were collected and immunoblotted for TLR2 and Actin. Endogenous TLR2 was also 
immunoprecipitated and followed by Ubiquitin immunoblotting. B. MLE cells were pretreated with MG-132 for 18h 
to induce accumulation of polyubiquitinated TLR2 protein. Endogenous TLR2 was immunoprecipitated using TLR2 
antibody and protein A/G beads. After washing, TLR2 beads were then incubated with different DUBs before being 
assayed for ubiquitin immunoblotting. C. TLR2 protein half-life determination in MLE cells transfected with Empty 
plasmid or Ubiquitin plasmid. Cells were collected and immunoblotted for TLR2, HA, and Actin. Below the panel 
levels of each protein on immunoblots were quantified densitometrically (Normalized to time zero) and shown 
graphically. Data represent mean values ± SEM (n=3); *, p < 0.05, significant compared to Control, Student’s t-test. 
D. Immunoblots showing levels of TLR2 proteins, V5, and Actin after PPP1R11 or PCGF1 plasmid dose over-
expression. E-F. TLR2 protein half-life determination in MLE cells with empty or PPP1R11 plasmid expression (E); 
TLR2 protein half-life determination with Control or PPP1R11 siRNA expression (F). Below each panel levels of each 
protein on immunoblots were quantified densitometrically (Normalized to time zero) and shown graphically. Data 
represent mean values ± SEM (n=3); *, p < 0.05, significant compared to Control, Student’s t-test. G. In vitro 
ubiquitination assay. Purified E1 and E2 components were incubated with TLR2-V5, PPP1R11, and the full 
complement of ubiquitination reaction components for different lengths of time. H. In vitro ubiquitination assay. 
PPP1R11-V5 was incubated with purified E1, varying E2s, biotinylated ubiquitin, and the full complement of 
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ubiquitination reaction components. The reaction mixture was subjected to streptavidin pulldown prior to V5 
immunoblotting. I. PPP1R11 protein was immunoprecipitated from cell lysate using a PPP1R11 antibody and coupled 
to protein A/G beads. PPP1R11 beads were then incubated with in vitro synthesized products expressing V5‐tagged 
E2 conjugating enzymes. After washing, proteins were eluted and processed for V5 immunoblotting. J. Endogenous 
PPP1R11 was also immunoprecipitated and immunoblotted for UBE2D. 
 
 
 
Figure 20 TLR2 is regulated by Ubiquitination 
(A) Coomassie blue staining of UBICrest supernatant following DuB assay. Stars represent indicated Dub signal 
(Figure 1B). (B) TLR2 immunoprecipitation from MLE cells prior to immunoblotting for K48-specific ubiquitin 
linkages. (C) TLR2 protein half-life study with MG132 or Leupeptin. Below the panel levels of each protein on 
immunoblots were quantified densitometrically and shown graphically. Data represent mean values ± SEM (n = 3); 
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*p<0.05, significant compared to Control, Student’s t-test. (D) Immunoblots showing levels of TLR2 proteins and 
HA-Ubiquitin after ectopic Ubiquitin plasmid expression. 
 
 
 
Figure 21 The RING E3 ligase PPP1R11 regulates TLR2 stability  
(A) MLE cells were transfected with LacZ or one of the other 10 randomly selected Ring-finger E3 ligases. 18 hr 
later, cells were collected and immunobloted. (B) TLR2 mRNA levels from MLE cells transfected with increasing 
amounts of PPP1R11. (C) TLR2 protein half-life determination with CON siRNA or PPP1R11 siRNA expression. 
Next to the panel levels of each protein on immunoblots were quantified densitometrically (Normalized to Time zero) 
and shown graphically. The data represent mean values ± SEM (n = 3); *p<0.05, significant compared to Control, 
Student’s t-test (D) Half-life determination with PCGF1 expression and (E) PCGF1 silencing in MLE cells. Next to 
the panel levels of each protein on immunoblots were quantified densitometrically (Normalized to Time zero) and 
shown graphically. The data represent mean values ± SEM (n = 3); NS, p>0.05, not significant compared to Control, 
Student’s t-test (F) Correlation between TLR2 and PPP1R11 levels in white blood cell samples from control patients 
(n = 8) compared to S. aureus-infected patients (n = 9). 
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Figure 22 PPP1R11 is a non-canonical RING E3 ligase 
(A) Schematic of putative atypical RING domains within PPP1R11. Candidate cysteine and histidine residues are 
listed, as well as a non-candidate H126. (B) MLE cells were transfected with increasing amounts of plasmid 
encoding WT or mutant PPP1R11. 18 hr later, cells were collected and immunoblotted for TLR2. 
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Figure 23 PPP1R11 does not regulate the stability of other TLR receptors 
MLE cells were co-transfected with V5 tagged TLRs and increasing amounts of plasmid encoding PPP1R11. 18 hr 
later, cells were collected and immunoblotted for V5. 
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3.1.4 PPP1R11 regulates Pam3CSK4-induced TLR2 protein degradation and inflammation  
To further elucidate the PPP1R11/TLR2 pathway in cells, we treated MLE cells with the 
TLR2 ligand, Pam3CSK4. We observed a time-dependent increase in PPP1R11 protein levels and 
decrease in TLR2 protein levels with this treatment (Figure 24A). Further, cell lysates from these 
conditions were subjected to TLR2 immunoprecipitation, and high levels of PPP1R11 protein were 
detected in cells treated with Pam3CSK4 for 4 and 6 hours. PPP1R11/TLR2 association at these 
time points also reflects the highest degree of TLR2 protein loss (Figure 24A). We also examined 
the role of PPP1R11 in Pam3CSK4-induced TLR2 protein degradation, and upon ectopic 
expression of PPP1R11, we observed an accelerated decay of TLR2 protein with Pam3CSK4 
treatment (Figure 24B). Last, we performed PPP1R11 knockdown in MLE cells, and we observed 
stabilized TLR2 protein levels as well as less ubiquitination upon Pam3CSK4 treatment as 
compared to control siRNA (Figure 24C). TLR2 immunoprecipitation also showed protein 
ubiquitination beginning at 1 hour post Pam3CSK4 treatment, which is consistent with increased 
PPP1R11/TLR2 association (Figure 24A). These studies suggest that the TLR2 ligand, 
Pam3CSK4, induces TLR2 degradation, in part, through the ubiquitination of TLR2 by the E3 
ligase PPP1R11. 
We also generated a series of TLR2 lysine mutants to further characterize the mechanism 
of ubiquitin transfer to TLR2. Mutation of lysine 754 to arginine (K754R) within TLR2 resulted 
in its highest level of stability, a much extended half-life (Figure 25A), and resistance to 
Pam3CSK4-induced degradation (Figure 25B). K754R TLR2 is also resistant to in vitro 
ubiquitination and degradation during PPP1R11 co-expression (Figure 25C-D). We confirmed that 
the K754R mutant TLR2 is expressed and localized normally in cells (Figure 25E). This suggests 
that the extended stability of the TLR2 K754R mutant is due to its inability to be ubiquitinated by 
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PPP1R11 and that K754 is a potential PPP1R11 ubiquitination site within TLR2. Since 
Pam3CSK4 induces the TLR2 signaling pathway that leads to cytokine release, we hypothesized 
that by ubiquitinating TLR2, the E3 ligase PPP1R11 is able to suppress the TLR2 signaling 
pathway. Indeed, ectopic expression of PPP1R11 reduces both IL-6 and CXCL1 cytokines by 40-
50% upon Pam3CSK4 treatment (Figure 24D-E), whereas PPP1R11 knockdown significantly 
increased both IL-6 and CXCL1 cytokine release in MLE cells (Figure 24F-G). Cytokine release 
upon overexpression and knockdown of fellow RING E3 ligase Trim52 resulted in no significant 
difference relative to controls (Figure 25F-G). Finally, we embarked on gene editing experiments 
to confirm the regulatory role of PPP1R11 on TLR2 and cytokine release. Utilizing CRISPR-Cas9 
technology, we generated a 2 bp deletion in the first exon of Ppp1r11 in MLE cells leading to an 
immediate pre-mature stop codon. Following colony expansion, we assayed protein half-life and 
observed stabilized TLR2 half-life in the Ppp1r11 KO cells relative to control (Figure 26A). We 
also challenged PPP1R11 KO cells with PAM3CSK4, and observed increased IL-6 and CXCL1 
cytokine release relative to control cells (Figure 26B-C). From these observations we believe 
PPP1R11 suppresses TLR2-linked inflammatory signaling. 
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Figure 24 PPP1R11 regulates Pam3CSK4-induced TLR2 protein degradation and inflammation  
A.MLE cells were treated with Pam3CSK4 in a time-dependent manner. Cells were collected and immunoblotted for 
PPP1R11, TLR2, and Actin. Endogenous TLR2 was also immunoprecipitated and immunoblotted for PPP1R11. B. 
MLE cells were transfected with either empty or PPP1R11 plasmid. 24h later, cells were exposed to Pam3CSK4 in a 
time-dependent manner. Cells were collected and immunoblotted for V5, TLR2, and Actin. C. MLE cells were 
transfected with either control or PPP1R11 siRNA. 48h later, cells were exposed to Pam3CSK4 in a time-dependent 
manner. Cells were collected and immunoblotted for V5, TLR2, and Actin. Endogenous TLR2 was also 
immunoprecipitated and followed by ubiquitin immunoblotting. D-E. MLE cells were transfected with either empty, 
PPP1R11, or TRIM52 plasmid. 24h later, cells were exposed to Pam3CSK4 in a time-dependent manner. Cell media 
was then collected and assayed for IL-6 and CXCL1 (Data represent mean values ± SEM n=4; *, p < 0.05, significant 
compared to Control, Student’s t-test). F-G. MLE cells were transfected with either control or PPP1R11 siRNA. 48h 
later, cells were exposed to Pam3CSK4 in a time-dependent manner. Cell media was then collected and assayed for 
IL-6 and CXCL1 (Data represent mean values ± SEM n=4; *, p < 0.05, significant compared to Control, Student’s t-
test). 
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Figure 25 TLR2 ubquitination is regulated through Lysine 754 
(A) Half-life study of WT and lysine mutant TLR2 in MLE cells. (B) MLE cells were transfected with WT or mutant 
TLR2 before Pam3CSK4 treatment. Cells were then immunoblotted for V5-TLR2. (C) In vitro ubiquitination assay 
using WT or K754R TLR2 as the substrate. (D) MLE cells were co-transfected with WT or TLR2 lysine mutants with 
or without PPP1R11. Cells were then collected and assayed for immunoblotting. (E) V5 tagged WT and K754R TLR2 
were transfected in MLE cells. 18 hr later, cells were fixed, permeabilized, immunostained for V5 (Green). The 
nucleus was counterstained with DAPI, and F-actin was counterstained with Alexa 488-Phalloidin. (F–G) MLE cells 
were transfected with either control or Trim52 siRNA. 72 hr later, cells were exposed to Pam3CSK4 in a time-
dependent manner. Cell media was then collected and assayed for IL-6 and CXCL1 (Data represent mean values ± 
SEM n = 3; NS, p>0.05, not significant compared to Control, Student’s t-test). 
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Figure 26 Ppp1r11 KO cells rescue TLR2 stability and function 
 
(A) Half-life study of TLR2 in Ppp1r11 CRISPR KO MLE cells and Ctrl MLE cells. The levels of each protein on 
immunoblots were quantified densitometrically (Normalized to Time zero) and shown graphically. The data represent 
mean values ± SEM (n = 3); *p<0.05, significant compared to Control, Student’s t-test. (B–C) Ppp1r11 KO and control 
cells were exposed to Pam3CSK4 in a time-dependent manner. Cell media was then collected and assayed for IL-6 
and CXCL1 (Data represent mean values ± SEM n = 3; *p<0.05, significant compared to Control, Student’s t-test). 
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3.1.5 PPP1R11 gene transfer reduces lung inflammation and decreases bacterial clearance 
To further characterize the role of PPP1R11 in TLR2-mediated infection, mice were 
infected with an empty lentivirus or lentivirus encoding PPP1R11. Mice were then challenged with 
Staphylococcus aureus (intratracheally, 10^8 CFU). S. aureus, a gram-positive bacterium, is a 
significant contributor to nosocomial pneumonia, sepsis-associated acute lung injury (ALI), and 
acute respiratory distress syndrome (ARDS)(46, 255).  Mice were euthanized before analysis of 
lung inflammation and systemic bacterial loads. PPP1R11 gene transfer significantly reduced lung 
inflammation shown by reduced lavage cytokines, protein concentrations, cell counts, and cell 
infiltrates (Figure 27A, B, C, D, E, and L). However, there were significantly higher bacterial loads 
in the lung, lavage fluid, blood, and liver (Figure 27F, G, H, and I), and there was a trend towards 
an increase in the spleen and kidney (Figure 27J and K). We also showed that in mice infected 
with S. aureus, PPP1R11 expression in the lung effectively reduced TLR2 protein levels (Figure 
27M). 
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Figure 27 PPP1R11 gene transfer in the lung reduces lung inflammation and decreases bacterial clearance 
Lenti-Empty or Lenti-PPP1R11 (107 PFU/mouse) was administered i.t. to C57BL/6J mice for 144h; mice were then 
infected i.t. with S. aureus (108 CFU). Mice were euthanized after 18h, and lungs were lavaged with saline, harvested, 
and then homogenized. Blood, liver, spleen, and kidney were also harvested and homogenized. A-E and G. Lavage 
cytokines, BAL protein, BAL cell counts, and BAL bacterial counts were measured. Data represent mean values ± 
SEM (n=8 mice per group; p < 0.05, significant compared to Control, Student’s t-test).  F and H-K. Lung, blood, liver, 
spleen, and kidney bacterial counts were measured. Data represent mean values ± SEM (n=8 mice per group; p < 0.05, 
significant compared to Control, Student’s t-test). L. H&E staining was performed on lung samples. Original 
magnification, 20X. Bar indicates 100 μm. M. Mice lungs were isolated and assayed for TLR2, PPP1R11, and Actin 
immunoblotting. 
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3.1.6 PPP1R11 knockdown induces lung inflammation and increases bacterial clearance 
To further confirm that PPP1R11 suppresses an inflammatory response through TLR2 in 
vivo, mice were first infected with lentivirus encoding control shRNA or Ppp1r11 shRNA and then 
challenged with S. aureus (intratracheally, 2.5*10^7 CFU).  PPP1R11 knockdown significantly 
increased lavage cytokines, protein concentrations, cell counts, and cell infiltrates (Figure 28A, B, 
C, D, E, and J). Interestingly, increased lung inflammation further cleared bacterial loads in the 
lavage fluids, lung, and blood (Figure 28F, G, and H), and there was a trend towards decreased 
bacterial loads in the liver (Figure 28I). We also showed that in mice infected with S. aureus, 
PPP1R11 knockdown effectively increased TLR2 protein levels in lung (Figure 28K). Taken 
together, these results suggest that PPP1R11 is a negative regulator of TLR2 signaling and 
inflammatory cytokine release, which mediates the clearance of S. aureus after acute infection. 
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Figure 28 PPP1R11 knockdown induces lung inflammation and increases bacterial clearance 
 
Lenti-control shRNA or Lenti-PPP1R11 shRNA (107 PFU/mouse) was administered i.t. to C57BL/6J mice for 144h; 
mice were then infected i.t. with S. aureus (2.5*107 CFU). Mice were euthanized after 18h, and lungs were lavaged 
with saline, harvested, and then homogenized. Blood, liver, spleen, and kidney were also harvested and homogenized. 
A-F. Lavage cytokines, BAL protein, BAL cell counts, and BAL bacterial counts were measured. Data represent mean 
values ± SEM (n=8 mice per group; p < 0.05, significant compared to Control, Student’s t-test). G-I. Lung, blood, and 
liver bacterial counts were measured. Data represent mean values ± SEM (n=8 mice per group; p < 0.05, significant 
compared to Control, Student’s t-test). J. H&E staining was performed on lung samples. Original magnification, 20X. 
Bar indicates 100 μm. K. Mice lungs were isolated and assayed for TLR2, PPP1R11, and Actin immunoblotting.  
3.1.7 Discussion 
Pattern recognition receptors play a critical role in mucosal immunity by sensing PAMPs 
from invading pathogens and initiating cellular responses to eliminate those pathogens.  Here we 
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show a novel mechanism by which the previously unrecognized RING finger E3 ligase, PPP1R11, 
attenuates TLR2 signaling in response to S. aureus infection by targeting TLR2 for proteasomal 
degradation.  PPP1R11 (Protein Phosphatase 1 Regulatory Subunit 11) was originally described 
to interact with and inhibit protein phosphatase 1 activity (256) . It also has another name, TcTex5 
(T-Complex-Associated-Testis-Expressed 5), and it was implied that mutation of TcTex5 is 
associated with a mouse sperm motility abnormality in sterile t-haplotype mutant mice (257, 258). 
However, its E3 ligase activity has never been described. Canonical RING finger domains contain 
the consensus sequence C-X2-C-X[9-39]-C-X[1-3]-H-X[2-3]-C-X2-C-X[4-48]-C-X2-C, where both 
cysteine and histidine residues are involved in zinc coordination(113). However, we believe that 
PPP1R11 has a non-canonical RING finger domain with all the characteristics of a Ring finger E3 
ligase (Figure 19G, H, I, Figure 22A). We show relative specificity of TLR2 targeting by 
PPP1R11, as none of the other TLRs tested were degraded by PPP1R11 expression (Figure 23). 
However, it is possible that other E3 ligases target TLR2 for ubiquitination as this phenomenon 
has been well described with other substrates, e.g. SCF E3 ligase subunits Fbxw1, Fbxw7, Fbxw8, 
Fbxl1, Fbxo4, and Fbxo31 are all capable of ubiquitinating cyclin D1(259). We do not rule out 
other RING finger E3 ligase or even other E3 ligase family members to potentially target TLR2 
for ubiquitination, however, our data suggest that PPP1R11 targets TLR2 for proteasomal 
degradation via ubiquitination.  
Targeted TLR2 degradation by PPP1R11 may act as a negative feedback mechanism in the 
lung to prevent a harmful, excessive inflammatory response that causes severe lung injury.  We 
have observed similar function of other E3 ligase proteins such as Fbxl19 in acute lung injury and 
pneumonia (260). Indeed, we showed that treatment of MLE cells with TLR2 ligand, Pam3CSK4, 
up-regulates PPP1R11 protein levels and gradually reduces TLR2 protein levels at about 4-6hr 
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(Figure 24A). We also showed that ectopic expression of PPP1R11 in MLE cells significantly 
reduced Pam3CSK4-induced cytokine release, and gene editing of PPP1R11 significantly 
increases ligand-induced cytokine release (Figure 24D-E; Figure 26B-C). This evidence suggests 
that PPP1R11 could be a natural inflammatory suppressor in cells, and this pathway could be 
utilized to target multiple types of stimuli-induced inflammation. While targeted degradation of 
TLR2 may restrain excessive inflammatory responses, activation of this pathway is also critical 
for pathogen clearance. By manipulating levels of TLR2 in murine lungs through PPP1R11, we 
showed effects in downstream inflammation and S. aureus bacterial clearance (Figure 27 and 
Figure 28).  These results are in line with previous studies showing TLR2 deficient mice were 
more susceptible to S. aureus infection (246). Specifically, higher inflammation in the lung might 
lead to lung injury, but also proved to be more efficient at clearing bacteria (Figure 28), whereas 
reduced inflammation in the lung is tissue-protective but fails to clear bacteria, which leads to 
systemic bacteremia (Figure 27).  One approach to potentially control the balance between the 
beneficial effects of the inflammatory pathway and the harmful and excessive responses to 
pathogens is to manipulate PPP1R11. These results suggest that PPP1R11 inhibition might confer 
a protective phenotype against S. aureus pneumonia by augmenting TLR2 signaling, which is 
critical for bacterial clearance.  As a proof-of-concept investigation, we observed a negative 
correlation between TLR2 and PPP1R11 protein levels in WBC pellets from S. aureus-infected 
patients. Interestingly, no correlation between PPP1R11 and TLR2 levels was observed in control 
patients (Figure 21). This experiment suggests that the PPP1R11/TLR2 pathway is only active 
during S. aureus infection. It is likely that other regulators such as kinases are also involved in 
PPP1R11-driven TLR2 ubiquitination, which is common in E3 ligase substrate targeting (176, 
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261). Further studies are warranted to investigate regulators that influence PPP1R11 expression 
and activity.  
In conclusion, we show that the previously uncharacterized RING E3 Ligase, PPP1R11, is 
up-regulated in response to the TLR2 ligand, Pam3CSK4, and subsequently targets TLR2 for 
proteasomal degradation by ubiquitinating it at lysine 754.  Down-regulation of TLR2 levels by 
PPP1R11 reduces pro-inflammatory cytokine secretion but impairs bacterial clearance in response 
to S. aureus.  Taken together, this study characterizes a novel innate immune regulatory 
mechanism involving PPP1R11-targeted degradation of the pattern recognition receptor TLR2. 
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3.1.9 Materials and Methods 
 Materials 
Sources of the murine lung epithelial (MLE) cell line was described previously(181, 182).  
QuikChange II XL Site-Directed Mutagenesis Kit (200522) was from Aglient Technologies. 
Nucleofector 2b and nucleofection kits (AAB-1001) were from Amaxa. High capacity RNA-to-
cDNA kits (4387406) were from Applied Biosystems. HEK293T cells (CRL-3216) were from 
ATCC. Thermal Cycler Life ECO (BYQ6078) was from BIOER Technology. Secondary 
antibodies (170-515/6) and CFX96 Touch Real-Time qPCR (1855196) were from BioRad. 
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UbiCRest assay kit (K-400) was from Boston Biochem. Anti-TLR2 (12276), anti-Ubiquitin (3936, 
RRID:AB_331292), and anti-HA (3724, RRID:AB_1549585) antibodies were from Cell 
Signaling. Lenti-X Packaging System (631276) was from Clontech. Murine IL-1b (88-7261) and 
murine IL-6 (88-7064, RRID:AB_2574986) ELISA kits were from eBioscience. Ubiquitin E1, 
E2s, biotinylated ubiquitin (BML-UW0400) and cycloheximide (BML-GR310) were from Enzo. 
FBS (100-106) was from Gemini. DNA sequencing was performed at Genewiz. Dulbecco’s 
Modified Eagle Medium-F12 (11965-092) was from Gibco. Anti-V5 antibody (R960, 
RRID:AB_159298) was from Invitrogen. PAM3CSK4 (tlrl-pms) was from InvivoGen. C57BL/6J 
mice (000664, RRID:IMSR_JAX:000664) were from Jackson Laboratory. SYBR Select Master 
Mix (4472918) was from Life Technologies. 35mm Glass Bottom MakTek dishes (P35GCOL-0-
10-C) were from MatTek. Alexa Fluor 488 Phalloidin (A12379, RRID:AB_2315147), Hoechst 
33342 (H3570), Alexa Fluor 488 conjugate Donkey anti-Mouse IgG (R3711), Alexa Fluor 568 
conjugate Goat anti-Mouse IgG (H+L) (A-11004), Normal Goat Serum (50197Z) were from 
Molecular Probes. TnT® T7 Quick Coupled Transcription/Translation System (L1170) was from 
Promega. Murine CXCL1 (DY453) and Murine TNF-a (DY410) ELISA kits were from R&D 
Systems. PPP1R11 CRISPR/Cas9 KO plasmid (SC-429347), Anti PPP1R11 antibody (SC-
135427, RRID:AB_10840420), Anti UBE2D (SC-166278, RRID:AB_2210152), Anti UBE2H 
(SC-100620, RRID:AB_2210469) were from Santa Cruz Biotechnology. Anti Actin antibody 
(A5441,  RRID:AB_476744), leupeptin (L2884), TSB (22092), and Agar (A5306) were from 
Sigma Aldrich. PureLink RNA Mini kit (12183020), Strepavidin agarose resin (20349), and 
pcDNA3.1D V5/HIS/TOPO kit (K490040) were from Thermo Fisher Scientific. MG-132 (F1100) 
was from UBPBio. 
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 Cell culture 
Murine Lung Epithelial 12 cells (MLE) were from ATCC (CRL-2110) and cultured 
according to manufacturer’s instructions. The identity of the cell lines was monitored by 
microscope based morphology analysis and immunoblotting with multiple markers. The cell lines 
were checked for mycoplasma contamination using MycoAlert™ Mycoplasma Detection Kit 
(Lonza, Switzerland). MLE cells were cultured in Dulbecco’s Modified Eagle Medium-F12 
(Gibco) supplemented with 10% fetal bovine serum (DMEM-F12-10). For PPP1R11 
overexpression in MLE cells, an Amaxa nucleofection kit was used following manufacturer’s 
protocol. 24h later, cells were treated with doses of Pam3CSK4 up to 10μg/ml. For PPP1R11 
knockdown studies in MLE cells, scramble siRNA and PPP1R11 siRNA were used to transfect 
cells for 48h using electroporation. Cell lysates were prepared by brief sonication in 150 mM NaCl, 
50 mM Tris, 1.0 mM EDTA, 2 mM dithiothreitol, 0.025% sodium azide, and 1 mM 
phenylmethylsulfonyl fluoride (Buffer A) at 4 °C. For half-life study, MLE cells were exposed to 
cycloheximide (40mg/ml) in a time dependent manner for up to 6h. Cells were then collected and 
immunoblotted. Protein densitometry was quantified through ImageJ and normalized to the zero 
time point for each set of condition. 
 UbiCRest assay 
TLR2 protein was analyzed for ubiquitin linkage specificity via the UbiCRest method and 
following manufacturer’s protocol (262). MLE cells were treated with MG-132 (20 μM) for 18 
hours prior to immunoprecipitation of endogenous TLR2 protein. TLR2 bound antibodies were 
conjugated to Protein A/G agarose resin and distributed among nine tubes. The TLR2-resins were 
incubated with deubiquitinases with varying specificities to the eight ubiquitin linkages. The 
deubiqutinases used and their working concentrations were USP2 (0.5 μM), OTULIN (0.5 μM), 
100 
OTUB1 (0.5 μM), ZRANB1 (0.5 μM), STAMBP (0.5 μM), OTUD3 (0.5 μM), OTUD7A (0.1 
μM), and OTU1 (0.5 μM). Following the reaction, TLR2 protein was eluted from resin and 
subjected to ubiquitin immunoblotting. 
 In vitro ubiquitin conjugation assays 
The assay was performed in a volume of 25ml containing 50 mM Tris pH 7.6, 5 mM 
MgCl2, 0.6 mM DTT, 2 mM ATP, 1.5 ng/ml E1, 10 ng/ml Ubiquitin E2 conjugating enzymes, 
1mg/ml ubiquitin (Calbiochem), 1 mM ubiquitin aldehyde, and in vitro synthesized V5-TLR2 and 
PPP1R11. Reaction products were immunoblotted for V5. 
 In vitro protein binding assays 
PPP1R11 protein was immunoprecipitated from 1mg MLE cell lysate using PPP1R11 
antibody (rabbit) and coupled to protein A/G agarose resin. PPP1R11 beads were then incubated 
with in vitro synthesized products (50ul) expressing V5-E2 conjugating enzymes. After washing, 
the proteins were eluted and processed for V5 immunoblotting.  
 RT–qPCR, cloning, and mutagenesis 
Total RNA was isolated and reverse transcription was performed followed by real-time 
quantitative PCR with SYBR Green qPCR mixture as described (185). All mutant PPP1R11 and 
TLR plasmid constructs were generated using PCR-based approaches using appropriate primers 
and subcloned into a pcDNA3.1D/V5-His vector. 
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 Immunostaining 
MLE cells were seeded in 35mm MatTek glass-bottom dishes before the plasmid 
transfection. Cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min, then 
exposed to 2% BSA, 1:500 mouse V5 antibody and 1:1000 Alexa 568nm chicken anti-mouse 
antibody sequentially for immunostaining. The nucleus was counterstained with DAPI and F-actin 
was counterstained with Alexa 488-Phalloidin. Immunofluorescent cell imaging was performed 
on a Nikon A1 confocal microscope using 405 nm, 488 nm, or 567 nm wavelengths. All 
experiments were done with a 60x oil differential interference contrast objective lens. 
 Lentivirus construction 
To generate lentivirus encoding PPP1R11, Plvx-PPP1R11 plasmid was co-transfected with 
Lenti-X HTX packaging plasmids (Clontech) into 293FT cells following the manufacturer’s 
instructions. 72 h later, virus was collected and concentrated using Lenti-X concentrator. 
 Gene Editing  
 CRISPR guide RNAs (gRNA) were generated by Santa Cruz Biotechnologies specific to 
the first exon of Ppp1r11 (TTGTAGGACGCCGTCCTTTG). MLE cells were transfected with 5 
ug of plasmid. Transfection efficiency was confirmed via GFP expression. Cells were diluted and 
seeding to single-cell concentrations and sequence confirmed prior to half-life and cytokine 
studies. 
 Animal studies 
All procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. For pneumonia studies, C57BL6 mice were deeply anesthetized using a 
102 
ketamine/xylazine mixture, and the larynx was well visualized under a fiber optic light source 
before endotracheal intubation with a 3/400 24-gauge plastic catheter. 107 CFU of lentivirus 
encoding genes for PPP1R11 or PPP1R11 shRNA was instilled i.t. for 144 h before the 
administration of S. aureus (strain 29213, 2.5*1e7-1e8CFU/mouse, i.t.) for 18 h, after which 
animals were euthanized and assayed for BAL protein, cell count, cytokines, lung infiltrates, and 
tissue bacterial count (175, 176, 251, 260). 
 Human Samples 
This study was approved by the University of Pittsburgh Institutional Review Board.  As 
part of an ongoing Acute Lung Injury Biospecimen Repository, blood was collected from critically 
ill, mechanically-ventilated patients admitted to the University of Pittsburgh Medical Center 
Presbyterian Hospital Medical Intensive Care Unit.  Whole blood was treated with red blood cell 
lysis solution, and leukocytes were washed once with PBS prior to pelleting.  Groups were 
separated into “control” and “injury” cohorts based on clinical evidence of or risk factors for Acute 
Respiratory Distress Syndrome (ARDS) as determined by an expert clinical panel.  Control 
patients were mechanically ventilated without clinical evidence of or risk factors for Acute 
Respiratory Distress Syndrome (ARDS), while the injury cohort had clinical evidence of or risk 
factor for ARDS.  For this study, samples were analyzed from a group of randomly selected control 
cohort patients (without S. aureus infection), as well as from patients with evidence of S. 
aureus infection (BAL, blood, or both) in the injury cohort.  The Biospecimen Repository provided 
de-identified samples to this laboratory, and cell pellets were assayed for TLR2 and PPP1R11 
proteins by immunoblotting, quantified using ImageJ software, and graphed in GraphPad.  All data 
acquisition and densitometry was performed blinded prior to revealing cohort groups.    
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 Statistical Analysis 
Statistical comparisons were performed with mean ± standard error of the mean (SEM) for 
continuous variables. All data were statistically analyzed by unpaired 2 sample t-test with p<0.05 
indicative of statistical significance. All analyses were performed using GraphPad Prism 6. 
  
104 
3.2 KIAA0317 Regulates Pulmonary Inflammation Through SOCS2 Degradation  
Adapted from: Lear and McKelvey et al., KIAA0317 regulates pulmonary inflammation through 
SOCS2 degradation. JCI Insight. 2019;4(19):e129110. https://doi.org/10.1172/jci.insight.129110., 
(263) 
 
Lung inflammation can be deleterious for humans, even in the context of infection. 
Exuberant inflammatory responses lead to extensive damage of the alveolar space, causing 
denudation of the basement membrane, edema formation, necrosis of pulmonary epithelial, and 
aberrant fibrotic response in an attempt to repair the damage (43). Together, these responses create 
conditions of acute lung injury leading to respiratory failure. Acute Respiratory Distress Syndrome 
is one example of this condition, in which runaway inflammatory signaling leads to respiratory 
failure in critical care patients (264). In this study we investigated a potent anti-inflammatory 
protein, SOCS2, and its regulation by the ubiquitin E3 ligase KIAA0317 in pulmonary epithelial 
cells. In the course of the lung’s response to insult, pulmonary epithelial cells initiate the 
inflammatory response(265). The hypothesis was that SOCS2 anti-inflammatory activity may be 
an early step in the process, and intervention in its KIAA0317-mediated degradation may be an 
avenue to halt deleterious inflammation before the runaway cycle begins.  
3.2.1 Overview 
Dysregulated pro-inflammatory cytokine release has been implicated the pathogenesis of 
several life-threatening acute lung illnesses such as pneumonia, sepsis, and acute respiratory 
distress syndrome. The suppressor of cytokine signaling proteins, particularly SOCS2, have 
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recently been described as anti-inflammatory mediators. However, the regulation of SOCS2 
protein has not been described. Here we describe a novel mechanism of SOCS2 regulation, by the 
action of the ubiquitin E3 ligase KIAA0317. KIAA0317-mediated degradation of SOCS2 
exacerbates inflammation in vitro and depletion of KIAA0317 in vivo ameliorates pulmonary 
inflammation. KIAA0317 knockout mice exhibit resistance to LPS-induced pulmonary 
inflammation, while KIAA03017 re-expression mitigates this effect. We uncovered a small 
molecule inhibitor of KIAA0317 protein (BC-1365), which prevents SOCS2 degradation and 
attenuates LPS- and P. aeruginosa- induced lung inflammation in vivo. These studies show 
KIAA0317 to be a critical mediator of pulmonary inflammation through its degradation of SOCS2, 
and a potential candidate target for therapeutic inhibition. 
3.2.2 Introduction 
The inflammatory response in the lung is a critical response to infection, and in maintaining 
pulmonary homeostasis. Pathogen sensing by the host initiates inflammation via cytokine 
signaling cascades(266), which facilitates the activation of the immune system and recruitment of 
leukocytes to the afflicted area. However, uncontrolled pulmonary inflammation can be deleterious 
as several acute pathologies including acute respiratory distress syndrome (ARDS), are associated 
with high pro-inflammatory cytokine levels(44). In the case of ARDS, dysregulated pulmonary 
inflammation results in capillary damage, disruption of the alveolar epithelium, alveolar damage 
caused by leukocytes, and the influx of edema fluid rich in connective tissue and protein (267). 
ARDS affects almost 0.25 million patients annually, whom suffer over 40% mortality (264, 267, 
268). Pulmonary inflammation is directly associated with pro-inflammatory cytokines such as IL-
1, -6, and TNF (48, 269). Alveolar macrophages from ARDS patients show more activated nuclear 
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factor-kappa B (NF-κB) (49), and subsequent research has shown that the NF-κB signaling 
pathway promotes the transcription of cytokines involved in ARDS pathogenesis (49, 52, 270, 
271). 
 SOCS proteins in anti-inflammatory signaling 
Several families of proteins are tasked with suppressing cytokine signal transduction, 
including the suppressor of cytokine signaling (SOCS) proteins (272, 273) . The protein SOCS2 
regulates the fate of many key signal transduction proteins, such as the protein kinases FLT3 and 
p38, the growth hormone receptor, and even other SOCS proteins (274-277). Research suggests 
that SOCS2 suppresses the NF-B pathway, similar to other SOCS family members such as 
SOCS1 and SOCS3 (278). Further, SOCS2 was observed to mediate the degradation of the kinase 
STK38, which is known to enhance the activity of NF-κB signaling (279). Indeed, SOCS2 
expression directly blunted NF-κB transactivation(280). In addition, SOCS2 was observed to 
regulate the stability of TRAF6, leading to inhibition of NF-kB pathways (281). Deletion of 
SOCS2 in mice leads to rampant systemic pro-inflammatory cytokine production following 
challenge with T. gondii or LPS (282). Despite these studies, there is little research into the role of 
SOCS2 in pulmonary inflammation and injury. Previous research suggests the stability of key 
proteins that regulate pulmonary inflammation influences lung pathology, such as the ubiquitin-
proteasome-dependent degradation of TLR2, PIAS1, and FBXL2 (60, 232, 283). To better 
understand the role of SOCS2 in pulmonary inflammation, we investigated the regulation of 
SOCS2 protein stability and its effects on pulmonary inflammation. 
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 The Regulation of SOCS2 through KIAA0317 
Here we report the ubiquitin-mediated degradation of SOCS2 protein and its effect on 
pulmonary inflammation. We characterized SOCS2 ubiquitination, which was dependent on 
Protein Kinase C-alpha (PKCa)-mediated phosphorylation and stimulated by LPS exposure, 
leading to SOCS2 protein degradation through the proteasome. Through affinity mass 
spectrometry, we identified the ubiquitin E3 ligase KIAA0317 (also known as AREL1) as an 
interacting partner with SOCS2 and elucidated a mechanism by which KIAA0317 potently 
regulated SOCS2 protein stability and signaling. Kiaa0317 knockdown in vivo increased SOCS2 
protein level and lessened the severity of bacterially-induced lung inflammation. Subsequently, 
we developed CRISPR-Cas9 Kiaa0317 knockout mice, which were resistant to LPS-induced 
pulmonary inflammation. Lentivirus rescue experiments with Kiaa0317 knockout mice ablated 
their protection from LPS-induced inflammation, which supported this putative mechanism. 
Finally, we screened and developed a small-molecule inhibitor of KIAA0317 which showed 
efficacy in vitro and in vivo in preserving SOCS2 protein and ameliorating pulmonary 
inflammation in both bacterial and LPS-driven models of lung inflammation. Taken together, these 
experiments describe a new mechanism controlling pulmonary inflammation and potential avenue 
for therapeutic intervention.    
3.2.3 SOCS2 is downregulated during pulmonary distress 
To test the in vivo significance of SOCS2 in pulmonary inflammation, we analyzed its 
protein expression by immunoblotting lysate from circulating white blood cells from seven control 
subjects and ten ARDS patients, as defined by Berlin criteria and agreed upon by a minimum of 
three members of an expert clinical panel (Table 1). De-identified human plasma samples were 
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obtained from the University of Pittsburgh Acute Lung Injury Biospecimen Repository (IRB 
number #PRO10110387). Following immunoblotting, we observed patients with ARDS had 
significantly less immunoreactive SOCS2 in leukocyte lysate versus control subjects, suggesting 
SOCS2 protein is depleted during pulmonary inflammation (Figure 29A). We next sought to 
explore the role of SOCS2 in lung tissue types. We conducted single-cell RNA sequencing of 
normal human tissue to characterize SOCS2 cellular expression.  Normal control lung tissue was 
obtained from organ donors, after rejection of the lungs for transplant prior to processing for RNA 
sequencing (209). The University of Pittsburgh Institutional Review Board approved procedures 
involving human samples. We observed SOCS2 to be predominantly expressed in pulmonary 
epithelia cells, specifically type-ii pneumocytes (Figure 29B). Lung epithelia play a critical role in 
pathogen detection and the initiative of inflammation during lung infection and stress (34, 284). 
We hypothesized that SOCS2 protein may be decreased in these cells in response to inflammatory 
stimuli such as LPS. We observed SOCS2 protein has a half-life between 2 and 4hr in murine lung 
epithelial cells (MLE), which is prolonged with proteasomal inhibitor MG132 treatment (Figure 
29C). Further, Socs2 protein showed a dose-dependent decrease upon expression of ubiquitin in 
MLE cells (Figure 29D) suggesting Socs2 protein stability is regulated via the ubiquitin-
proteasome system. We performed UbiCREST analysis to characterize Socs2 ubiquitination and 
observed Socs2 predominantly assembled ubiquitin chains with lysine-48 linkages (Figure 29E). 
Further, we expressed several ubiquitin constructs with all lysines mutated except for a specific 
one, thus impairing linkage-specific poly-ubiquitin chains. We observed that ubiquitin with solely 
lysine-48 was the only construct sufficient to generate high-molecular weight Socs2 
polyubiquitination protein signal (Figure 29F). Finally, treatment of MLE with LPS led to 
decreased Socs2 protein signal and an increase in poly-ubiquitinated Socs2, suggesting SOCS2 
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ubiquitination and degradation is stimulated by LPS (Figure 29G). LPS treatment of MLE cells 
did not result in a significant change in Socs2 mRNA (Figure 29H). 
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Table 1 Clinical Parameters of ARDS Patients 
Age Sex 
Primary 
Etiology 
WBC 
Vasopressor 
Use 
LIPS 
Score 
FiO2 PEEP 
Duration of 
Mechanical 
Ventilation 
(Days) 
30-Day 
Mortality 
71 Male Pneumonia 15.1 Yes 6.5 80 12 25 No 
43 Female Aspiration 9.5 Yes 7 50 8 20 No 
36 Female Pneumonia 7.5 No 4.5 60 14 12 No 
18 Female 
Non-
pulmonary 
sepsis 
12.1 Yes 5 40 10 
61 No 
43 Female 
Non-
pulmonary 
sepsis 
23.3 Yes 6 100 15 
4 No 
73 Male Aspiration 19.1 Yes 7.5 60 5 3 Yes 
45 Female Pneumonia 15.1 Yes 6.5 40 5 9 No 
72 Female Pneumonia 10.2 No 3.5 90 14 36 No 
51 Male Pneumonia 10.8 Yes 7.5 50 8 15 No 
59 Female Pneumonia 13.9 Yes 7.5 60 10 25 No 
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Figure 29 SOCS2 protein is ubiquitinated and degraded during pulmonary inflammation 
A. Immunoblot analysis of leukocyte pellets from ARDS patients or control serum samples. Data represent means 
±SEM, (n = 7-10; ***, p < 0.001 compared with Control, Mann-Whitney U-Test).  B. Cell type clustering results of 
control lung tissue cells from single-cell RNA-sequencing of SOCS2 transcript. C. Immunoblotting following 
cycloheximide (CHX, 50 μg/mL), MG132 (20 μM), or leupeptin (50 μg/mL) treatment for indicated times with ectopic 
expression of V5-tagged SOCS2 in MLE cells. D. Immunoblotting following overexpression of ubiquitin in MLE 
cells. E. UbiCREST analysis of SOCS2 ubiquitination following immunoprecipitation from MLE cells, digestion 
supernatant shown below with deubiquitinase enzymes indicated with (*). F. Immunoblot analysis following 
expression of SOCS2-V5 and Ubiquitin lysine-to-arginine mutants. G. Immunoblotting analysis of MLE cells 
following SOCS2-HIS and HA-Ubiquitin expression. Following HIS PD, eluate was immunoblotted for HA ubiquitin 
signal. H. qPCR analysis of MLE cells treated with LPS for indicated times. Data represent mean values ± SEM (n = 
3; NS, p > 0.05 compared with 0hr, Student’s two-tailed unpaired t-test). C-G. Data are representative of n=2-3 
independent experiments. 
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3.2.4 KIAA0317 targets SOCS2 for ubiquitination 
The process of substrate ubiquitination is facilitated by substrate-engaging ubiquitin E3 
ligases. We utilized recombinant GST-tagged SOCS2 as bait during incubation with epithelial cell 
BEAS-2B lysate prior to SOCS2 pull-down (PD) (Figure 30A). Following pull-down, we 
subjected the eluate to mass spectrometry analysis through MS BioWorks services (Ann Arbor, 
USA). Analysis uncovered several differentially detected peptides among SOCS2 PD relative to 
control GST PD. Among these, we observed the protein KIAA0317 (79 peptides detected), which 
has been previously described as an Homologous to the E6-AP Carboxyl Terminus (HECT)-
domain ubiquitin E3 ligase (141, 164, 285, 286). Expression of KIAA0317 in MLE cells 
accelerated SOCS2 degradation in half-life studies, while shRNA silencing of Kiaa0317 prolonged 
SOCS2 stability (Figure 30B-E). KIAA0317 overexpression specifically decreased SOCS2 in a 
dose-dependent manner; a randomly selected HECT E3 ligase, UBE3B, was also tested as a 
negative control (Figure 30F-G). KIAA0317 enhanced SOCS2 poly-ubiquitination in an in vivo 
ubiquitination assay (Figure 30H), and this effect was also observed through in vitro ubiquitination 
assays (Figure 30I). Expression of HIS-tagged SOCS2 in addition to LPS exposure led to an 
increased poly-ubiquitination signal upon HIS-SOCS2 pulldown. This signal is enhanced upon co-
expression of KIAA0317 (Figure 30J), suggesting LPS enhances KIAA0317 induced poly-
ubiquitination of SOCS2. As SOCS2 is suggested to suppress NF-B signaling (280), we tested 
the role of KIAA0317 in this signaling. Silencing Kiaa0317 silencing significantly reduced NF-
B promoter activity following stimulation with LPS or TNF (Figure 30K-L). These data 
suggested KIAA0317 is a candidate E3 ligase regulating SOCS2 ubiquitination and degradation. 
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Figure 30 KIAA0317 Ubiquitinates and Degrades SOCS2 in Response to Bacterial Insult   
A. Protein staining of eluate from Ctrl-GST and SOCS2-GST bait and capture of BEAS-2B lysate prior to mass 
spectrometry analysis. B. Immunoblotting following cycloheximide treatment (CHX, 50 μg/mL) for indicated times 
with ectopic expression of empty plasmid or V5-tagged KIAA0317 in MLE cells. C. SOCS2 protein densitometry 
(normalized to Actin) for B. (n=2). C. Immunoblotting following cycloheximide treatment (CHX, 50 μg/mL) for 
indicated times with ectopic expression of Ctrl shRNA or Kiaa0317 shRNA in MLE cells. E. SOCS2 protein 
densitometry (normalized to Actin) for D. (n=2).  F-G. SOCS2 Immunoblotting following F. KIAA0317 and G. 
UBE3B expression in MLE cells. H. in vivo ubiquitination assay and SOCS2 immunoprecipitation following co-
expression with KIAA0317 and Ubiquitin. I. in vitro ubiquitination assay of SOCS2 protein. J. Immunoblot analysis 
of SOCS2 pull-down following KIAA0317 expression and LPS exposure. K.-L. NF-B promoter activity assays in 
293T cells transfected with control shRNA (CON) or KIAA0317 shRNA and exposed to K. LPS (10μg/ml) or L. TNF 
(10ng/ml) for indicated times. Data represent mean values ± SEM (n = 4; *, p < 0.05; ****. <0.0001; NS, p > 0.05; 
compared to indicated treatment, to control shRNA 6hr treatment (^), or to control shRNA 18hr treatment (#), Two-
way ANOVA with Bonferroni’s multiple comparisons). F-J. Data are representative of n=2-3 independent 
experiments. 
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3.2.5 LPS stimulates site-specific SOCS2 phosphorylation and KIAA0317-mediated 
ubiquitination and degradation 
Substrates are ubiquitinated often by conjugation to critical lysine sites. We mapped the 
putative ubiquitin acceptor site and the KIAA0317 binding site within SOCS2 (Figure 31A). To 
uncover the critical ubiquitin-acceptor site within SOCS2, we constructed several SOCS2 lysine 
to arginine mutants and assayed their protein half-lives (Figure 31B). Of the SOCS2 point mutants 
tested, only SOCS2 K173R exhibited an extended half-life (Figure 31B). We also probed the 
KIAA0317 binding site within SOCS2. KIAA0317 protein was first immunoprecipitated from cell 
lysates and coupled to protein A/G resin. We then incubated KIAA0317-resin with in vitro 
synthesized SOCS2-V5 mutants. After washing and elution, we analyzed via immunoblotting. We 
determined that KIAA0317 binds within the N-terminus of SOCS2 (Figure 31C).  
We hypothesized this binding region within SOCS2 contained a critical moiety for 
recognition by KIAA0317. Ubiquitinated substrates are often post-translationally modified (e.g. 
phosphorylation), and these sites function as “degrons” for E3 ligase targeting (287). Thus, we set 
out to determine if there existed a key phospho-degron within SOCS2 for KIAA0317 recognition. 
Database analysis indicated that SOCS2 serine-52 is a candidate phosphorylation site within its N-
terminus (NetPhos 2.0 software prediction, (288, 289)). Additionally, there is a naturally occurring 
missense polymorphism (S52N) (rs3741676) within this codon, and the SOCS2 S52N mutant 
exhibited an extended half-life (Figure 31D) and displayed lessened binding to KIAA0317 (Figure 
31E). Finally, we observed that SOCS2 S52N as well as the K173R mutant was resistant to 
degradation when co-expressed with KIAA0317 (Figure 31F).  
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Figure 31 KIAA0317 targets SOCS2 phosphodegron for binding and ubiquitination 
A. Schematic of SOCS2 deletional or point mutants used in mechanistic studies. B. Deletion mapping of SOCS2 site 
for binding KIAA0317. C. Immunoblot analysis of MLE cells expressing SOCS2 lysine mutants followed by 
cycloheximide (CHX, 50 μg/mL) treatment for the indicated times. D. Immunoblot analysis of MLE cells expressing 
SOCS2 S52N followed by cycloheximide (CHX, 50 μg/mL) treatment for the indicated times. E. Immunoblot analysis 
of SOCS2 S52N binding KIAA0317. F. Immunoblotting of MLE cells co-transfected with WT, SOCS2 S52N, or 
K173R mutant without or with KIAA0317. The lanes were run on the same gel but were noncontiguous. G. Schematic 
of KIAA0317 deletional or point mutants used in mechanistic studies. H-I. Deletion and point mapping of KIAA0317 
site for binding SOCS2. J. KIAA0317 P779L binding assay with SOCS2. K. KIAA0317 Peptide binding assay. L. 
Immunoblot analysis of MLE cells expressing KIAA0317 WT and P779L at the increasing doses. WT (wild-type). B-
F, H-L. Data are representative of n=2 independent experiments. IP: Immunoprecipitated, IB: Immunoblotted. 
 
We sought out to determine the kinase responsible for SOCS2 phosphorylation at Serine 
52. We screened for kinases via SOCS2 immunoprecipitation and immunoblot analysis. Of the 
kinases probed, only PKCA was detected in the SOCS2 immunoprecipitate (Figure 32A).  We 
further observed that PKCA directly phosphorylated SOCS2 in an in vitro kinase assay (Figure 
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32B). PKCA affects SOCS2 protein stability, as PKCA expression decreased the protein half-life 
of SOCS2 in a cycloheximide chase (Figure 32C-D). Similarly, silencing of Pkca drastically 
stabilized SOCS2 protein (Figure 32E-F). LPS time and dose treatment promotes SOCS2 
association with PKCA and KIAA0317, as well as the emergence of a phosphoserine signal 
corresponding to the predicted size of SOCS2 (~25kDa) (Figure 32G, H). This signal is reduced 
when Pkca is silenced (Figure 32I). Further, LPS increased KIAA0317 protein levels and 
decreased SOCS2 protein levels in both a time- and dose-dependent manner, as well as increasing 
the association between the two proteins (Figure 32G, H). To better understand the mechanism of 
KIAA0317 targeting of SOCS2, we embarked on a candidate mapping approach to identify the 
critical site within KIAA0317 for SOCS2 binding (Figure 31G). Through in vitro protein binding 
assays, we determined KIAA0317 binds to SOCS2 through the KIAA0317 C-terminus (Figure 
31H-I). Interestingly, previous mapping studies have suggested KIAA0317 binds to substrates 
through specific C-terminal residues (such as proline-779) (141). Additionally, KIAA0317 P779 
contains a naturally occurring polymorphism (rs371610162) resulting in P779L missense 
mutation. We observed that KIAA0317 P779L mutant protein has weakened binding with SOCS2 
(Figure 31J), as does a peptide corresponding to the P779L sequence (Figure 31K). Finally, SOCS2 
protein is insensitive to dose-dependent overexpression of P779L relative to WT (Figure 31L). 
Together, these results suggest that in response to LPS exposure, KIAA0317 facilitates the 
ubiquitination and degradation of SOCS2 protein, mediated by PKCA-mediated phosphorylation. 
This is consistent with the results of previous studies that suggested PKCA plays a role in inducing 
pro-inflammatory signaling, specifically through the NF-κB pathway (290-292). We hypothesized 
that this interaction plays a role in mechanisms of pulmonary inflammation.  
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Figure 32 SOCS2 is phosphorylated by PKCA leading to its degradation 
A. Endogenous SOCS2 immunoprecipitation from MLE cells and subsequent immunoblotting of several kinases 
(n=2). B. In vitro PKCA kinase assay. * indicates heat inactivated PKCA. C. Immunoblot analysis of MLE cells 
following expression of Empty or PKCA plasmids and exposure to CHX (100μg/mL) for the indicated times. D. 
SOCS2 protein densitometry (normalized to Actin) for C. (n=2). E. Immunoblot analysis of MLE cells following 
expression of CON shRNA or Pkca shRNA plasmids and exposure to CHX (100μg/mL) for the indicated times. F. 
SOCS2 protein densitometry (normalized to Actin) for E. (n=2). G. Immunoblot analysis of MLE cells exposed to 
LPS (8hr) for the indicated doses prior to endogenous SOCS2 immunoprecipitation. H. Immunoblotting of MLE cells 
exposed to LPS (10μg/mL) for the indicated times prior to endogenous SOCS2 immunoprecipitation. I. Silencing of 
Pkca and LPS time course prior to SOCS2 immunoprecipitation and immunoblot analysis in MLE cells. A-B, G-I. 
Data are representative of n=2 independent experiments. 
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3.2.6 Kiaa0317 knockdown ameliorates pseudomonas-induced lung injury in vivo 
To explore the role of Kiaa0317 in pulmonary inflammation, we pursued in vivo 
knockdown studies. Mice were first infected with lentivirus encoding empty shRNA or Kiaa0317 
shRNA for 144h (1e7 PFU/mouse, i.t) and then challenged with PA103 (1e4 CFU/mouse, i.t.) for 
an additional 18h (Figure 33A). Mice were sacrificed and samples were processed for metrics of 
pulmonary inflammation. Kiaa0317 knockdown significantly decreased lavage protein 
concentrations, lavage cell counts, and cell infiltrates without affecting bacterial load (Figure 33B, 
C, D, I). Further, Kiaa0317 knockdown significantly decreased lavage cytokine levels of IL-6 and 
TNF (Figure 33E, F), and improved survival (Figure 33G). Pulmonary parenchymal tissue from 
Kiaa0317-silenced mice show higher SOCS2 protein (Figure 33H) and fewer inflammatory 
infiltrates (Figure 33I).  
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Figure 33 Kiaa0317 knockdown ameliorates pseudomonas-induced lung injury in vivo 
A. Treatment strategy of lentiviral infection (1e7 PFU/mouse) and PA103 exposure (1e4 CFU/mouse). Mice were 
euthanized, and lungs were lavaged with saline and harvested. B-D. Protein concentration, cell count, and bacterial 
count measurements from bronchoalveolar lavage fluid (BALF) from treated mice, (n = 6-8 mice per group). D. Box 
represents the interquartile range, the line is the median, and the whiskers represent highest and lowest observations.  
E-F. ELISA analysis of BALF cytokines, E. IL-6, and F. TNF. G. Survival studies of mice exposed to PA103 (i.t. 1e5 
CFU/mouse, n=8 mice per group). Mice were carefully monitored over time; moribund, preterminal animals were 
immediately euthanized and recorded as deceased. Kaplan-Meier survival curves were generated and compared; data 
represent mean values (n = 8 mice per group). H. Immunoblot analysis from representative murine lung homogenate, 
n=4 per group. I. Histology of murine lungs following H&E staining, bar indicates 100 μm. **, p < 0.01; ***, p < 
0.001; ****, p < 0.0001; NS, p>0.05; compared with control shRNA, two-tailed unpaired Student’s t-test (B-F) or 
compared with control shRNA, log-rank (Mantel-Cox) test (G).  
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3.2.7 KIAA0317 -/- mice are resistant to LPS-induced lung inflammation 
As transient silencing of KIAA0317 in C57BL6/J mice conferred a protective phenotype 
against PA103-induced pulmonary inflammation, we extended these studies by generating 
Kiaa0317-deficient mice. Kiaa0317-knockout mice were generated using CRISPR-Cas9 
technology using previously described techniques (293). A sgRNA targeting exon 13 of 
KIAA0317 introduced a double stranded break, and subsequent NHEJ repair resulted in a 91 base 
pair deletion in the genomic DNA sequence, with no effects in mouse morphology or the predicted 
off-targeting regions (Figure 34A-D). Sequencing of the cDNA of the generated knockout revealed 
that the genomic DNA deletion produces a cDNA transcript missing exon 13. Splicing of exon 12 
to 14 generates a frame-shift in exon 14 at amino acid 500 resulting in the introduction of a stop 
codon at position 503 of the knockout transcript (Figure 34A, B). 
We next sought to explore the role of Kiaa0317 genetic deletion in experimental pulmonary 
inflammation. We observed decreased Kiaa0317 transcript signal from Kiaa0317+/- mice, and 
transcript depletion in Kiaa0317-/- mice (Figure 35A-B). To test the role of Kiaa0317 knockout in 
pulmonary inflammation, we challenged Kiaa0317+/+, +/-, and -/- mice with LPS (3 mg/kg) for 18 
hours. Mice were euthanized prior to analysis of parameters of inflammatory injury. Relative to 
wild-type, Kiaa0317+/- and -/- mice showed significant and step-wise decreases in indicators of 
inflammatory injury, such as bronchoalveolar lavage fluid (BALF) protein concentration (Figure 
35C), cell count (Figure 35D), as well as decreases in pro-inflammatory cytokine release (Figure 
35E-G). Histological analysis revealed fewer inflammatory infiltrates among Kiaa0317+/- and -/- 
mice (Figure 35H). These data suggest Kiaa0317 deletion confers protection against experimental 
pulmonary inflammation. 
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Figure 34 Generation of Kiaa0317-/- knockout mice  
A-B. CRISPR-Cas9 gene editing of C57BL6/J mice. B. CRISPR editing resulted in 91bp deletion in exon 13. C. 
Female and Male Kiaa0317+/- and Kiaa0317-/- mice do not show morphological differences from WT. D. PCR 
amplification and sequencing detected no off-target effects in Kiaa0317-/- mice among top predicted targets, n=2 mice 
per genotype. 
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Figure 35 Kiaa0317 knockout confers protection from LPS-induced lung inflammation 
A. sgRNA target site amplification from Kiaa0317+/+, +/-, and -/- mice.  B. Kiaa0317 transcript levels among 
Kiaa0317+/+, +/-, and -/- mice. Data represent mean values ± SEM (n = 3 mice). C-G.  Kiaa0317+/+, +/-, and -/- mice 
were intra-tracheally inoculated with LPS (3mg/kg) for 18h. Data represent mean values ± SEM (n = 3 mice per 
group). C-D. Cell count and protein concentration from bronchoalveolar lavage fluid (BALF). E. BALF TNF 
concentration. F. BALF IL-1 concentration. G. BALF IL-6 concentration. H. Histology of murine lungs following 
H&E staining, bar indicates 100 μm. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; compared to indicated 
group or to sex-specific +/+ group, One-Way ANOVA with Tukey’s multiple comparisons (B) or One-Way ANOVA 
with Dunnett’s multiple comparisons (C-G). 
 
3.2.8 KIAA0317 re-expression sensitizes Kiaa0317-/- to LPS-induced pulmonary 
inflammation 
To further validate the role of Kiaa0317 in pulmonary inflammation, we conducted a series 
of lentiviral rescue experiments utilizing KIAA0317 WT and the binding-deficient P779L mutant, 
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and with LPS challenge (Figure 36).  Kiaa0317 -/- mice with empty lentivirus showed lower BALF 
protein concentration, cell counts, and cytokine release relative to Kiaa0317+/+ mice (Figure 36A-
E). However, an inflammatory phenotype was observed upon lentiviral expression of KIAA0317 
WT in Kiaa0317-/- mice. Interestingly, KIAA0317 P779L Kiaa0317-/- mice phenocopied control 
Kiaa0317-/- mice. Further, the distinct effect of KIAA0317 WT and P779L expression was 
observed in BALF leukocyte differential counts (Figure 36F-H). BALF from both Kiaa0317+/+ 
and -/- mice expressing KIAA0317 showed a large count and proportion of neutrophils. However, 
BALF from KIAA0317-/- mice expressing Empty or P779L-encoded lentivirus contained fewer 
leukocytes, and a smaller proportion of neutrophils (Figure 36G). Histological staining showed 
less inflammatory infiltration among Kiaa0317-/- mice expressing Empty and KIAA0317 P779L 
(Figure 36I). From these data, we conclude that the resistance to pulmonary inflammation by 
Kiaa0317-/- mice is due to KIAA0317.  
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Figure 36 Re-expression of KIAA0317 in Kiaa0317-/- mice ablates resistance to inflammation 
Mice were infected i.t. with lentivirus encoding empty, KIAA0317 WT, or KIAA0317 P779L (1e7 PFU/mouse) prior 
to LPS exposure (3 mg/kg). Following exposure, mice were euthanized, and lungs were lavaged with saline and 
harvested. A-B. Protein concentration and cell count measurements from bronchoalveolar lavage fluid (BALF). C-E. 
BALF cytokine concentrations. F-H. BALF leukocyte differential. A-H. Data represent mean values ± SEM (n = 4-7 
mice; *, p < 0.05; **, p<0.01; ***, p<0.001; compared with Kiaa0317+/+ mice, One-Way ANOVA with Dunnett’s 
Multiple Comparisons). I. Histology of murine lungs following H&E staining, bar indicates 200 μm.  *, p < 0.05; **, 
p < 0.01; ***, p < 0.001; compared to Kiaa0317+/+ mice, One-Way ANOVA with Dunnett’s multiple comparisons 
(A-H). 
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3.2.9 Kiaa0317-/- resistance to pulmonary inflammation is ablated upon depletion of 
SOCS2 
Next, we wanted to explore the role of SOCS2 in Kiaa0317-/- mice. To study this, we 
conducted lentiviral SOCS2 silencing experiments and LPS challenge with Kiaa0317+/+ and -/- 
mice (Figure 37). We recapitulated previous results showing the susceptibility of SOCS2-silenced 
WT (Kiaa0317+/+) mice to LPS-induced inflammation, and extended these observations to a lung 
inflammation model (282). BALF from these SOCS2-silenced-Kiaa0317+/+ mice showed higher 
protein and cell concentration, cytokine secretion, and leukocyte recruitment relative to control 
shRNA (Figure 37A-H). Similar to earlier observations above (Figure 35), control-Kiaa0317-/- 
mice showed resistance to LPS-induced pulmonary inflammation. However, SOCS2-silenced-
Kiaa0317-/- mice phenocopied SOCS2-silenced WT (Kiaa0317+/+) mice. We hypothesize that 
silencing of the putative substrate of KIAA0317, SOCS2, removes the protection of KIAA0317 
knockout. Finally, histological analysis showed enhanced inflammatory infiltration among both 
SOCS2-silenced Kiaa0317+/+ and -/- mice (Figure 37I). These rescue experiments suggest that 
Kiaa0317 is both necessary and sufficient for LPS-induced pulmonary inflammation. Further, this 
inflammatory phenotype operates through a KIAA0317-SOCS2 axis, as depletion of SOCS2 
enhances inflammation, even in the background of Kiaa0317 genetic knockout. Collectively, the 
above studies suggest Kiaa0317 plays an integral role in mediating cytokine-driven inflammation 
via the SOCS2-cytokine axis. 
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Figure 37 Protected phenotype of Kiaa0317-/- mice requires SOCS2 
Mice were infected i.t. with lentivirus encoding empty, Control shRNA, or Socs2 shRNA (1e7 PFU/mouse) prior to 
LPS exposure (3 mg/kg). Following exposure, mice were euthanized, and lungs were lavaged with saline and 
harvested. A-B. Protein concentration and cell count measurements from bronchoalveolar lavage fluid (BALF). C-E. 
BALF cytokine concentrations. F-H. BALF leukocyte differential. A-H. Data represent mean values ± SEM (n = 5-6 
mice) I. Histology of murine lungs following H&E staining, bar indicates 200 μm. *, p < 0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001; compared with Control shRNA-Kiaa0317+/+ mice or as indicated, One-Way ANOVA with 
Tukey’s Multiple Comparisons. 
127 
3.2.10 KIAA0317 domain analysis and inhibitor screening 
KIAA0317 harbors a conserved HECT domain within its C-terminus (294, 295). Since the 
HECT domain carries out the E3 ligase activity of transferring ubiquitin to the substrate, we 
hypothesized that small molecule inhibition of the HECT domain would disrupt KIAA0317 
substrate targeting. We constructed an in silico homology model using the NEDD4 HECT domain 
(296, 297) (2XBF.pdb) (Figure 38A) to assay potential ligands on the KIAA0317-HECT domain 
3-D structure (Figure 38B). We used molecular docking analysis and score-ranking operations 
through the LibDock program (Discovery Studio 3.5) to virtually screen 5e5 small molecules. The 
top ten score-ranking molecules were selected and evaluated further using in vitro experiments 
(Data not shown). In this model, the inhibitors interact with distinct residues within the HECT 
domain (Figure 38C). We tested one of the selected compounds, termed BC-1365, in an in vitro 
binding assay, which resulted in potent inhibition of the KIAA0317/SOCS2 interaction (Figure 
38D). We also tested this compound in MLE cells and observed increased SOCS2 protein levels 
while KIAA0317 protein was unaffected (Figure 38E). BC-1365 titration also did not alter mRNA 
levels of Socs2 (Figure 38F). To probe the effect of BC-1365 on the activity of other HECT E3 
ligases, we treated MLE and BEAS-2B cells with BC-1365 and immunoblotted for known HECT 
E3 ligase substrate protein levels (Table 2). We did not observe increase in any other HECT E3 
ligase substrate relative to the increase in SOCS2 (Figure 39A-B). Additionally, we conducted 
target validation studies using RNAi knockdown of Kiaa0317 prior to treatment with BC-1365 
and LPS (Figure 39C-F). We observed that BC-1365 treatment of MLE cells increased SOCS2 
protein level, but not to a higher extent in the background of Kiaa0317 silencing (Figure 39C). We 
also tested the supernatant of these cells for pro-inflammatory cytokine release and observed 
decreased IL-6 and CXCL-1 during Kiaa0317 depletion compared to control, however we 
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observed no difference upon BC-1365 treatment among Kiaa0317 depleted cells (Figure 39D-E). 
Finally, we assayed the effect of BC-1365 on primary human PBMCs. We observed a dose-
dependent effect of BC-1365 in decreasing the secretion of pro-inflammatory cytokines IL-6, TNF, 
and IL-1β from human primary PBMCs exposed to LPS (Figure 41A-C). These data suggest 
chemically inhibiting KIAA0317 protein prevents SOCS2 degradation and dampens pro-
inflammatory signaling. 
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Figure 38 Chemical inhibition of KIAA0317 prevents SOCS2 degradation and inflammation in vitro  
A. Structural analysis of the KIAA0317 HECT domain revealed a major cavity within the C-terminus of the HECT 
domain. B-C. Docking study of candidate inhibitor BC-1365 with the KIAA0317-HECT domain. D. BC-1365 
Competition Assay. SOCS2 protein was incubated with KIAA0317-bound resin and a titration of BC-1365 prior to 
immunoblot analysis. The relative amounts of SOCS2 detected in the pull-downs was normalized to vehicle and 
quantified. Data represent mean values ± SEM (n=3). E. Immunoblot analysis of MLE cells following exposure to a 
titration of BC-1365, Data represent mean values ± SEM (n=4). F. MLE cells were exposed to a titration of BC-1365 
for 18h before qPCR analysis, data represent mean values ± SEM (n = 4).  NS, p>0.05; *, p < 0.05; **, p<0.01; 
compared with vehicle treatment, One-Way ANOVA with Dunnett’s Multiple Comparisons (E-F) 
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Table 2 HECT E3 ligase Homology to KIAA0317 
E3 Ligase 
Homology 
Ranking 
Characterized 
Substrate 
Reference 
KIAA0317/AREL1 0   
NEDD4L 1 SMAD2 (298) 
NEDD4 2 GRB10 (299) 
HACE1 3 Rac1 (1/2/3) (300) 
ITCH 4 CXCR4 (301) 
WWP2 5 Oct-3/4 (302) 
HUWE1 6 Mcl-1 (303) 
HECW1 7 DVL (304) 
SMURF1 8 SMAD1 (305) 
HECW2 9 Hp1a (306) 
SMURF2 10 SMAD2 (same as#2) (307) 
WWP1 11 TGFBR1 (308) 
UBE3C 12 IRF-7 (309) 
UBE3B 13 BCKDK (310) 
UBE3A 14 P27 (311) 
HECTD2 15 PIAS1 (283) 
HERC3 16 P65 (312) 
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Figure 39 BC-1365 is specific to KIAA0317   
A-B. Immunoblotting Analysis of known HECT-E3 Ligase substrates from MLE-12 and BEAS-2B cells treated with 
BC-1365. Parentheses after substrate name indicates HECT E3 ligase shown to regulate it (e.g. GRB10 targeted by 
NEDD4). C. SOCS2 blotting from MLE treated with Control or Kiaa0317 siRNA without or with BC-1365 treatment 
prior to LPS exposure. D-E. ELISA analysis of supernatant from cells treated in C. for inflammatory cytokines: D. 
IL-6 and E. CXCL1, data represent mean values ± SEM (n = 3-8). NS, p>0.05; *, p < 0.05; ***, p<0.001; compared 
with untreated Control, One-Way ANOVA with Tukey’s Multiple Comparisons (D-E). A-C. Data are representative 
of n=2-3 independent experiments. 
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3.2.11 Anti-inflammatory activity of a KIAA0317 small molecule inhibitor in vivo 
To assess in vivo anti-inflammatory activity of BC-1365, we exposed C57BL/6J mice to 
P. aeruginosa (PA103) and BC-1365. Briefly, PA103 was administered i.t. (1e4 CFU) 
immediately followed by BC-1365 delivery i.p. (10 mg/kg) for 18hr exposure. BC-1365 did not 
affect BALF bacterial counts (Figure 40A), however, BC-1365-treated mice displayed 
significantly decreased lavage protein concentrations, cell counts, and cell infiltrates relative to 
vehicle-treated (Figure 40B, C, I). Further, BC-1365 significantly decreased lavage cytokine levels 
(Figure 40D-F), increased SOCS2 protein levels (Figure 40H), and reduced histological infiltrates 
(Figure 40I). As an alternative approach, we tested BC-1365 in vivo using an LPS model (Figure 
41D-H). Briefly, LPS (3mg/kg, i.t.) and BC-1365 (10 mg/kg, i.p.) were co-administered to 
C57BL/6J mice. Following 18 hours, mice were euthanized, and lungs were lavaged with saline. 
BC-1365 treatment led to significantly decreased lavage protein concentrations, cell counts, and 
cell infiltrates in LPS-stimulated mice (Figure 41D, E, H). Further, BC-1365 treatment 
significantly decreased lavage cytokine levels (Figure 41F-G). Hence, small molecule targeting of 
the KIAA0317-SOCS2 pathway reduces severity of cytokine-driven lung inflammation (Figure 
42). 
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Figure 40 KIAA0317 small molecule inhibitor is anti-inflammatory in vivo  
A-E. C57BL/6J mice were exposed to PA103 and treated with BC-1365 for 18hr. Following exposure, mice were 
sacrificed, and lungs were lavaged with saline and harvested. Box represents the interquartile range, line is the median, 
and the whiskers represent highest and lowest observations. A-C. Bacterial count, protein concentration, and cell count 
measurements from bronchoalveolar lavage fluid (BALF). D-F. BALF cytokine concentrations. A-F. Data represent 
mean values ± SEM (n = 4-8 mice; *, p < 0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; compared with Control 
mice or as indicated, One-Way ANOVA with Tukey’s Multiple Comparisons). H. Immunoblotting of mouse lung 
homogenate for Kiaa0317 and Socs2 protein signal, n=3 mice per treatment. I. Representative histology of murine 
lungs following hematoxylin and eosin staining, bar indicates 100μm. NS, p>0.05; *, p < 0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001; compared with control treatment or as indicated, One-Way ANOVA with Tukey’s Multiple 
Comparisons (A-F). 
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Figure 41 BC-1365 shows efficacy in cell and animal models of inflammation 
A-C. ELISA analysis of cytokine release from LPS-treated PBMC co-treated with BC-1365 atindicated doses. Data 
represent mean values ± SEM (n = 3). D-H. C57BL/6J mice were intratracheally inoculated with LPS (3mg/kg) and 
intraperitoneal BC-1365 treatment (10mg/kg). 18h later, mice were sacrificed, and lungs were lavaged with saline and 
harvested. (D-E) Protein concentration and cell count measurements from bronchoalveolar lavage fluid (BALF). (F-
G) BALF cytokine concentrations. D-G. Data represent mean values ± SEM (n = 4 mice). J. Histology of murine lungs 
following H&E staining, bar indicates 100μm. NS, p>0.05; *, p < 0.05; **, p<0.01; compared with Vehicle, One-Way 
ANOVA with Dunnett’s Multiple Comparisons (A-C), or , two tailed unpaired Student’s t-test (D-G). 
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3.2.12 Discussion 
These studies have established a mechanism of SOCS2 protein regulation leading to the 
control of pulmonary inflammation. We showed the ubiquitin E3 ligase KIAA0317 targets SOCS2 
for ubiquitination and degradation by the proteasome and modulating pro-inflammatory signaling. 
In mouse models of LPS and PA-103 exposure, KIAA0317 depletion and deletion reduced 
markers of pulmonary inflammation and rescued SOCS2 protein. Re-introduction of KIAA0317 
protein into these models removed any protective phenotype; however, re-introduction of a binding 
deficient KIAA0317 mutant preserved the protection from experimental inflammation. We also 
uncovered a small molecule inhibitor of KIAA0317 activity, BC-1365, which preserved SOCS2 
protein from degradation in vitro and lessened cytokine release from primary tissue samples. BC-
1365-treated mice also displayed resistance to experimental pulmonary inflammation.  
SOCS2 mediates the degradation of a variety of proteins and functions as a feedback 
inhibitor to cytokine signaling (57). While SOCS2 has been shown to regulate several cytokine 
related pathways (282, 313), recently SOCS2 has been observed to directly regulate NF-κB 
signaling (280, 281). Similarly, the silencing of KIAA0317 weakened LPS and TNF-induced NF-
κB promoter activity in 293 cells (Figure 30K-L). LPS has been shown to induce cellular 
ubiquitination (314, 315), and we have previously observed E3 ligase induction and substrate-
association by such insult (60, 283). We observed that LPS exposure promoted SOCS2 association 
with KIAA0317, and accelerated SOCS2 protein ubiquitination and degradation (Figure 32H, I). 
LPS also increased SOCS2 polyubiquitin signal, which was further increased by co-expression 
with KIAA0317 (Figure 30J). These data show that KIAA0317 functions as a pro-inflammatory 
E3 ligase.  
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Mapping studies elucidated the critical regions of SOCS2-KIAA0317 binding. We 
observed that SOCS2 requires serine-52 for binding with KIAA0317, potentially functioning as a 
phosphodegron Figure 31C-F). Interestingly, there exists a naturally occurring polymorphism 
causing a S52N mutation (rs3741676). S52N SOCS2 protein was unable to bind KIAA0317, and 
resisted KIAA0317-mediated degradation (Figure 31D-F). PKCA was found to associate with 
SOCS2, facilitate its phosphorylation, and regulate its protein stability (Figure 32). This finding is 
interesting given that previous research show that PKCA upregulates NF-κB signaling (292, 316), 
potentially through the regulation of SOCS2 protein stability. Further, we observed that the C-
terminal region, and proline-779, within KIAA0317 is critical for SOCS2 binding (Figure 31G-
L). This residue itself is part of a naturally occurring polymorphism resulting in P779L mutation 
(rs371610162). KIAA0317 with P779L mutation is unable to degrade SOCS2 protein (Figure 
31L). Additionally, P779L-expressed Kiaa0317-/- mice were resistant to LPS-induced pulmonary 
inflammation, compared to WT KIAA0317-expressed Kiaa0317-/- mice (Figure 36). These data 
further underscore the protective phenotype conferred by P779L mutation, potentially through the 
inability to degrade SOCS2 protein. Studies into the prevalence of these polymorphisms among 
populations and among patient cohorts are needed to investigate the pathological implications in 
humans. 
Inflammatory lung diseases such as ARDS are often triggered by opportunistic infection, 
including gram-negative bacteria such as P. aeruginosa, leading to runaway inflammation and 
cytokine storm. We showed that shRNA knockdown of Kiaa0317 in a P. aeruginosa mouse model 
led to reduced lung inflammation and less cytokines and immune infiltrates compared to control, 
without changing P. aeruginosa bacteria levels in a mouse model. We further explored this 
relationship through CRISPR/Cas9-mediated deletion of Kiaa0317 in C57BL/6 mice (Figure 35). 
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Kiaa0317+/- and -/- mice showed increasing protection from pulmonary inflammation relative to 
wild-type. This effect could be due to the difference in effector protein abundance, as we observed 
depletion in KIAA0317 transcript through qPCR analysis (Figure 35B). Cytokine signal 
transduction pathways related to inflammation and innate immunity undergo significant cross-talk 
and pleiotropy, which impairs the generalizability of reductionist studies. To address this, we re-
expressed our deleted KIAA0317 protein in Kiaa0317-/- mice (Figure 36). As we observed a 
similar pro-inflammatory phenotype among KIAA0317 rescued mice compared to WT, we 
hypothesize that KIAA0317 protein is the driving effector in this model. Additionally, E3 ligases 
often regulate multiple substrates, specifically seen in fellow-HECT E3 ligase ITCH (317). To test 
the link between SOCS2 and KIAA0317, we silenced SOCS2 in Kiaa0317-/- mice, prior to LPS 
challenge (Figure 37). By silencing SOCS2 expression in the background of KIAA0317, we 
questioned if the protection conferred by KIAA0317 deletion occurred in the absence of SOCS2. 
However, SOCS2-silenced Kiaa0317-/- mice were susceptible to LPS-induced pulmonary 
inflammation and phenocopied SOCS2-silenced WT mice. This shows that the protective effect 
of KIAA0317 silencing is dependent of SOCS2. This interplay suggests the criticality of the two 
proteins in experimental lung inflammation. We suspect this KIAA0317-SOCS2 axis plays an 
essential role in regulating pulmonary innate immunity. 
There are limited therapeutic options for treating diseases of pulmonary inflammation. 
Previous efforts utilized systemic corticosteroids or inhibition of immune cell surface receptors or 
secreted cytokines (318-320). These broad-spectrum agents such as corticosteroids have shown 
adverse effects in clinical trials that outweigh any potential benefit (321). Chemical inhibition of 
ubiquitin E3 ligases has been shown to alleviate experimental lung inflammation (62, 283). We 
screened a chemical library in silico against the C-terminus of KIAA0317, and uncovered a 
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chemical, termed BC-1365 (Figure 38A-C). BC-1365 abrogated SOCS2-KIAA0317 binding in 
vitro, restored SOCS2 protein levels in cells (Figure 38D-F) and reduced the abundance of pro-
inflammatory cytokines secreted from PBMCs (Figure 41A-C). Based on these data, we tested 
BC-1365 in both P. aeruginosa- and LPS-induced murine models of ARDS. BC-1365 was also 
effective in vivo as BAL protein concentrations, BAL cell counts, lavage cytokine levels, and 
histological evidence of lung injury were all decreased in both models upon BC-1365 treatment 
(Figure 40) Small molecule inhibition of the KIAA0317/SOCS2 interaction reduces the severity 
of NF-κB-driven, cytokine-induced lung inflammation by modifying the abundance of SOCS2. 
These results suggest that KIAA0317 may be a promising new therapeutic target in the treatment 
of pulmonary inflammation. Future studies focusing on evaluating the safety profile, distribution, 
elimination, and metabolism of this antagonist are needed to fully understand the effects of this 
treatment, but the discovery of a novel therapy specific to a critical mechanism of pulmonary 
inflammation would be a crucial advancement in this field. 
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Figure 42 Proposed model of action 
Microbial infection or stimuli robustly trigger inflammation by decreasing anti-inflammatory proteins such as SOCS2 
in cells. Specifically, during microbial infection, KIAA0317 targets SOCS2 for its ubiquitination at Lys173; this 
process is facilitated by PKCA phosphorylation of SOCS2 at Ser52. A smallmolecule KIAA0317 inhibitor, BC-1365, 
lowered inflammation in the animal model of acute lung injury by antagonizing the actions of KIAA0317 on SOCS2-
cytokine signaling. 
 
3.2.13 Methods 
 Reagents and Materials 
Rabbit Polyclonal anti-SOCS2 (Cat# ab3692, RRID:AB_304007) and recombinant human 
PKC alpha protein(Cat# ab55672) were from Abcam. Recombinant Human SOCS-2 Protein (Cat# 
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H00008835-P01) was from Abnova. WesternBright Sirius HRP substrate (Cat# K-12043) was 
from Advansta. QuikChange II XL Site-Directed Mutagenesis Kit (Cat# 200521) was from Agilent 
Technologies. AnaSed (xylazine sterile solution) (Cat# 59399-110-20) was from Akorn. PureLink 
RNA Mini Kit (Cat# 12183025) was from Ambion. High-Capacity RNA-to-cDNA Kit (Cat# 
4387406) and SYBR Select Master Mix for CFX (Cat# 4472942) were from Applied Biosystems 
PA-103 (Cat# 29260), MLE-12 (Cat# CRL-2110, RRID:CVCL_3751), Hek293T(Cat# 
CCL-2, RRID:CVCL_0030), and BEAS2-B (Cat# CRL-9609, RRID:CVCL_0168) were from 
ATCC. Life ECO Thermal Cycler (Cat# BYQ6078) was from BIOER. Goat anti-Rabbit HRP
BioRad (Cat# 170-6515 RRID:AB_11125142), Goat anti-Mouse HRP (Cat# 170-6516 
RRID:AB_11125547), Rabbit anti-Goat HRP (Cat# 172-1034 RRID:AB_11125144), DC Protein 
Assay Kit (Cat# 5000111), CFX96 Touch Real-Time PCR Detection System (Cat# 1855196), 
Personal Molecular Imager™ (PMI™) System(Cat# 1709400), ChemiDoc™ XRS+ System (Cat# 
1708265), and TC20 Automated Cell Counter (Cat# 1450102) were from BioRad. Mouse 
Monoclonal anti-HA-Tag (clone 6E2) (Cat# 2367S RRID:AB_10691311), Rabbit Polyclonal anti-
SOCS1 (clone A156) (Cat# 3950S RRID:AB_2192983), and Mouse Monoclonal anti-
Phosphothreonine (Cat# 9386S RRID:AB_331239) were from Cell Signaling Technology. Lenti-
X Packaging System (Cat# 631276) was from Clontech. Human TNF alpha Recombinant Protein 
(Cat# 14-8329-81) and Mouse IL-6 ELISA Ready-SET-Go! (Cat# 88-7064-22 
RRID:AB_2574986) were from eBioscience. LPS, E. Coli O111:B4 (Cat# LPS25) was from EMD 
Millipore. Cycloheximide (Cat# BML-GR310) and Ubiquitinylation kit (Cat# BML-UW9920-
0001) were from Enzo. TNF alpha Mouse ELISA Kit (Cat# BMS607-3TEN), IL-1 beta Mouse 
ELISA Kit Invitrogen (Cat# KMC0011), pcDNA3.1D-V5-HIS-TOPOInvitrogen(Cat# 
K490001), and pcDNA3.1D-V5-HIS-Empty Invitrogen (Cat# K490001) were from Invitrogen. 
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C57BL/6J Mus musculus (RRID:IMSR_JAX:000664) were from JAX. Mouse Monoclonal Anti-
Ubiquitin (VU-1) (Cat# VU101) were from Life Sensors. ATP, [γ-32P]- 3000Ci/mmol 10mCi/ml 
(Cat# BLU002A) was from PerkinElmer. Pierce Streptavidin Magnetic Beads (Cat# 88816) were 
from Pierce. TnT T7 Quick Coupled Transcription/Translation (Cat# L1170) was from Promega. 
Cignal NFkB Pathway Reporter Assay Kit (LUC) (Cat# CCS-013L) was from Qiagen. X-
tremeGENE 9 (XTG9-RO) (Cat# XTG9-RO) was from Roche. Rabbit Polyclonal anti-SOCS3 
(clone H-103) (Cat# sc-9023 RRID:AB_2193305), Mouse Monoclonal anti-CaMKI (clone H-8)
(Cat#sc-137225, RRID:AB_2069999), Rabbit Polyclonal anti-ERK1 (clone C-16) (Cat# sc-93 
RRID:AB_631453), Rabbit Polyclonal anti-MAPK14 (p38α) (clone C-20) (Cat# sc-535 
RRID:AB_632138), Mouse Monoclonal anti-PKC alpha (clone H-7) (Cat# sc-8393 
RRID:AB_628142), Goat Polyclonal anti-p-PKCa (Ser 657) (Cat# sc-12356 RRID:AB_2168557), 
Mouse Monoclonal anti-Phosphoserine (Cat# sc-81516 RRID:AB_1128626), and Mouse 
Monoclonal anti-PKCz (Cat# sc-17781 RRID:AB_628148) were from Santa Cruz Biotechnology. 
Leupeptin (Cat# L2884), ATP (Cat# A2383), Mouse Monoclonal anti-beta-Actin (clone AC-15) 
(Cat# A5441 RRID:AB_476744), and Rabbit Polyclonal anti-KIAA0317 (Cat# SAB2108763) 
were from Sigma-Aldrich. Recombinant Glutathione S-Transferase Protein (Cat# 11213-HNAB) 
was from SinoBiological. Mouse Monoclonal anti-V5 Tag (Cat# R960-25 RRID:AB_2556564), 
Protein A/G Magnetic Beads (Cat# 88802), E. coli One Shot TOP10 (Cat# C404003), pcDNA3.1 
Directional TOPO Expression Kit (Cat# K490001), were from Thermo Fisher Scientific. pRK5-
HA-Ubiquitin-WT (Cat#17608, RRID:Addgene17608) Was a gift from Ted Dawson (322). 
 Contact for Reagent and Resource Sharing 
Further information and requests for reagents may be directed to, and will be fulfilled by 
the corresponding author Bill B. Chen (chenb@upmc.edu) 
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 Experimental Model and Subject Details 
Human Studies (Acute Respiratory Distress Syndrome (ARDS)):  
Adults aged 18-90 admitted to the Medical ICU in the UPMC Presbyterian Hospital with 
acute respiratory failure requiring mechanical ventilation via endotracheal tube were enrolled as 
patients if the onset of acute respiratory failure was associated with established risk factors for 
developing acute lung injury (sepsis, pneumonia, aspiration, blood transfusion, pancreatitis, or 
trauma) or if intubation was performed for airway protection in the setting of non-pulmonary 
critical illness. Enrollment took place within 48 h of the initiation of mechanical ventilation. After 
enrollment, patients were retrospectively sub-classified by an expert clinical panel into categories: 
1) ‘ARDS’, as defined by Berlin criteria and agreed upon by a minimum of three members of an 
expert clinical panel, or 2) ‘ventilated control,’ as defined by intubation and mechanical ventilation 
for non-pulmonary critical illness without risk factor for ARDS. Cells were purified from whole 
blood and white cells were pelleted for further study.  
Mouse experiments: 
Mice were from Jackson Laboratories. For lentiviral studies, mice were confirmed as 
anesthetized prior to intratracheal instillation of 0.1 % (w/v) lysophosphatidylcholine (LysoPC) 
(specifically Palmitoyl:Stearoyl C16:C18) as an adjuvant. Following one hour, mice were intra-
tracheally administered VSV-G pseudotyped lentivirus encoding Empty, KIAA0317 WT, or 
KIAA0317 P779L (pLVX); or Control shRNA or Kiaa0317 shRNA (pLKO.1) (1e7 PFU/mouse). 
Plasmid expressed for 144 hours prior to subsequent treatment. Mice were intra-tracheally 
inoculated with LPS (3 mg/kg) or given P. aeruginosa (strain PA103, 1e4 CFU) for 18h. Following 
exposure, mice were euthanized, and lungs were lavaged with saline and harvested and subjected 
to analysis. Survival studies of mice were performed on mice that were given P. aeruginosa (strain 
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PA103, 1e5 CFU per mouse, intratracheally). For drug studies, mice were deeply anesthetized as 
above. PA103 (1e4 CFU) or LPS (3 mg/kg) was administered intratracheally before BC-1382 (10 
mg/kg) was administered to the mice through an intraperitoneal injection. Eighteen hours later, 
animals were euthanized and analyzed as above. 
 Method Details 
Plasmid Transfection— For protein overexpression in MLE-12 and BEAS-2B cells, cells 
were nucleofected using Nucleofector 2B (Amaxa), program T-13. For protein overexpression in 
HEK293T cells, XtremeGENE transfection reagents were used following the manufacturer’s 
protocol. Expression was confirmed via western blotting. 
 
Immunoblotting— Cell sample lysates were collected and digested in Buffer A (150 mM 
NaCl, 50 mM Tris, 1.0 mM EDTA, 2 mM dithiothreitol, 0.025% sodium azide, and 1 mM 
phenylmethylsulfonyl fluoride) on ice. Lysates were prepared by brief sonication at 4°C. Insoluble 
cellular debris were precipitated through centrifugation at 15,000x rcf for 10 min at 4°C. Lysate 
supernatant was normalized for protein concentration, and diluted in denaturing loading buffer, 
with a final 1X formulation of: 50 mM Tris HCl pH 6.8, 2% SDS, 10% Glycerol and 100 mM 
DTT. Protein concentration was determined by Lowry assay, and samples were normalized for 
content. Samples were resolved via SDS-PAGE prior to immunoblotting. Signal was detected via 
chemiluminescence on a Kodak Imaging Station.  
 
Chemical and Compound treatment – MLE-12 and other cell lines were seeded to a density 
of 0.20x106 cells/mL in polystyrene 6-wells dishes treated by vacuum gas plasma in media 
supplemented with 2% FBS for 18h. LPS, MG-132 (10 µM), Leupeptin (10 µM), Cycloheximide 
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(50 μg/mL), or BC compound was added to cells at indicated doses for indicated time periods prior 
to subsequent analysis. 
 
In vitro ubiquitin conjugation assays—The assay was performed in a volume of 20 µl 
containing 50 mM Tris, pH 7.6, 5 mM MgCl2, 0.6 mM DTT, 2 mM adenosine triphosphate (ATP), 
400 µM MG132, 50 nM Ubiquitin activating enzyme, 0.5 µM UbcH5, 0.5 µM UbcH7, 2 µM 
ubiquitin, and 1 µM ubiquitin aldehyde. TnT coupled reticulocyte in vitro–synthesized tagless-
KIAA0317 and SOCS2-V5 proteins were purified via HisPur Resin, and reaction products were 
processed for V5 immunoblotting. 
 
Promoter Assays—HEK293 cells were co-transfected with Cignal NF-κB luciferase 
reporter assay plasmids and Empty, KIAA0317, SOCS2, CON shRNA, or KIAA0317 shRNA for 
24-48 h before exposure to LPS (10 µg/mL) and TNF (10 ng/mL) for an additional 6 or 18 h. Cells 
were then collected and assayed for luciferase activity according to manufacturer’s instructions. 
 
In vitro protein binding assays— KIAA0317 protein was immunoprecipitated from 1 mg 
MLE cell lysate using 1:100 dilution of KIAA0317 antibody (rabbit) for four hours at 25°C in IP 
buffer (50 mM Tris HCl pH 7.6, 150 mM NaCl, 0.25 % v/v Triton-X-100) and coupled to protein 
A/G agarose resin for an additional hour. V5-tagged SOCS2 deletion and point mutants (50 μl) 
were in vitro synthesized using TnT translation kits for 90 minutes at 30°C. KIAA0317-bound 
resin was then incubated with the in vitro synthesized bait protein for 18 hours at 4°C. Following 
binding, resin was washed with IP buffer, and eluted in 1X Laemmli buffer at 88°C for five minutes 
prior to immunoblotting analysis. Similarly, SOCS2 protein was immunoprecipitated from MLE 
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cell lysate subjected to binding against V5-tagged KIAA0317 mutants prior to immunoblotting 
analysis, as described above. 
 
Immunoprecipitation Assays— MLE cells were cultured and treated as indicated prior to 
collection. Cell pellets were lysed with IP buffer (0.25% Triton-X-100 in 1x PBS, pH 7.6, 0.025% 
sodium azide, and 1 mM phenylmethylsulfonyl fluoride) on ice. Lysates were prepared by brief 
sonication at 4°C. Insoluble cellular debris were precipitated through centrifugation at 15,000x rcf 
for 10 min at 4°C. Lysate supernatant was normalized for protein concentration. Supernatants were 
exposed to a 1:50 dilution of the indicated antibody for three hours at 25°C. Immunoprecipitated 
protein was captured with 10 µL magnetic protein A/G resin per 1mL of lysate for 1 hour prior to 
two rounds of washing with IP buffer (1 mL). Protein was eluted by dilution in denaturing loading 
buffer, with a final 1X formulation of: 50 mM Tris HCl pH 6.8, 2% SDS, 10% Glycerol and 100 
mM DTT and boiling for 5 minutes. Eluted samples were resolved via SDS-PAGE and subjected 
to immunoblotting. 
 
shRNA Knockdown— For gene silencing studies in cells, shRNA were derived from the 
RNAi Consortium (TRC-Hs1.0, Human) and purchased from GE Dharmacon. pLKO.1 plasmids 
encoding control or gene-specific shRNA were transfected using plasmid transfection protocol 
above. Following 24 hours, media was exchanged for 0%-serum-containing media. After another 
24 hours, cells were collected for subsequent analysis.  
 
146 
ELISA— Enzyme-linked immunosorbent assays were conducted on BALF samples from 
treated mice. BALF IL-1, IL-6, and TNF was detected by following manufacturer’s instructions, 
and absorbance read using microplate reader. 
 
Tissue staining—Murine lung samples were fixed in 10% neutral buffered formalin and 
embedded in paraffin and sectioned. Sections were stained with eosin and hematoxylin. Images 
were acquired from 20× lens from random fields from each section.  
 
Molecular docking studies— The docking experiments were carried out using Discovery 
Studio 3.5. KIAA0317 domain structural analysis revealed a major drug binding cavity within the 
c-terminal region. The binding cavity was adopted into the LibDock algorithm to screen for the 
optimum inhibitor. A library containing 3 million approved or experimental drugs was first used 
to screen potential ligands for KIAA0317. Based on the docking score and best-fit analysis of 
suitable ligands, ten compounds were selected and tested.   
 
In vitro drug-binding assays—KIAA0317 protein was HIS-purified from KIAA0317 
expressed in 293T cells using Talon metal affinity resin. Resins were then extensively washed 
before exposure to BC-1365 at indicated concentrations. Purified recombinant SOCS2 protein was 
then incubated with drug-bound KIAA0317 resins overnight. Resins were washed, and proteins 
were eluted and resolved on SDS-PAGE. The relative amounts of SOCS2 detected in the pull-
downs were normalized to loading and quantified. 
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GST-Bait and Pull-down— Recombinant GST-SOCS2 protein was used as bait for BEAS-
2B lysate incubation prior to pull-down and analysis, as previously described (323). Briefly, 1µg 
of GST-SOCS2 protein or recombinant GST protein was immobilized onto 0.5 mL of Glutathione 
Sepharose 4B resin in binding buffer (1x PBS + 0.2% v/v Triton X-100) for 2hr at +4C with 
agitation. Following capture, the bait and resin were incubated with 1mg of BEAS-2B cell lysate 
for 4hr at +4C. The resin was washed 5 times (1mL) with binding buffer prior to freezing of resin 
and shipment to MSBioWorks for analysis.   
 Quantification and Statistical Analysis 
Protein Signal densitometry was quantified via ImageJ. Statistical comparisons were 
performed through Prism (GraphPad) utilizing two-tailed t-tests, Mann-Whitney U-Tets, one-way 
ANOVA with Tukey or Dunnett’s multiple comparisons tests where described, and with p<0.05 
indicative of significance.  
 Study Approval 
The University of Pittsburgh Institutional Review Board approved procedures involving 
human samples. Normal control lung tissue was obtained from organ donors, after rejection of the 
lungs for transplant.  All procedures were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee (Protocols 17030095 and 18114128). C57BL/6J males aged 8-
10 weeks were acclimated to new housing for at least three days following shipping. Each house 
contained 4-5 mice with access to food and drink ad libitum in a room with a twelve-hour light/dark 
cycle. We confirmed mice were between 25 and 30g before any procedures. Mice were deeply 
anesthetized using a ketamine/xylazine mixture (80–100 mg/kg intraperitoneally (i.p.) prior to 
experimentation. Mice were carefully monitored over time; moribund, preterminal animals were 
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immediately euthanized and recorded as deceased. De-identified human plasma samples were 
obtained from the University of Pittsburgh Acute Lung Injury Biospecimen Repository (IRB 
number #PRO10110387). Informed consent was provided by all participants or their surrogates in 
accordance with the Declaration of Helsinki. Leukocyte was obtained from patient blood with a 
protocol approved by the University of Pittsburgh Investigational Review Board.  
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3.3 The RNFT2/IL-3Rα Axis Regulates IL-3 Signaling and Innate Immunity 
Adapted from: Tong, Lear, and Evankovich et al., The RNFT2/IL-3Rα axis regulates IL-3 
signaling and innate immunity. JCI Insight. 2020 Feb 13;5(3). pii: 133652. doi: 
10.1172/jci.insight.133652. PMID: 31990690, (324) 
 
Following the activation of inflammatory signaling in the lung, pulmonary epithelial cells 
release cytokines to begin the immune response to the distressed lung. Indeed, cytokines derived 
from the pulmonary epithelia can act in a paracrine or autocrine fashion to further stimulate 
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inflammatory signaling. In this study we investigate the proteolytic regulation of the interleukin-3 
receptor subunit alpha in pulmonary epithelia, and its effect on inflammatory signaling. IL-3 
treatment sensitized epithelial cells to LPS exposure, leading to an enhanced inflammatory 
response. While this study does not conclusively determine the source of IL-3 (we hypothesize it 
arises from the systemic vasculature), this study demonstrate a clear synergism between IL-3 and 
LPS/bacterial treatment in affecting inflammatory signaling, and presents the RING E3 ligase 
RNFT2 as a mediator of IL-3 signaling in the lung. 
3.3.1 Overview 
Interleukin-3 (IL-3) receptor α (IL-3Rα) is the α subunit of the ligand-specific IL-3R and 
initiates intracellular signaling in response to IL-3. IL-3 amplifies proinflammatory signaling and 
cytokine storm in murine sepsis models. Here we found that RNFT2 (RING finger transmembrane-
domain containing protein 2, also TMEM118), a previously uncharacterized RING finger ubiquitin 
E3 ligase, negatively regulated IL-3-dependent cellular responses through IL-3Rα ubiquitination 
and degradation in the proteasome. In vitro, IL-3 stimulation promoted IL-3Rα proteasomal 
degradation dependent on RNFT2, and we identified IL-3Rα lysine 357 as a ubiquitin acceptor 
site. We determined that LPS priming reduces RNFT2 abundance, extends IL-3Rα half-life, and 
sensitizes cells to the effects of IL-3, acting synergistically to increase proinflammatory signaling. 
In vivo, IL-3 synergized with LPS to exacerbate lung inflammation in LPS and Pseudomonas 
aeruginosa-challenged mice; conversely, IL-3 neutralization reduced LPS-induced lung injury. 
Further, RNFT2 overexpression reduced lung inflammation and injury, whereas Rnft2 knockdown 
exacerbated inflammatory responses in LPS-induced murine lung injury. Last, we examined 
RNFT2 and IL-3Rα in human lung explants from patients with cystic fibrosis and also showed that 
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IL-3 is elevated in mechanically ventilated critically ill humans at risk for acute respiratory distress 
syndrome. These results identify RNFT2 as a negative regulator of IL-3Rα and show a potential 
role for the RNFT2/IL-3Rα/IL-3 axis in regulating innate immune responses in the lung.  
 
Figure 43 Graphical Abstract  
Schematic of the RNFT2-IL3R model of activity. Under normal homeostatic conditions, IL3R is ubiquitinated by 
RNFT2 and proteolytically processed by the proteasome. During infection or acute lung inflammation, concurrent 
stimulation with LPS and exogenous IL3 leads to impaired RNFT2-mediated degradation of IL-3Ra and persistent 
pro-inflammatory signaling through NF-κB, leading to cytokine production, release, and increased inflammation. 
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3.3.2 Introduction – IL3 signaling in inflammation 
Interleukin-3 (IL3), a cytokine that regulates hematopoiesis (325), also amplifies cytokine 
storm in murine sepsis(326), and in septic humans elevated circulating IL3 is associated with 
mortality (326). The downstream effects of IL3 are mediated by binding to its receptor, a  complex 
that contains an alpha subunit (IL3R or CD123) and a beta subunit (IL3Rβ or CSF2RB) (327). 
IL3R neutralizing antibodies are protective in murine sepsis (326, 328)  and IL3 predicts 
responsiveness to corticosteroid therapy in septic humans (329). Thus, the IL3/ IL3R axis may 
be a therapeutic target in sepsis and other acute inflammatory disorders. Here we show a previously 
uncharacterized mechanism regulating IL3R abundance through the ubiquitin/proteasome 
system (UPS), directed by the E3 ligase RING finger transmembrane-domain containing protein 
2 (RNFT2). 
 Mechanism of IL-3 Signaling 
IL3-initiated intracellular signaling is dependent on receptor subunits IL3R and IL3Rβ 
(325, 330). The beta subunit IL3Rβ, also known as the beta-common receptor (βc), is a shared 
receptor subunit that detects several colony-stimulating factor cytokines, including IL3, GM-CSF, 
and IL-5 (325, 327, 330). Depending on the stimulus (IL3, GM-CSF, or IL-5) and the cell type, 
several intracellular signaling pathways can be activated. The most well characterized signaling 
mechanisms include activation of the Janus kinase 2 (JAK2)/signal transducer and activator of 
transcription 5 (STAT5) pathway and the PI3 kinase pathway (331). Further, activation of the NF-
κB pathway through TRAF6 recruitment to the beta subunit has been described (332). The 
consequences of these signaling pathways is diverse and context specific, as βc cytokines have 
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been implicated in several inflammatory diseases, including allergic asthma, inflammatory bowel 
disease, multiple sclerosis, and sepsis, among others(333). In murine sepsis, IL3 potentiates 
cytokine storm, a phenomenon associated with end-organ damage and mortality,  and blockade of 
the IL3 receptor subunit IL3R protects against the deleterious effects of IL3 (326). Several E3 
ligases have been shown to regulate innate immunity and inflammation in lung injury (141, 232, 
334) (283, 335, 336), and here we characterize the E3 ligase RNFT2 as negative regulator of 
IL3R. 
 Post-Translational Regulation of IL3R 
In this study, we show the IL3 receptor subunit IL3R is targeted for ubiquitination and 
degradation by the E3 ligase RNFT2 (RING finger transmembrane-domain containing protein 2, 
also TMEM118). We identify IL3R Lys357 as a critical residue regulating IL3R stability. In 
vitro, IL3 promotes RNFT2-dependent IL3R proteasomal degradation, an effect mitigated by 
LPS-priming. Using models of LPS and Pseudomonas aeruginosa (PA) murine lung injury in 
vivo, we show that while exogenous IL3 administration amplifies inflammation and organ damage, 
while IL3 neutralization is protective. Further, in LPS murine lung injury models, RNFT2 over-
expression conferred protection from the deleterious effects of IL3, while Rnft2 knockdown 
augmented IL3-dependent effects and lung injury severity. Lastly, in humans we show IL3 is 
elevated in subjects with Acute Respiratory Distress Syndrome (ARDS), and that IL3R and 
RNFT2 abundance are inversely correlated in lung homogenates from lung explants in cystic 
fibrosis patients. These data show RNFT2 is a previously unrecognized regulator of IL3-dependent 
cellular effects by controlling IL3R stability.  
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3.3.3 IL3Rα is degraded in the proteasome in response to IL3  
We sought out to determine IL3Rα protein stability. We confirmed IL3Rα expression in 
MLE-12 (MLE) cells and RAW cells (Figure 44A and Figure 45A). IL3Rα transcript was also 
present in RNA-Seq experiments from MLE cells (GEO accession GSE94680)(337). MLE cells 
were treated with cycloheximide (CHX) and IL3Rα half-life was observed to be ~ 6h; additionally, 
we found CHX-induced IL3Rα degradation was prevented by the proteasome inhibitor MG132, 
but not by the lysosomal inhibitor leupeptin (Figure 44A). We observed a similar half-life and 
preservation with MG132 treatment in RAW cells (Figure 45A). As IL3Rα protein is protected by 
proteasomal blockage, we hypothesized that IL3Rα degradation is regulated by the ubiquitin 
proteasome system. Indeed, expression of ubiquitin in MLE cells led to a dose-dependent decrease 
in IL3Rα protein (Figure 45B). Further, IL3Rα protein is retained following co-expression of 
ubiquitin and MG132 treatment (Figure 44B), an effect not seen with leupeptin treatment.  
We next characterized the ubiquitination linkage type, as substrate ubiquitination controls 
several diverse cellular functions (97). We performed UbiCREST analysis, in which HIS-tagged 
IL3Rα was expressed in MLE cells prior to MG132 treatment, HIS-pulldown, and in vitro 
exposure to de-ubiquitinases (DuB) with differential activity to specific ubiquitin chain linkages 
(338). We observed digestion of IL3Rα polyubiquitination by DuBs with affinity for K48-, K27-, 
K29-, K33-, K11-, and K63-type linkages (Figure 45C). K48-linked polyubiquitination is a 
common linkage associated with proteasomal degradation (97, 339). As an orthogonal approach, 
we co-expressed IL3Rα and ubiquitin constructs with specific K→R mutations, prior to MG132 
treatment and IL3Rα pull-down, followed by immunoblotting. We observed that the expression of 
several mutants, especially K48R and K63R mutants, resulted in reduced poly-ubiquitinated-
IL3Rα compared to WT-Ubiquitin (Figure 45D). Taken together, these results suggest IL3Rα 
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ubiquitination is a signal for degradation. Ubiquitin is conjugated to substrate proteins at target 
lysine (K) residues, and we generated IL3Rα lysine-to-arginine (K→R) mutants to identify 
putative ubiquitin acceptor sites, as arginine (R) is unable to accept ubiquitin. We found the IL3Rα 
K357R mutant protein was resistant to degradation in CHX chase experiments (Figure 44C). Thus, 
K357 is a candidate ubiquitin acceptor site for IL3Rα. These experiments suggest that IL3Rα 
protein is regulated through ubiquitination leading to proteasomal degradation.  
We examined whether IL3 stimulation would promote proteasomal degradation of IL3Rα 
and affect its downstream signaling. IL3Rα abundance decreased in a time- and dose-dependent 
manner following IL3 stimulation (Figure 44D), an effect that was mitigated by pre-treatment with 
MG132, but not leupeptin (Figure 44E). Additionally, IL3 stimulation reduced amounts of ectopic 
IL3Rα WT, but not IL3Rα K357R, in MLE cells (Figure 44F). These results suggest that IL3Rα 
undergoes ligand-induced degradation in the proteasome. Lastly, we examined if IL3Rα affected 
IL3 dependent downstream effects. TRAF6-dependent NF-κB activation has been shown as a 
cellular response to IL3(332)  and we observed that IL3 stimulation of MLE cells increased TRAF6 
abundance as well as RelB and phospho-P100, proteins involved in the NF-κB signaling cascade 
(Figure 44G). Further, over-expression of IL3Rα augmented these effects (Figure 44G). 
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Figure 44 IL3Rα is degraded in the proteasome in response to IL3   
(A) Immunoblot analysis of IL3Rα protein abundance in MLE cells treated with cycloheximide (CHX) with or without 
MG-132 or Leupeptin in a time-dependent manner, Data and means ± SEM of 3 independent experiments. (B) 
Immunoblotting of IL3Rα-V5 HIS pull-down (HIS PD) from MLE cells after co-expression of IL3Rα-V5 and HA-
Ubiquitin, and treatment with MG132 or leupeptin. (C) Immunoblot analysis of MLE cells transfected with WT or 
lysine mutant (K357R) IL3Rα and treated with CHX. Data and means ± SEM of 3 independent experiments. (D) 
Immunoblotting of IL3Rα protein abundance from MLE cells treated with recombinant IL3 protein (rIL3) in a dose 
or time-dependent manner. (E) Immunoblot analysis of IL3Rα protein amount from MLE cells treated with rIL3 with 
or without MG-132 or Leupeptin in a time-dependent manner. Data and means ± SEM of 3 independent experiments. 
(F) Immunoblot analysis of IL3Rα-V5 protein amount from MLE transfected with WT or K357R mutant IL3Rα and 
treated with rIL3 treatment. Data and means ± SEM of 3 independent experiments. (G) Immunoblot analysis of MLE 
cells transfected with IL3Rα or empty plasmid, and then were challenged with or without rIL3. Data and means ± 
SEM of 3 independent experiments. *P ＜0.05, **P ＜0.01, ***P ＜0.001 by F-test (A, C, E, F), or by one-way 
ANOVA with Tukey’s post hoc test (G). 
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Figure 45 IL-3Rα is ubiquitinated and assembles specific poly-ubiquitin linkage types  
(A) Western blot analysis of IL-3Rα abundance in lysates of RAW 264.7 cells treated with cycloheximide (CHX) 
with or without MG-132 or Leupeptin over time. Blots are representative of 2 independent experiments. (B) Western 
blot analysis of IL-3Rα abundance in lysates of MLE cells transfected with increasing amounts of a HA-Ubiquitin 
construct. Blots are representative of 2 independent experiments. (C) UbiCREST analysis of IL-3Rα 
immunoprecipitates from lysate of MLE cells after MG132 treatment. Blots are representative of 2 independent 
experiments. (D) Western blot analysis of IL-3Rα and Ubiquitin in IL-3Rα immunoprecipitates from lysate of MLE 
cells transfected with V5-IL-3Rα and HA-Ubiquitin K→R point mutants after MG132 treatment. Blots are 
representative of 2 independent experiments. 
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3.3.4 RING Finger E3 ligase RNFT2 regulates IL3Rα stability and signaling  
We next investigated the mechanism involved in IL3Rα protein ubiquitination and 
degradation. We over-expressed E3 ligases in MLE cells(60, 141, 340, 341)  and observed that the 
uncharacterized E3 ligase RNFT2 decreased IL3Rα protein amounts (Figure 46A), without 
affecting its mRNA expression (Figure 47A). Expression of RNFT2 led to a dose-dependent 
decrease of IL3Rα protein, but not that of IL3Rβ protein (Figure 46B). We observed that RNFT2 
protein associated with IL3Rα in MLE cells by RNFT2 pull-down (Figure 46C). Thus, RNFT2 is 
a candidate E3 ligase targeting IL3Rα as a substrate for ubiquitination and degradation. 
To confirm that RNFT2 functioned as an E3 ligase to ubiquitinate IL3Rα, we performed 
an in vitro ubiquitination assay. RNFT2 protein in addition to the full complement of ubiquitination 
machinery was sufficient to ubiquitinate IL3Rα in vitro (Figure 46D). As a complementary 
approach, we showed that co-expression of RNFT2 with HA-Ubiquitin and IL3Rα-HIS-V5 led to 
degradation of IL3Rα protein and increased the HA-ubiquitin signal upon IL3Rα-HIS pulldown 
as compared to control (Figure 46E). As a putative RING Finger E3 ligase, RNFT2 functions 
through its RING domain (Figure 47B). Mutation of critical residues within this region led to 
preservation of IL3Rα protein relative to WT (Figure 47C). To further confirm RNFT2 activity as 
an authentic ubiquitin E3 ligase, we performed in vitro binding assays and observed that RNFT2 
indeed bound to several ubiquitin E2 enzymes (Figure 46F). We also confirmed the association of 
RNFT2 with endogenous UBE2D protein through cell-based pull-down assays (Figure 46G). 
Lastly, to demonstrate the specificity of RNFT2 to target IL3-Rα, we co-over-expressed RNFT2 
with WT or K357R IL3-Rα. RNFT2 over-expression reduced amounts of IL3Rα WT, but not 
IL3Rα K357R (Figure 46H). Hence, we confirmed that RNFT2 is an authentic E3 ligase that 
targets IL3Rα as a substrate. 
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Figure 46 RING Finger E3 ligase RNFT2 regulates IL3Rα stability and IL3 signaling 
(A) Immunoblot analysis of IL3Rα from MLE cells transfected with LacZ or one of the other 10 randomly selected 
Ring-finger E3 ligases. IL3Rα/Actin Densitometry normalized to LacZ treatment is shown belowF IL3Rα bands.  (B) 
Immunoblotting of IL3Rα from MLE cells transfected with a dose course of RNFT2. Data and means ± SEM of 3 
independent experiments. (C) Immunoblot analysis of MLE cells following expression of RNFT2-HA and 
immunoprecipitation (IP) of RNFT2-HA. (D) Immunoblotting of in vitro ubiquitination assay involving the full-
complement of ubiquitination machinery (E1, E2, Ubiquitin, ATP, Mg++) and RNFT2 protein. (E) Immunoblot 
analysis of in vivo ubiquitination assay in MLE cells expressing IL3Rα-HIS-V5 with HA-Ubiquitin and RNFT2 prior 
to MG132 treatment and HIS-tag pulldown (HIS PD) of IL3Rα-HIS-V5. (F) Immunoblotting of in vitro protein 
binding assay between V5-tagged ubiquitin E2 enzymes (Ub E2) and immunoprecipitated RNFT2 protein (IP 
RNFT2). (G) Immunoblot analysis of MLE cells expressing RNFT2-HIS-V5 prior to HIS pulldown (HIS PD) of 
RNFT2. (H) Immunoblot analysis of MLE cells co-transfected with WT or K357R IL3Rα lysine mutants with or 
without RNFT2, Data and means ± SEM of 3 independent experiments. *P ＜0.05, ***P ＜0.001 by one-way 
ANOVA with Dunnett’s post hoc test (B), or by one-way ANOVA with Tukey’s post hoc test (H). 
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Figure 47 RNFT2 is a RING Ubiquitin E3 ligase and is transcriptionally down-regulated by LPS   
(A) RT-qPCR analysis of IL-3Rα mRNA expression in MLE cells transfected with increasing amounts of RNFT2. 
Data are pooled from 3 independent experiments. (B) Schematic of RNFT2 sequence and critical residues within its 
predicted RING domain. (C) Western blot analysis of IL-3Rα abundance in lysates of MLE cells transfected with 
increasing amounts of RNFT2 WT and RING mutant constructs. (D) Immunoblot analysis of MLE cells treated with 
CHX time course without or with LPS co-treatment. (E) RT-qPCR analysis of RNFT2 mRNA expression in MLE 
cells treated with a time course of LPS and represented as fold change relative to 0hr time point. Blots are 
representative of 2-3 independent experiments. Data and means ± SEM of 3 independent experiments NS, P > 0.05, 
*P ＜0.05, **P ＜0.01; by one-way ANOVA with Dunnett’s post hoc test (A, E). 
 
160 
Next, we investigated whether RNFT2 affected IL3Rα abundance and signaling in 
response to IL3. RNFT2 overexpression significantly enhanced rIL3-induced IL3Rα degradation 
(Figure 48A), whereas Rnft2 knockdown markedly preserved IL3Rα protein with IL3 stimulation 
(Figure 48B). We found that ectopic expression of RNFT2 decreased TRAF6 protein amount in 
rIL3-stimulated MLE cells (Figure 48C), whereas Rnft2 knockdown significantly increased 
TRAF6 protein abundance (Figure 48D).  
 
Figure 48 RNFT2 regulates IL3Rα protein levels and IL3Rα-dependent inflammatory signaling 
(A) Immunoblotting of MLE cells transfected with empty or RNFT2 plasmid before IL3 treatment. Data and means 
± SEM of 3 independent experiments. (B) Immunoblot analysis of MLE cells transfected with con-siRNA or Rnft2 
siRNA before rIL3 treatment. Data and means ± SEM of 3 independent experiments. (C) Immunoblotting of MLE 
cells transfected with empty or RNFT2 plasmid and challenged with or without rIL3. Data and means ± SEM of 3 
independent experiments. (D) Immunoblot analysis of MLE cells transfected with RNFT2 siRNA or control siRNA 
and were then challenged with or without rIL3. Data and means ± SEM of 3 independent experiments. *P ＜0.05, **P 
＜0.01, ***P ＜0.001, ****P ＜0.0001 by F-test (A, B), or by one-way ANOVA with Tukey’s post hoc test (C, D). 
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3.3.5 IL3 augments pro-inflammatory cellular responses to LPS through IL3Rα and 
RNFT2 
IL3 exacerbates the pro-inflammatory effects of LPS(326).  We hypothesized that this 
effect could be partially mediated through LPS-dependent modulation of IL3Rα stability. LPS 
treatment in MLE cells led to an increase in IL3Rα protein abundance and a concomitant decrease 
in RNFT2 protein levels (Figure 49A, B). While RNFT2 protein levels did not differ over an 8-
hour CHX chase with or without LPS co-treatment, we observed that LPS treatment decreased 
Rnft2 gene transcription (Figure 47D, E). The LPS-mediated effect on IL3Rα protein levels was 
specific, as IL3Rβ protein levels were not affected by LPS (Figure 49C). Further, the increase in 
IL3Rα protein abundance was independent of changes in IL3Rα gene transcription (Figure 49D). 
We also found that in CHX chase experiments, LPS pre-treatment extended IL3Rα half-life 
(Figure 49E). Co-treatment of LPS with IL3 increased supernatant cytokine levels of IL-6 and 
CXCL-1 compared to LPS treatment alone, an effect further exacerbated with IL3Rα over-
expression (Figure 49F, G).  
We then examined the effect of RNFT2 over-expression or knockdown on cytokine 
secretion in MLE cells in response to LPS/IL3. RNFT2 over-expression mitigated the effect of 
LPS/IL3 co-treatment on CXCL-1 secretion (Figure 49H), while Rnft2 knockdown exacerbated 
this effect (Figure 49I). Lastly, we co-over-expressed WT or K357R IL3Rα with an empty vector 
or RNFT2 and stimulated MLE cells with LPS/IL3. RNFT2 over-expression mitigated TRAF6 
abundance as well as IL-6 and CXCL-1 cytokine secretion in cells co-overexpressed with WT 
IL3Rα; however, RNFT2 over-expression had no effect on TRAF6 abundance, or IL-6 and 
CXCL1 cytokine secretion in cells co-overexpressed with K357R IL3Rα (Figure 50A-C). Thus, 
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the degradation-resistant K357R IL3Rα mutant was not affected by RNFT2 over-expression. 
Taken together, these data suggest that LPS sensitizes cells to IL3 through stabilization of IL3Rα. 
 
Figure 49 IL3 augments pro-inflammatory cellular responses to LPS through IL3Rα and RNFT2 
(A-C) Immunoblot analysis of IL3Rα (A), RNFT2 (B), and IL3Rβ (C) protein abundances in Murine lung epithelial 
(MLE) cells treated with LPS at the indicated times. Blots (top) are representative of 3 independent experiments. 
Quantified data (lower) are means ± SEM from all experiments (n=3). (D) RT-qPCR analysis of IL3Rα mRNA 
expression in Murine lung epithelial (MLE) cells treated with LPS at the indicated times. Quantified data are means 
± SEM from all experiments (n=3). (E) Immunoblot of IL3Rα in MLE cells treated with cycloheximide (CHX) and 
control (Con) or LPS, as indicated. Blots (top) are representative of 3 independent experiments. Quantified data 
(lower) are means ± SEM from all experiments (n=3). (F and G) ELISA analysis of IL-6 and CXCL-1 in supernatants 
from MLE cells transfected with IL3Rα or empty plasmid, and challenged with LPS and rIL3, as indicated. Data are 
means ± SEM from all experiments. (H) ELISA analysis of CXCL-1 in MLE cells transfected with RNFT2 or empty 
plasmid before treatment with LPS with or without rIL3. Data and means ± SEM of 3 independent experiments. (I) 
ELISA analysis of CXCL-1 in MLE cells transfected with con-siRNA or RNFT2 siRNA before treatment with LPS 
with or without rIL3. Data and means ± SEM of 3 independent experiments. *P ＜0.05, **P ＜0.01, ***P ＜0.001, 
****P ＜0.0001 by F-test (E), by one-way ANOVA with Dunnett’s post hoc test (A-D), by one-way ANOVA with 
Tukey’s post hoc test (F-I). 
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Figure 50 RNFT2 effect on inflammation proceeds through IL-3Rα  
(A) Immunoblot analysis of IL3Rα, IL-3Rβ, and TRAF6 from MLE co-expressing WT or ubiquitin-resistant K357R 
mutant IL-3Rα and RNFT2 prior to LPS and IL-3 treatment. Data and means ± SEM of 5 independent experiments. 
(B-C) ELISA analysis of IL-6 and CXCL-1 abundances from MLE co-expressing WT or ubiquitin-resistant K357R 
mutant IL-3Rα and RNFT2 prior to LPS and IL-3 treatment. Data and means ± SEM of 3 independent experiments 
NS, P > 0.05, *P ＜0.05, **P ＜0.01, ***P ＜0.001, ****P ＜0.0001 by one-way ANOVA with Tukey’s post hoc 
test (A-C). 
 
3.3.6 IL3 augments LPS-induced murine lung injury  
To determine whether IL3 contributed to the pathology of lung injury we used a clinically 
relevant model for pneumonia and severe lung injury initiated by intratracheal administration of 
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LPS. After we treated mice with vehicle (PBS), LPS, recombinant IL3 (rIL3), or their combination 
intratracheally, we determined lung histology and protein concentration in Bronchoalveolar lavage 
fluid (BALF) were assayed 18 h later. LPS increased BALF protein amounts, and the abundance 
of the inflammatory cytokines IL-6, TNF-α, & IL-1β, and the DAMP HMGB1 in BALF. In 
contrast, IL3 treatment alone had only a modest effect on the same parameters. However, co-
treatment of IL3 with LPS dramatically increased the amount of BALF protein, and abundance of 
the inflammatory cytokines IL-6, TNF-α, & IL-1β, and HMGB1 (Figure 51A-E) compared to LPS 
alone. BALF cell counts also displayed a similar pattern, with IL3/LPS co-treatment increasing 
BALF cell counts most dramatically among treatment groups (Figure 51F). Additionally, we 
observed increased numbers of BALF neutrophils and lymphocytes, but not macrophages, in mice 
co-treated with IL3 and LPS compared to PBS, LPS, or IL3 alone (Figure 51G-I). Lung 
histopathology was consistent in that IL3/LPS co-treatment caused the most severe lung injury 
compared to PBS, LPS, or IL3 alone (Figure 51J). Taken together, these results suggest that IL3 
amplifies LPS-induced lung injury.  
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Figure 51 IL-3 aggravates LPS-induced lung injury in vivo 
(A to E) ELISA analysis of total protein (A), IL-6 (B), TNF (C), IL-1β (D) and HMGB1 (E) concentration in BAL 
fluid from mice intratracheally treated with LPS and PBS or recombinant IL-3, as indicated. (F to I) Number of total 
cells (F), macrophages (G), neutrophils (H), and lymphocytes (I) in BAL fluid from mice treated intratracheally with 
LPS and PBS or recombinant IL-3, as indicated. Data are means ± SEM of 3 mice per group from 2 independent 
experiments. (J) Histological analysis of lung samples from mice treated as indicated. Images are representative of 
all independent experiments. Scale bar, 100 μm. *P ＜0.05, **P ＜0.01, ***P ＜0.001, ****P ＜ 0.0001, by one-
way ANOVA with Tukey’s post hoc test (A-I). 
 
3.3.7 IL3 neutralization reduces inflammation in LPS-induced murine lung injury. 
In separate experiments, we co-treated mice with LPS and either IgG (control) or a 
neutralizing antibody against IL3. We observed that BALF protein, and inflammatory cytokines 
IL-6, TNF-α, & IL-1β, and HMGB1 abundance were all significantly reduced in mice treated with 
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anti-IL3 compared to IgG-treated control mice (Figure 52 A-E). Further, blocking-IL3 treatment 
reduced BALF cell counts and neutrophils but had no effect on macrophage or lymphocyte counts 
(Figure 52F-I). Blocking IL3 antibody co-treatment reduced the severity of lung injury in 
histopathological sections (Figure 52J). Thus, IL3 may drive inflammation in LPS-induced lung 
injury. 
 
 
Figure 52 IL-3 blocking antibody attenuates LPS-induced lung injury 
 (A to E) ELISA analysis of total protein (A), IL-6 (B), TNF (C), IL-1β (D) and HMGB1 (E) concentration in BAL 
fluid from intratracheally treated with LPS and control or neutralizing IL-3 antibody, as indicated. Mice were 
euthanized after 18h, and lungs were lavaged with saline, and BALF were measured from mice. (F to I) Number of 
total cells (F), macrophages (G), neutrophils (H), and lymphocytes (I) in BAL fluid of mice treated intratracheally 
with LPS and control or neutralizing IL-3 antibody, as indicated. (J) Histological analysis of lung samples from mice 
treated as indicated. Images are representative of all independent experiments. Scale bar, 100 μm. Data are means ± 
SEM of 3 mice per group from 2 independent experiments. NS, P > 0.05, *P ＜0.05, **P ＜0.01, ***P ＜0.001, 
****P ＜0.0001, by Student’s t-test (AI). 
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3.3.8 The RNFT2/IL3Rα/IL3 axis regulates lung inflammation in vivo and in vitro 
We next examined the role of RNFT2 during acute lung injury. RNFT2 is an 
uncharacterized E3 ligase.  We first performed IHC on mouse lung sections and confirmed RNFT2 
was expressed in the mouse lung (Figure 53A). We then measured RNFT2, IL3Rα, and IL3Rβ 
protein amounts in lung homogenates after intratracheal LPS and observed that RNFT2 abundance 
decreased, IL3Rα abundance increased, and IL3Rβ amounts were unchanged compared to control 
mice (Figure 54A, B).  We also observed increased IL3 in the BALF of LPS-treated mice compared 
to controls (Figure 53B) To validate these observations in another infectious acute lung injury 
model, we treated mice with Pseudomonas aeruginosa (PA) and measured abundance of RNFT2, 
IL3Rα, and IL3Rβ and observed a similar pattern of protein signal, and of IL3 signal in murine 
BALF (Figure 53C-G). 
To determine the role of RNFT2 in LPS/IL3-induced lung injury, we infected mice 
intratracheally with empty lentivirus or lentivirus encoding Rnft2, and subsequently challenged 
them with LPS with or without rIL3. Rnft2 gene transfer significantly reduced lung inflammation 
and injury caused by LPS and rIL3 co-treatment as shown by decreased BALF cell counts, protein 
concentrations, cytokine release, and lung infiltrates (Figure 54C-G, K). Specifically, the BALF 
leukocyte differential revealed that the total decrease in inflammatory cells was mostly from 
neutrophils and lymphocytes, but not macrophages (Figure 55A-C). 
  Next, we administered lentivirus intratracheally encoding control shRNA or Rnft2 shRNA 
and then exposed to LPS with or without rIL3. Rnft2 knockdown significantly enhanced lung 
inflammation and injury caused by LPS and rIL3 treatment as shown by increased BALF cell 
counts, protein concentrations, cytokines release, and lung infiltrates (Figure 54H-J, L). 
Specifically, the differential cell counts of BALF revealed that the total increase in inflammatory 
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cells was mostly from neutrophils and lymphocytes, but not macrophages (Figure 55D-F). These 
results suggest that RNFT2 modulates lung inflammation in vivo.  
 
Figure 53 Bacterial infection influences Rnft2:Il3ra protein levels  
(A) Immunohistochemical staining of Rnft2 in murine lung, scale bar = 100µm, Isotype control staining is also shown 
(B). ELISA analysis of Il3 in mouse BAL fluid treated intratracheally with LPS and PBS as indicated. Data are means 
± SEM of 3 mice per group from 2 independent experiments. (C-F). Immunoblot analysis of mouse lung homogenate 
from Control or PA103-treated mice. (C). Protein densitometry analysis of RNFT2 (D), IL-3Rα (E), and IL-Rβ(F), 
from data in (C). (G). ELISA analysis of Il3 in mouse BAL fluid treated intratracheally with PA103 and PBS as 
indicated. Data are means ± SEM of 3 mice per group from 2 independent experiments. NS, P > 0.05, *P ＜0.05, **P 
＜0.01, ***P ＜0.001, by Student’s t-test (B, D, E-G). 
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Figure 54 The RNFT2/IL3Rα axis regulates lung innate immunity and inflammation in vivo 
(A) Immunoblot analysis of RNFT2, IL3Rα, and IL3Rβ from mice intratracheally treated with control or LPS, as 
indicated. Data and means ± SEM of 4 mice per group. (C) Cell concentration, (D) total protein analysis, (E-G) ELISA 
analysis of (E) IL-6 (F), TNF, (G) IL-1β from BAL fluid of mice intratracheally treated with Lenti-Empty or Lenti-
RNFT2 and then treated with LPS and PBS or recombinant IL3, as indicated. Data and means ± SEM pooled of 3 
mice per group are from 2 independent experiments. (H) Cell concentration, (I) total protein analysis, (J) ELISA 
analysis of IL-6 from BAL fluid of mice intratracheally treated with Lenti-control shRNA or Lenti-RNFT2 shRNA 
and then treated with LPS and PBS or recombinant IL3, as indicated. Data and means ± SEM pooled of 3 mice per 
group are from 2 independent experiments. (K-L) Histological analysis of lung samples from mice treated as indicated. 
Images are representative of all independent experiments. Scale bar, 100 μm. *P ＜0.05, **P ＜0.01, ***P ＜0.001, 
****P ＜0.0001, by Student’s t-test (B) or by one-way ANOVA with Tukey’s post hoc test (C-J). 
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Figure 55 RNFT2 regulates neutrophils counts in lung inflammation and injury 
(A to C) Total number of cells (A), neutrophils (B), and lymphocytes (C) in BAL fluid from mice that received 
LentiEmpty or Lenti-RNFT2 intratracheally before treatment with LPS with rIL-3, as indicated. Mice were euthanized 
after 18h, and lungs were lavaged with saline, and lavage cells were then processed for WrightGiemsa stain; lavage 
macrophages, neutrophils, and lymphocytes were counted and graphed (A-C). (D to F) Total number of macrophages 
(D), neutrophils (B), and lymphocytes (C) in BAL fluid from mice that received Lenti-control shRNA or Lenti-RNFT2 
shRNA intratracheally before treatment with LPS and rIL3, as indicated. All data and means ± SEM of 2-3 mice per 
group are from 2 independent experiments. *P ＜0.05, **P ＜0.01, and ***P ＜0.001 by one-way ANOVA with 
Tukey’s post hoc test (A-F). 
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3.3.9 The IL3/IL3Rα/RNFT2 axis is relevant in human inflammatory lung disease 
To determine protein expression patterns of IL3Rα and RNFT2 in clinically relevant 
human disease, we assayed parenchymal explant lung samples from human cystic-fibrosis patients 
colonized with PA by immunoblot for RNFT2 and IL3Rα protein amounts, and we quantified their 
relative expression normalized to Tubulin. We observed a significant negative correlation between 
RNFT2 and IL3Rα protein signal (Figure 56A) (Pearson r2=0.278). These studies suggest that the 
RNFT2/IL3Rα pathway may be relevant in response to PA infection in patients, where decreased 
amounts of RNFT2 result in reciprocally increased IL3Rα abundance. 
Circulating IL3 may be a potentiator of cytokine storm, and in a cohort of 60 patients with 
septic shock, high IL3 (>89.4 pg/mL) amount were associated with mortality. In this cohort, there 
was no significant difference in circulating IL3 protein abundance at Day 0 vs. Day 1 or Day 2 of 
following sepsis diagnosis (326).  However, in a separate cohort, IL3 was significantly elevated in 
septic patients relative to healthy controls (342). We sought out to determine if circulating IL3 
differed in a more homogenous population at risk for ARDS (acute respiratory distress syndrome), 
as a subset of patients at risk or with ARDS have excessive inflammation and cytokine storm in 
the lung (343, 344). We assayed IL3 in plasma from mechanically-ventilated subjects at risk for 
ARDS vs. mechanically-ventilated subjects without lung injury (Table 3). Subjects at-risk for 
ARDS had increased plasma IL3 compared to subjects without lung injury (Figure 56B). Further, 
IL3 levels were associated with other plasma pro-inflammatory cytokines in this cohort, including 
TNFα and IL1β (Figure 56C-D). We also measured RNFT2 gene expression through RT-qPCR 
from white blood cell pellets from the same subjects, but found no significant correlations to the 
same pro-inflammatory cytokines (Figure 56E-F). Thus, high circulating IL3 may be an additional 
biomarker to identify subjects at risk for ARDS with excessive lung inflammation. Further studies 
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with increased power are warranted to determine if IL3 could be a new biomarker in patients with 
or at risk for ARDS.  
In summary, our studies demonstrate IL3Rα stability is regulated through the ubiquitin-
proteasome system, dependent on the previously uncharacterized E3 ligase RNFT2. These findings 
may have implications for pulmonary inflammatory disorders including acute lung injury.  We 
characterize RNFT2 as an authentic E3 ligase that directs IL3Rα ubiquitination and degradation 
and identify Lysine 357 on IL3Rα as a critical residue regulating its stability, as K357R IL3Rα 
mutants are resistant to RNFT2-directed degradation.  In vivo, we show 1.) IL3 exacerbates LPS-
induced lung injury, 2.) IL3 neutralization reduced inflammation in LPS-induced lung injury, 3.) 
RNFT2 over-expression is protective in LPS/IL3-induced lung injury and mitigates the effects of 
IL3, and 4.) Rnft2 knock-down exacerbates LPS/IL3 induced lung injury, and exacerbates the 
effects of IL3.  
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Figure 56 The IL3Rα/RNFT2 signaling axis is relevant in human lung disease  
 (A) Immunoblot analysis of RNFT2, IL3Rα and tubulin from Human CF subjects lung explants with Pseudomonas 
colonization. Data and means ± SEM (n=12). (B) ELISA analysis of plasma IL3 in mechanically ventilated patients 
without lung injury (n=4) or At Risk for ARDS (n=16). Subject classification was blinded to the operator. Bars and 
error bars represent median and IQR, respectively. Data were analyzed by Mann Whitney U test. *P<0.05 by Mann-
Whitney U Test. (C-D) Linear regression of plasma IL3 vs. plasma TNF (C) and IL1β (D) in ARFA subjects (n=16); 
*<P<0.05, ***P<0.001. (E-F) Linear regression of RNFT2 gene expression normalized to control patient vs. plasma 
TNF (E) and IL1β (F) in ARFA subjects (n=15). 
 
Table 3 Acute Lung Injury Biospecimen Repository baseline parameters analyzed for plasma IL3 Levels  
Variable No Lung Injury 
At Risk for ARDS 
(ARFA) 
N 4 16 
Age, mean (SD), yrs 64.9 (12.8) 51.8 (14.8) 
Males, N (%) 4 (100) 10 (62.5) 
SOFA score, median (IQR)* 5.0 (4.5-5.5) 7.0 (5.75-9.25) 
PaO2:FIO2 ratio, mean (SD), mmHg 281.5 (187.7) 217.1 (101.5) 
WBC, mean (SD), x 10-9 per liter 14.5 (10.8) 13.6 (8.7) 
ICU LOS, median (IQR), days 4.5 (3.75-7.25) 6.5 (4.75-9.75) 
30 Day mortality, N (%) 1 (25) 2 (12) 
Data are presented as mean (standard deviation) for normally distributed continuous variables or median 
(interquartile range) for not normally distributed continuous variables, and N (%) for categorical variables. 
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3.3.10 Discussion 
IL3 has recently been implicated in the pathogenesis of several inflammatory disorders, 
including collagen-induced arthritis (345), autoimmune encephalitis (346), and lupus nephritis 
(347). In some of these models, IL3 blockade reduced disease severity scores and was associated 
with decreased systemic inflammatory markers, whereas administration of IL3 exacerbated these 
effects (346, 347). Our findings are in line with these studies, as we show that IL3 blockade reduces 
lung injury and inflammatory markers in a murine model of severe lung injury, and that addition 
of IL3 exacerbates organ damage. Our results are also consistent with those of Weber, et al, who 
demonstrated that IL3 alone is not sufficient to induce a systemic inflammatory response, but 
rather serves to “amplify” signaling initiated by an initial insult (CLP, or intra-tracheal LPS) (326). 
Here we extensively studied the role of the IL3/IL3Rα axis in lung innate immunity and 
inflammation. We found IL3 amounts were increased in BALF of mice subjected to LPS or 
Pseudomonas (PA) treatment, and rIL3 co-treatment with LPS drastically enhanced pro-
inflammatory cytokine release and immune cell activation in murine lungs. We observed IL3 
treatment synergizes with bacterial PAMP-exposure to strongly activate downstream signaling 
through NF-κB activation, leading to pro-inflammatory cytokine release. Our model is consistent 
with the ‘second-hit’ theory or multi-causal effect mentioned in previous studies (348, 349).  
IL3 classically signals through the JAK/STAT pathway (333) , but has also been linked to 
NF-κB through tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) (332). TRAF6 
is one of the six well-characterized TRAF proteins, which are critical contributors to inflammatory, 
innate, and adaptive immune responses(342, 350, 351). Specifically, TRAF6 is a key mediator of 
TLR signaling and downstream NF-κB signaling(352-354). We found TRAF6 increased in MLE 
cells treated with rIL3, suggesting TRAF6 is a candidate contributor to the synergy of IL3 and NF-
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κB activation. We also observed that ectopic expression of the IL3 receptor (IL3R) significantly 
increased TRAF6 amount and enhanced cytokine release upon IL3/LPS co-treatment. These 
studies suggest that IL3 along with its receptor IL3R synergize with bacterial PAMP exposure 
through downstream NF-κB signaling.  
In this study, we found that IL3Rα protein abundance is regulated post-translationally 
through ubiquitination. Protein ubiquitination is a universal cellular mechanism controlling protein 
amount and innate immunity (336, 355-358). Recently, we have shown that several E3 ligases 
regulate substrate ubiquitination in pulmonary inflammatory conditions(141, 232, 283). During 
systemic insults induced by infection, alterations of E3 ligase activity or targeting can affect 
substrate protein abundance and their downstream effector functions. We showed that intratracheal 
treatment of LPS or PA in vivo increases substrate IL3Rα protein amount, and that LPS treatment 
of MLE cells increases IL3Rα. Lung tissue from PA-treated mice showed decreased abundance of 
the putative E3 ligase RNFT2, with a correlative increase in IL3Rα protein, suggesting the 
exogenous insult manipulated RNFT2 protein amount, and thus the protein stability of its substrate 
IL3Rα. We characterized RNFT2 as an authentic E3 ligase by showing its interaction with the E2 
enzyme UBE2D in vitro. We further found that RNFT2 regulated the rIL3-induced increase in 
TRAF6 protein and affected CXCL-1 secretion in MLE cells. Specifically, ectopic expression of 
RNFT2 in MLE cells significantly suppressed co-treatment (LPS with rIL3) induced cytokine 
release, whereas Rnft2 knockdown enhanced CXCL-1 secretion. RNFT2 gene transfer and 
knockdown in vivo also has similar phenotype in cytokine release and immune cell activation such 
as neutrophils in lung. Our data imply that RNFT2 functions as an inflammatory suppressor protein 
that controls IL3 signaling in innate immunity, and the RNFT2/IL3R axis may be important in 
the lung innate immune response chain.  
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This study also provided two additional human translational links that suggest the 
IL3/IL3Rα signaling axis may play a role in human inflammatory lung diseases. We show that 
plasma IL3 protein amounts are increased in humans at risk for ARDS compared to mechanically 
ventilated subjects without lung injury. These findings warrant examination in larger lung injury 
cohorts and suggest that IL3 may be a previously unrecognized cytokine associated with excessive 
inflammation. We also examined protein abundance of RNFT2 and IL3Rα in explanted lung tissue 
from patients with chronic pseudomonas infection. We discovered there was an inverse correlation 
between RNFT2 and IL3Rα protein amount, suggesting that our newly described mechanism of 
RNFT2-dependent IL3Rα degradation may be operant in humans with chronic infection. Further 
studies are warranted to delineate the role of RNFT2 in these inflammatory disorders. 
There are limitations to these studies.  While our in vivo work clearly identifies a role for 
IL3 in LPS and PA murine acute lung injury, we do not identify the cell type responsible for IL3 
secretion.  In murine sepsis models, IRA-B cells are thought to be responsible for IL3 secretion 
(326, 359).  Further, T cells and B cells are classically regarded as the main IL3 producers in other 
models of disease(331, 333, 345, 346). Whether IRA-B cells are also responsible for IL3 secretion 
in acute lung injury models is an active area of investigation. Further, whether these cells express 
RNFT2 is also unknown. Recent single cell RNA sequencing studies on murine airway cells 
showed no detection or extremely low levels of Il3 gene expression, which was not significantly 
altered among different airway cell types(360-362), suggesting that lung cells are not a primary 
producer of IL3.  Additionally, while we show in vitro that IL3Rα abundance increases and RNFT2 
abundance decreases in LPS-stimulated MLE12 cells, the changes in RNFT2 and IL3Rα 
abundance in lung homogenates after in vivo during lung injury could also be explained by 
differences in infiltrating immune cells between control and LPS/PA-treated mice.  Thus, while 
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our in vitro work provides mechanistic insight into RNFT2/IL3Rα, additional work remains to 
further characterize this pathway in vivo.  
We use the MLE12 cell line to characterize IL3Rα stability and test the role of RNFT2 in 
modulating IL3Rα-dependent downstream effects.  MLE12 cells are an immortalized cell line that 
closely resembles, but does not fully mirror, Type II alveolar epithelial cells.  We have identified 
several E3 ligase/substrate interactions relevant in pulmonary inflammatory conditions using the 
MLE-12 cells(59, 60, 363, 364). Future studies will focus on examining the RNFT2/IL3Rα 
expression in other pulmonary cell types, including primary human cells. We chose to examine 
NF-κB signaling (TRAF6 abundance, IL-6 secretion, CXLC-1 secretion) because our laboratory 
has previously shown role for TRAFs in experimental lung injury(60), and IL3 signaling has been 
linked to TRAF6 recruitment (332).  However, whether RNFT2 also has similar effects on IL3Rα-
dependent signaling in immune cells is unknown.  
Lastly, our in vitro findings provide a framework to interrogate the role of RNFT2 in vivo 
in pathological disease states where IL3 is implicated.  Related to our studies, it will be critical to 
determine which cell types are responsible for mediating the effects we observed after intratracheal 
lentiviral RNFT2 over-expression or knockdown. More broadly, these findings could have 
implications in other disease states where IL3Rα expression is altered.  For example, IL3Rα is 
over-expressed in several hematologic malignancies and is the basis for novel therapies including 
chimeric antigen receptor (CAR) T cell therapies (365, 366). The role of RNFT2 in these 
conditions is unknown, and one could postulate that reduced RNFT2 expression or function could 
be partially responsible for aberrant IL3Rα expression.  Further, pharmacological targeting of 
RNFT2 with a small molecule inhibitor could potentially enhance IL3Rα expression.   
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In conclusion, we showed that IL3 synergizes with LPS to exacerbate lung inflammatory 
injury, resulting in increased NF-κB activation and lung injury. This synergy proceeds through the 
IL3R subunit, whose protein stability is weakened by IL3 treatment but preserved by LPS 
exposure. IL3R protein is processed by the ubiquitin proteasome system, and the previously 
uncharacterized RING E3 Ligase, RNFT2, targets IL3Rα for proteasomal degradation by 
ubiquitinating it at lysine 357. The RNFT2/IL3Rα axis controls pro-inflammatory cytokine and 
immune cell release in murine lung inflammation models. Taken together, this study characterized 
a regulatory mechanism involving RNFT2-targeted degradation of the IL3 cytokine receptor IL3. 
3.3.11 Methods 
 Reagents 
Anti-IL3Rα antibodies (MBS2542745; sc-74522) were obtained from MYBioSource and 
Santa Cruz Biotechnology. Anti-IL3Rβ (MBS2534790) antibody was from MYBioSource. 
Monoclonal anti-HA-Tag (clone 6E2) (Cat# 2367S RRID:AB_10691311), Anti-TRAF6 (Cat# 
8028, RRID:AB_10858223), Anti-RelB (Cat# 10544, RRID:AB_2797727), and Anti-Phos-P100 
(Cat# 4810, RRID:AB_659925) were from Cell Signaling Technology. Anti-V5 antibody (R960, 
RRID: AB_159298) was from Invitrogen. Anti-Actin antibody (A5441, RRID: AB_476744) and 
leupeptin (L2884) were from Sigma Aldrich. Goat anti-Rabbit IgG-HRP (Cat# 170-6515 
RRID:AB_11125142), Goat anti-Mouse IgG-HRP (Cat# 170-6516 RRID:AB_11125547), and 
CFX96 Touch Real-Time qPCR (1855196) were from BioRad. MG-132 (F1100) was from 
UBPBio. Recombinant Murine IL3 was from PeproTech. Murine CXCL1 (DY453) and Murine 
TNF-a (DY410) ELISA kits were from R&D Systems. Murine IL-1β (88–7261) and murine IL-6 
(88–7064, RRID: AB_2574986) ELISA kits were from eBioscience. SYBR Select Master Mix 
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(4472918) was from Life Technologies. QuikChange II XL Site-Directed Mutagenesis Kit 
(200522) was from Aglient Technologies. High capacity RNA-to-cDNA kits (4387406) were from 
Applied Biosystems.  
 Cell Culture 
Murine Lung Epithelial 12 cells (MLE) (CRL-2110) were obtained from ATCC and 
cultured in Dulbecco’s Modified Eagle Medium-F12 (Gibco) with 10% fetal bovine serum 
(DMEM-F12-10). For RNFT2 overexpression in MLE cells, electroporation was used, and 24 or 
48hr later, cells were treated with stimulators. For RNFT2 knockdown, scramble siRNA and 
RNFT2 siRNA were used to transfect MLE cells for 48hr by electroporation. Cell lysates were 
collected in Lysis Buffer (150 mM NaCl, 50 mM Tris, 1.0 mM EDTA, 2 mM dithiothreitol, 0.025% 
sodium azide, and 1 mM phenylmethylsulfonyl fluoride), and prepared by brief sonication at 4˚C. 
Additionally, MLE cells were treated with cycloheximide (100μg/ml) for half-life studies. 
RAW264.7 cells were from ATCC (TIB-71) and cultured in DMEM with 10% fetal bovine serum. 
THP-1 cells were from ATCC (TIB-202) PBMCs and THP-1 cells were cultured in RPMI Medium 
1640 (Gibco) with 10% fetal bovine serum. Pseudomonas aeruginosa (PA103) was from ATCC 
(29260). 
 RT–qPCR, cloning, and mutagenesis 
Total RNA was isolated and reverse transcription was performed followed by real-time 
quantitative PCR with SYBR Green qPCR mixture as described (141).  
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 In vitro ubiquitin conjugation assays 
The assay was performed in a volume of 20µl containing 50 mM Tris, pH 7.6, 5mM 
MgCl2, 0.6mM DTT, 2mM adenosine triphosphate (ATP), 10µM MG132, 100nM Ubiquitin 
activating enzyme, 0.5 µM UBE2D, 2µM ubiquitin, and 1µM ubiquitin aldehyde. TnT-coupled 
reticulocyte in vitro–synthesized proteins (tagless-RNFT2 and HIS-purified IL3Rα-V5) and 
reaction products were processed for V5 immunoblotting. 
 Plasmid Transfection 
For protein overexpression in MLE-12 cells, cells were nucleofected using Nucleofector 
2B (Amaxa), program T-13. For protein overexpression in HEK293T cells, XtremeGENE 
transfection reagents were used following the manufacturer’s protocol. Expression was confirmed 
by western blotting. 
 Recombinant DNA Constructs  
Total RNA was isolated from untreated human PBMCs using RNeasy Mini Kit, and 
reverse transcribed to cDNA using High-Capacity RNA to cDNA kits. RNFT2 cDNA were PCR 
amplified, isolated, and sequence confirmed prior to PCR-cloning into pcDNA3.1D-V5-HIS 
vector. Deletion mutants were generated by PCR-cloning. Point mutants of RNFT2 and IL3Rα 
were generated using the QuikChange II XL kit, per the manufacturer’s protocol. pRK5-HA-
Ubiquitin-WT was a gift from Ted Dawson (Addgene plasmid # 17608, (322)) (Johns Hopkins 
University School of Medicine, Baltimore, MD) 
181 
 In vitro protein binding assays 
RNFT2 protein was immunoprecipitated from 1 mg MLE cell lysate using 1:100 dilution 
of RNFT antibody (rabbit) for four hours at 25°C in IP buffer (50 mM Tris HCl pH 7.6, 150 mM 
NaCl, 0.25 % v/v Triton-X-100) and coupled to protein A/G agarose resin for an additional hour. 
V5-Ubiquitin E2 enzymes (20 μl) were in vitro synthesized using TnT translation kits for 90 
minutes at 30°C. RNFT2-bound resin was then incubated with the in vitro synthesized proteins for 
18 hours at 4°C. Following binding, resin was washed with IP buffer, and eluted by dilution in 
denaturing loading buffer, with a final 1X formulation of: 50 mM Tris HCl pH 6.8, 2% SDS, 10% 
Glycerol and 100 mM DTT and incubation at 88°C for five minutes prior to immunoblotting 
analysis.  
 Immunoprecipitation Assays 
MLE cells were cultured and treated as indicated prior to collection. Cell pellets were lysed 
with IP buffer (0.25% Triton-X-100 in 1x PBS, pH 7.6, 0.025% sodium azide, and 1 mM 
phenylmethylsulfonyl fluoride) on ice. Lysates were prepared by brief sonication at 4°C. Insoluble 
cellular debris was precipitated through centrifugation at 15,000x rcf for 10 min at 4°C. Lysate 
supernatant was normalized for protein concentration. Supernatants were exposed to a 1:50 
dilution of the indicated antibody for three hours at 25°C. Immunoprecipitated protein was 
captured with 10µL magnetic protein A/G resin for 1 hour prior to two rounds of washing with IP 
buffer (1 mL). Protein was eluted by dilution in denaturing loading buffer, with a final 1X 
formulation of: 50 mM Tris HCl pH 6.8, 2% SDS, 10% Glycerol and 100 mM DTT and incubation 
at 88°C for five minutes. Eluted samples were resolved by SDS-PAGE and subjected to 
immunoblotting. 
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 HIS-Pulldowns Assays 
MLE cells were cultured and treated as indicated prior to collection. Lysate was recovered 
in PD buffer (0.25% Triton-X-100 in 1x PBS pH 8.0, 30mM imidazole, and 1 mM 
phenylmethylsulfonyl fluoride) on ice, before brief sonication and sedimentation by centrifugation 
(15,000x rcf, 10min, 4°C). Lysate supernatants were subjected to HIS-pulldown by 10µL magnetic 
HisPur resin for 1 hour prior to two rounds of washing with PD buffer (1mL). Protein was eluted 
by dilution in denaturing loading buffer, with a final 1X formulation of: 50mM Tris HCl pH 6.8, 
2% SDS, 10% Glycerol and 100mM DTT and boiling for 5 minutes. Eluted samples were resolved 
by SDS-PAGE and subjected to Immunoblotting. 
 Animal studies 
C57BL/6J mice were purchased from the Jackson Laboratory. Animals were between 7-9 
weeks of age and around 25g weight at time of experiment. All procedures were approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee. Models of endotoxin-
induced lung injury (IT LPS) or Lung Injury by Live Bacteria (IT Pseudomonas) were employed 
in accordance with ATS guidelines on animal models of experimental lung injury (367). The 
principal objective in these models is the physiological assessment of lung injury, and studies were 
powered to detect a two-fold difference BAL protein amount, which is a well-established primary 
end point for animal models of ALI, and based on our prior published results using these models 
of lung injury(59, 60, 141, 232, 283, 341, 368). For intratracheal injection studies, C57BL/6J mice 
were anesthetized using a ketamine/xylazine mixture, and the larynx was well visualized under a 
fiber optic light source before endotracheal intubation with a 3/400 24-gauge plastic catheter. LPS 
with or without IL3 (rIL3) (LPS: 1.5mg/kg; rIL3: 6µg) were administered i.t. for 18h, after which 
animals were euthanized and assayed for BAL protein amounts by Lowry assay and 
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immunoblotting, cell count by TC20 automated cell counter, cytokine abundance by ELISA, and 
lung tissue H&E staining. In another study, LPS with or without IL3 neutralization antibody (Cell 
Signaling, Cat#D6C1) (LPS: 1.5mg/kg; -IL3: 5µg) were administered i.t. for 18h, after which 
animals were euthanized and assayed for BAL protein amounts by immunoblotting, cell count, 
cytokine abundance by ELISA, and lung tissue H&E staining. For lentiviral study, 1x107 PFU of 
lentivirus encoding genes for RNFT2 or Rnft2 shRNA was treated i.t. for 144 hr before the 
administration of LPS with or without rIL3 (LPS: 1.5mg/kg; rIL3: 6µg in RNFT2 overexpression 
mice, 3µg in RNFT2 shRNA mice) for 18 hr, after which animals were euthanized and assayed 
for BAL protein amounts by immunoblotting, cell count, cytokine abundance by ELISA, and lung 
tissue H&E staining. 
 Human Studies (Acute Respiratory Distress Syndrome (ARDS))  
De-identified human plasma samples were obtained from the University of Pittsburgh 
Acute Lung Injury Biospecimen Repository (IRB number #PRO10110387). Informed consent was 
provided by all participants or their surrogates in accordance with the Declaration of Helsinki. 
Adults aged 18-90 admitted to the Medical ICU in the UPMC Presbyterian Hospital with acute 
respiratory failure requiring mechanical ventilation by endotracheal tube were enrolled as patients 
if the onset of acute respiratory failure was associated with established risk factors for developing 
acute lung injury (sepsis, pneumonia, aspiration, blood transfusion, pancreatitis, or trauma) or if 
intubation was performed for airway protection in the setting of non-pulmonary critical illness. 
Enrollment took place within 48 h of the initiation of mechanical ventilation. After enrollment, 
patients were retrospectively sub-classified by an expert clinical panel into categories: 1) ‘ARDS’, 
as defined by Berlin criteria and agreed upon by a minimum of three members of an expert clinical 
panel, 2) ‘at risk,’ as defined as Lung Injury Prediction Score (LIPS) score >4 and the presence of 
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a clinically identifiable risk factor for ARDS, and 3) ‘ventilated control,’ as defined by intubation 
and mechanical ventilation for non-pulmonary critical illness without risk factor for ARDS. We 
performed a preliminary sample size calculation to detect a three-fold difference in two means (30 
pg/mL vs. 90 pg/mL) between ventilated control and lung injured-patients with a power of 0.8, α 
of 0.05, an estimated standard deviation of 35, and a sampling ratio of 0.25 ventilated control/lung-
injured patients (given there are fewer control patients enrolled in our study). We chose values of 
30 and 90 pg/mL based on published literature showing an IL3 of >89.4 pg/mL is associated with 
poor outcomes in sepsis(326), and estimated baseline amounts from manufacturer data and 
published literature. The predicted samples size was 4 “control” patients and 14 “lung-injured” 
patients. With this, n=4 ‘ventilated control,’ n=16 ‘at risk for ARDS,’ were randomly selected from 
the cohort for analysis.  
 Human Studies (Cystic Fibrosis, CF)  
Following attainment of informed consent, CF lung tissue was obtained from excess 
pathological tissue following lung transplantation in accordance with a protocol approved by the 
University of Pittsburgh Investigational Review Board. 1cm2 sections of lung parenchyma were 
frozen and stored at -80 until use. ~100mg of lung tissue were homogenized in RIPA buffer 
followed by protein immunoblotting.  
 Statistics  
Protein Signal densitometry was quantified by ImageJ. Comparisons of two groups were 
carried out with unpaired, two-tailed Student’s T-test. Comparisons of more than two groups were 
tested with One-ANOVA with Tukey or Dunnett’s post-hoc test for multiple comparisons as noted. 
Non-linear regression plots were tested with F-Test. All tests used p < 0.05 as indicative of 
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statistical significance. All statistical analyses were carried out using the Graph Pad Prism 8.0 
program. 
 Study Approval  
C57BL/6J mice were purchased from the Jackson Laboratory. All procedures were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee.  For 
ARDS human studies, de-identified human plasma samples were obtained from the University of 
Pittsburgh Acute Lung Injury Biospecimen Repository (IRB number #PRO10110387). Informed 
consent was provided by all participants or their surrogates in accordance with the Declaration of 
Helsinki. Following attainment of informed consent, CF lung tissue was obtained from excess 
pathological tissue following lung transplantation in accordance with a protocol approved by the 
University of Pittsburgh Investigational Review Board. 
 Author contributions 
B.B.C., Y.L., and M.J.J designed the study, analyzed the data; Y.T., T.L., J.E. and B.B.C. 
wrote the manuscript; Y.T., T.L., J.E., K.C.L, Y.C., and J.D.L. performed all in vitro experiments 
and animal experiments; J.E., M.M.M, Y.Z., I.D.P., J.F.M, and B.J.M. designed and executed the 
human studies. B.B.C. directed the study 
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3.4 RNF113A Regulates CXCR4 stability and signaling  
Adapted from: Lear, Dunn et al., RING finger protein 113A regulates C-X-C chemokine receptor 
type 4 stability and signaling. Am J Physiol, Cell Physiol. Nov 01; 313(5) C584-C592 DOI: 
10.1152/ajpcell.00193.2017, PMID: 28978524, PMCID: PMC5792167, (369) 
 
As an inflammatory response in the lung progresses, immune cells for the vasculature 
extravasate the pulmonary endothelia barrier. The influx of these cells is reliant on specific 
molecular signals known as chemokines. The chemokine CXCL-12 is an important signal for 
cellular motility and is recognized by the chemokine receptor CXCR4. In addition to cell migratory 
ability, CXCR4 is a receptor important for HIV cellular invasion (370). In this short study we 
investigated CXCR4 protein stability, and its regulation by the E3 ligase RNF113A. 
 
3.4.1 Overview 
As an α-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also called 
CXCL12), C-X-C chemokine receptor type 4 (CXCR4) plays a vital role in chemotactically 
attracting lymphocytes during inflammation. CXCR4 also regulates HIV infection due to its role 
as one of the chemokine coreceptors for HIV entry into CD4+ T cells. Chemokine receptors and 
their signaling pathways have been shown to be regulated by the process of ubiquitination, a 
posttranslational modification, guided by ubiquitin E3 ligases, which covalently links ubiquitin 
chains to lysine residues within target substrates. Here we describe a novel mechanism regulating 
CXCR4 protein levels and subsequent CXCR4/CXCL12 signaling pathway through the 
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ubiquitination and degradation of the receptor in response to ligand stimulation. We identify that 
an uncharacterized really interesting new gene (RING) finger ubiquitin E3 ligase, RING finger 
protein 113A (RNF113A), directly ubiquitinates CXCR4 in cells, leading to CXCR4 degradation, 
and therefore disrupts the signaling cascade. We determined that the K331 residue within CXCR4 
is essential for RNF113A-mediated ubiquitin conjugation. Overexpression of RNF113A 
significantly reduces CXCL12-induced kinase activation in HeLa cells, whereas RNF113A 
knockdown enhances CXCL12-induced downstream signaling. Further, RNF113A expression and 
silencing directly affect cell motility in a wound healing assay. These results suggest that 
RNF113A plays an important role in CXCR4 signaling through the ubiquitination and degradation 
of CXCR4. This mechanistic study might provide new understanding of HIV immunity and 
neutrophil activation and motility regulated by CXCR4. 
 Chemokine Receptor Type 4 Signaling in Inflammation 
C-X-C Chemokine Receptor Type 4 (CXCR4) is a G-protein coupled receptor on the 
cellular membrane, and is expressed across many tissue types. It serves as the main receptor for 
the chemokine stromal cell-derived factor 1 (CXCL12). The binding of CXCL12 leads to signaling 
through several G-Protein dependent pathways (371). Specifically, this activates G-protein 
subunits and phosphorylates SRK kinases, leading to signaling through the ERK pathway (372). 
This signaling pathway is critical for cellular processes such as chemotaxis and proliferation. 
Concurrently, CXCR4 signaling activates phosphatidylinositide 3-kinases (PI3Ks), initiating a 
signaling cascade of second messengers resulting in downstream activation of RAC-alpha 
serine/threonine-protein kinase (Akt) and mitogen associated protein kinase (MAPK) (373, 374). 
As with ERK, these kinases are important regulators of cell adhesion, migration, and survival. 
Following ligand binding, CXCR4 is extensively phosphorylated by G protein-coupled receptor 
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kinases, causing desensitization, and leading to its internalization (375, 376). Following 
internalization, CXCR4 can be recycled back to the membrane for additional signaling, or sorted 
to endosomes for eventual degradation.  
 Dysregulation of CXCR4 Activity in Disease 
Dysregulated CXCR4 activity exists in human pathologies. CXCR4 was initially 
characterized as one of two co-receptors aiding HIV-1 viral entry into cells (370). Classically, 
HIV-1 uses the CD4-lymphocyte receptor as the main coordinating anchor, with CCR5 or CXCR4 
receptors as a secondary receptor. Use of CXCR4 as a co-receptor is primarily associated with the 
later stages of infection, for reasons that remain unclear (377). CCR5 has been the focus of several 
receptor antagonist therapeutics currently approved or in clinical trials (378). However, efforts to 
inhibit CXCR4 have not proven clinically meaningful, despite its importance as a co-receptor. 
CXCR4 plays a role in patients with co-morbidities as well. Macrophages from patients with TB 
show higher pulmonary expression of CXCR4, which leads to an acceleration of HIV infection 
(379). While CXCR4 functions as a co-receptor most notably for T-cell invasion, pulmonary 
epithelia are susceptible to CXCR4-mediated HIV infection (380). Due to the chemotactic 
consequences of its signaling, CXCR4 is implicated in cancer progression (381). Li et al. have 
demonstrated CXCR4 is linked to HER2-mediated breast cancer metastasis (382). Specifically, 
they observed that HER2 prevents ligand-induced CXCR4 degradation and increases the protein 
expression of CXCR4, thus facilitating cell migration. Moreover, depletion of CXCR4 through 
siRNA can block the ability of breast and liver cancer cells to migrate in vitro (383, 384). Overall, 
CXCR4 protein level is known to be elevated in cancerous tissue, and to be associated with 
worsened patient outcomes (385). Thus, CXCR4 protein expression, regulation, and stability are 
directly tied to disease progression. 
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 Molecular Mechanisms of CXCR4 Regulation 
There are multiple mechanisms regulating the expression and stability of CXCR4 (371). 
CXCR4 is regulated as the transcriptional level by transcription factors such as Nuclear 
Respiratory Factor-1 (NRF-1), SP-1, and negatively regulated by YY1 (386). This has disease 
implications, as infections such as HIV hijack NRF-1 to increase CXCR4 expression, and increase 
the infectivity of cells. Post-translational modifications also regulate the stability of CXCR4. The 
extensive phosphorylation that occurs following ligand binding not only regulates receptor 
activity, but serves as a scaffold for protein binding. These binding sites have been recognized as 
phospho-degrons for subsequent ubiquitination and degradation (375). In fact, ligand binding 
actually promotes ubiquitination leading to internalization and sorting prior to recycling (387). It 
has been reported that a HECT-domain Ubiquitin E3 ligase ITCH (E3 ubiquitin-protein ligase 
Itchy homolog) mediates ubiquitination of CXCR4 (301). ITCH specifically interacts with 
Arrestins on the ESCRT machinery leading to CXCR4 ubiquitination and endosomal transport to 
the lysosome (388). However, researchers have also observed other E3 ligases to manipulate 
CXCR4, specifically DTX3L, which antagonizes ITCH activity, maintaining CXCR4 stability 
(389). Regulation of CXCR4 degradation is a highly regulated and complex process (390). These 
recent discoveries suggest multiple proteins and multiple ubiquitin E3 ligases work to regulate 
CXCR4 stability. 
 The search for new regulators of CXCR4 
We screened a library of RING E3 ligases to assay their activity on CXCR4 stability and 
observed a previously uncharacterized E3 ligase, RING finger protein 113A (RNF113A), mediates 
CXCR4 degradation. Here we report RNF113A is a bona-fide RING E3 ligase that directly binds 
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CXCR4, shortens CXCR4 protein half-life, downregulates CXCR4 signaling, and impairs cellular 
motility. This study represents a new means in regulating CXCR4 stability. 
3.4.2 RNF113A is an ubiquitin E3 ligase regulating CXCR4 
We prepared a library of over 200 E3 ligases and expressed them in HeLa cells to assess 
their effect on the protein abundance of CXCR4 (141, 283). A representative panel of E3 ligase 
overexpression was shown in Figure 57A. We observed RNF113A expression decreases protein 
abundance of CXCR4 (Figure 57A). Ligand binding is known to stimulate CXCR4 ubiquitination 
and degradation (387). To examine the role of RNF113A and CXCL12 on CXCR4 ubiquitination, 
we co-expressed HIS-tagged CXCR4 with RNF113A prior to treatment with CXCL12 (6 nM) for 
1 hour. Lysates were subjected to HIS pull-down, washed, and the eluate was processed for 
Ubiquitin immunoblotting (Figure 57B). We recapitulated that CXCR4 protein is degraded upon 
CXCL12 exposure, as well as increased ubiquitin signal with pulled-down CXCR4 following 
CXCL12 treatment. Furthermore, we observed an even greater degradation and greater ubiquitin 
signal upon co-expression of RNF113A, suggesting RNF113A aids in CXCR4 ubiquitination and 
degradation in response to CXCL12 stimulant (Figure 57B). Next, we observed that the 
overexpression of RNF113A resulted in the decrease in CXCR4 protein level in a dose-dependent 
manner, but not of its paralogue RNF113B (Figure 57C). RING E3 ligases have a canonical RING 
domain containing critical Cys and His residues for zinc coordination (391). To validate the 
activity of RNF113A, we mutated two critical residues within the RING domain of RNF113A: 
C262 and C277. We observed that C262A and C277A mutants were unable to reduce CXCR4 
protein levels as compared to wild-type RNF113A (Figure 57D). Upon the blockage of protein 
synthesis by exposure to cycloheximide (CHX), the overexpression of RNF113A led to an 
191 
accelerated degradation of CXCR4, compared to the empty vector control group (Figure 58A). 
Silencing of RNF113A via several different shRNA all led to the increased CXCR4 protein 
abundance (Figure 58B). Combination of shRNA silencing of RNF113A and CHX treatment 
significantly slowed down CXCR4 protein turnover (Figure 58C).  
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Figure 57 RNF113A facilitates C-X-C chemokine receptor type 4 (CXCR4) degradation  
A: RING E3 ligase screening. A library of RING E3 ligases were transfected in HeLa cells before CXCR4 
immunoblotting. CXCR4 densitometry relative to LacZ is shown beneath immunoblot. B: HeLa cells were 
cotransfected with CXCR4-HIS and RNF113A before CXCL12 treatment (6 nM, 1 h.), HIS pull-down, and 
immunoblotting. C, top: V5-tagged RNF113A and its paralogue RNF113B were expressed in HeLa cells in a dose 
course before CXCR4 immunoblotting. Bottom: densitometry on CXCR4 protein signal normalized to 0 µg for each 
treatment. Data represent mean values ± SE (n = 4, *P < 0.05, significant compared with RNF113A, two-way 
ANOVA, Bonferroni multiple comparisons). D, top: point mutants of RNF113A RING domain (V5-tagged) were 
expressed in HeLa cells before CXCR4 immunoblotting. Bottom: densitometry on CXCR4 protein signal normalized 
to 0 µg for each treatment. Data represent mean values ± SE (n = 4, *P < 0.05, significant compared with RNF113A 
WT signal at indicated dose, two-way ANOVA, Bonferroni multiple comparisons). 
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Figure 58 RNF113A decreases CXCR4 stability and half-life  
A, left: HeLa cells were transfected with RN113A-V5 plasmid before cycloheximide (CHX) chase (50 μg/ml), and 
CXCR4 immunoblotting. Right: densitometry on CXCR4 protein signal normalized to time 0 for each treatment. Data 
represent mean values ± SE (n = 4, *P < 0.05, significant compared with Empty at indicated time, two-way ANOVA, 
Bonferroni multiple comparisons). B: screening of shRNA against RNF113A. HeLa cells were transfected with 
shRNA plasmids targeted against RNF113A before CXCR4 immunoblotting. Densitometry of RNF113A and CXCR4 
signal relative to control (Ctrl) shRNA is shown beneath immunoblots. C, left: HeLa cells were transfected with 
shRNA scramble or shRNA plasmids targeted against RNF113A before CHX chase (50 μg/ml). Cells were then 
subjected to immunoblotting. Right: densitometry on CXCR4 protein signal normalized to time 0 for each treatment. 
Data represent mean values ± SE (n = 4, *P < 0.05, significant compared with Ctrl at indicated time, two-way 
ANOVA, Bonferroni multiple comparisons). D, top: HeLa cells were cotransfected with RNF113A and CXCR4 K-R 
lysine mutants before immunoblotting. Bottom: densitometry on CXCR4-V5 protein signal normalized to (−) 
RNF113A for each treatment. Data represent mean values ± SE (n = 3, NS, P > 0.05, not significant, *P < 0.05, 
significant compared with CXCR4 WT + RNF113A, one-way ANOVA, Bonferroni multiple comparisons). E, left: 
candidate lysine point mutants were transfected into HeLa cells before CHX chase (50 μg/ml). Right: densitometry 
on CXCR4-V5 protein signal normalized to time 0 for each treatment. Data represent mean values ± SE (n = 3, *P < 
0.05, significant compared with WT at indicated time, two-way ANOVA, Bonferroni multiple comparisons). 
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3.4.3 CXCR4 K331 is critical for RNF113A-mediated degradation 
We next sought to identify a potential ubiquitin lysine site within CXCR4. The intracellular 
C-terminal tail of CXCR4 contains several lysines. Previous reports have shown that the CXCR4 
triple mutant of lysine to arginine (lysines 327, 331, and 333) is resistant to ubiquitin mediated 
degradation (387, 392). We further constructed single CXCR4 K-R point mutants, and observed 
K331R to be resistant to RNF113A-mediated degradation (Figure 58D). As a negative control, 
K310R remained susceptible to RNF113A-dependent degradation. Further, K331R CXCR4 
exhibited a prolonged half-life during CHX chase, compared to CXCR4 wild-type (WT) and 
K310R mutant (Figure 58E) 
3.4.4 RNF113A binds CXCR4 through a positively charged region 
E3 ligases are known to target substrates through specific motifs on the E3 ligase and the 
target substrate (261, 393). ITCH uses a specific targeting sequencing, called a WW domain 
containing conserved tryptophan residues, to target CXCR4 for binding and ubiquitination (394). 
To further characterize the interaction of RNF113A and CXCR4, we employed a reductionist 
mapping approach to elucidate the putative binding regions within RNF113A and CXCR4. A 
series of N-terminal and C-terminal truncation mutants of RNF113A were prepared, in vitro 
expressed and subjected to CXCR4 binding (Figure 59A). We observed a loss of association 
between CXCR4 immunoprecipitate and RNF113A when the 15-residue region between 50 and 
65 was deleted (Figure 59B). Finer mapping experiments narrowed this region down to ten 
residues (Figure 59C). The RNF113A construct with an internal deletion of these 10 residues 
largely decreased the interaction between RNF113A and CXCR4 (Figure 59D), and its 
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overexpression in HeLa cells failed to induce CXCR4 degradation (Figure 59E). This led to the 
conclusion that this ten-residue region is the putative binding site. Conversely, we designed C-
terminal truncation mutants of CXCR4 and conducted binding assays with immunoprecipitated 
RNF113A (Figure 59F). We observed that a loss of association between RNF113A 
immunoprecipiate and CXCR4 when the region between residues 322-333 was deleted (Figure 
59G). As serine 324 and 325 within this region have been described to be phosphorylated (375), 
we hypothesized they are critical for RNF113A association. Mutation of these serines to alanine 
prevented the binding of CXCR4 to RNF113A (Figure 59H). These residues have also been 
implicated as critical facilitators for ITCH-mediated ubiquitination of CXCR4 (394). However, as 
a positive control, deletion of the final 19 residues of CXCR4 preserved its binding affinity to 
RNF113A (Figure 59H). 
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Figure 59 RNF113A binds CXCR4 in a positively charged region  
A: schematic of RNF113A deletion mutants constructed for the binding studies. B and C: binding assays between 
RNF113A and CXCR4. HeLa cell lysate (100 μg protein) was subjected to CXCR4 immunoprecipitation (IP). 
RNF113A mutants were synthesized via in vitro transcription and translation (TnT), and allowed to bind to overnight 
with immunoprecipitated resin. Eluates were subjected to immunoblotting (IB). Asterisk (*) indicates full-length 
RNF113A, which runs at the same size as IgG heavy chain (HC). D: V5-tagged RNF113A internal deletion mutant 
was expressed in HeLa cells before HIS pull-down (PD) and CXCR4 immunoblotting. E: V5-tagged RNF113A 
internal deletion mutant was expressed in HeLa cells in a dose course before CXCR4 immunoblotting. F: densitometry 
of E. Data represent mean values ± SE (n = 3, NS, P > 0.05, slope not significantly different from 0, F-test). G: 
schematic of CXCR4 deletion mutants constructed for the binding studies. H and I: binding assays between RNF113A 
and CXCR4. HeLa cell lysate (100 μg protein) was subjected to RNF113A immunoprecipitation. CXCR4 mutants 
were synthesized via in vitro transcription and translation (TnT) and allowed to bind to overnight with 
immunoprecipitated resin. Eluates were subjected to immunoblotting. 
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3.4.5 RNF113A regulates CXCR4 signaling 
Next, we investigated the effect of RNF113A on the CXCR4 signaling pathway. HeLa 
cells were transfected with RNF113A and treated with 6 nM CXCL12 in a time course before 
immunoblotting. RNF113A expression accelerates CXCL12-mediated degradation of CXCR4 
(Figure 60A). Further, RNF113A expression decreased the activation of downstream kinases in 
CXCR4 signaling, specifically the phosphorylation of Akt1 and ERK1/2, without affecting total 
kinase levels (Figure 60A). Next, we silenced RNF113A in HeLa cells before CXCL12 treatment. 
We observed RNF113A depletion led to increased CXCR4 protein signal. Further, RNF113A 
depletion increases the activation of downstream kinases in CXCR4 signaling, specifically the 
phosphorylation of Akt1 and ERK1/2 (Figure 60B). 
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Figure 60 RNF113A regulates CXCR4 signaling and cellular motility 
A: HeLa cells were transfected with RNF113A-V5 before CXCL12 treatment and immunoblotting for phosphorylated 
kinases. Densitometry relative to Empty at time 0 is shown beneath immunoblots. B: HeLa cells were transfected with 
plasmid encoding shRNA targeting RNF113A before treatment with CXCL12 (6 nM) for the indicated times. Cells 
were collected and immunoblotted for activation of downstream CXCR4 signalers. Densitometry relative to Ctrl 
shRNA at time 0 is shown beneath immunoblots. C and D: wound healing assay. HeLa cells were transfected with 
empty or RNF113A-encoded plasmids, or with plasmids encoding shRNA against scramble or RNF113A and allowed 
to grow to 80–90% confluency before starvation and wounding with pipette tip. Extent of gap closure was measured 
at 48 or 72 h and in the absence or presence of CXCL12. Gap closure is quantified below. Data represent mean 
values ± SE (n = 3–4 per group; *P < 0.05, significant between indicated groups, NS, P > 0.05, not significant between 
indicated groups, two-sided t-test). “KD” refers to shRNA. 
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3.4.6 RNF113A affects cell motility 
Finally, we investigated the functional role of RNF113A on cellular motility through its 
regulation of CXCR4. The CXCR4 signaling cascade mediates cellular motility, especially in the 
presence of CXCL12. Manipulation of CXCR4 signaling through antagonist inhibition or siRNA 
silencing has been shown to affect cellular motility in a wound healing assay (384, 395). Further, 
CXCL12 treatment can accelerate wound healing (395). HeLa cells were transfected with 
RNF113A-V5 plasmid or shRNA against RNF113A, and seeded to a density of 80-90%. Confluent 
cells were starved and wounded using 200 µL pipette tip to create a 400 μm gap in the monolayer. 
Additionally, cells were exposed to CXCL12 (12 nM) during course of healing. The monolayer 
was imaged and gap closure was quantified (n=3-4). RNF113A overexpression significantly 
precluded gap closure, compared to empty plasmid (Figure 60C). Moreover, treatment with 
CXCL12 resulted in a significantly increased gap closure with empty plasmid cells. However, 
compared to CXCL12 treatment, additional overexpression of RNF113A only slightly increased 
gap closure, and only closely within significance (p = 0.0458). From these observations, we 
conclude RNF113A expression affects cell motility through regulating CXCR4. As a 
complementary assay, we used shRNA to silence RNF113A prior to wound healing assay (Figure 
60D). We further confirmed that CXCL12 enhanced gap closure among the control shRNA plasmid 
group. Furthermore, additional depletion of RNF113A significantly increased gap closure, 
compared to CXCL12 treatment alone. 
These data demonstrate that RNF113A is a negative regulator of CXCR4 protein stability, 
signaling, and CXCR4-mediated cellular motility. 
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3.4.7 Discussion 
Here we report a new mechanism in the regulation of CXCR4 protein stability. We 
observed RING ubiquitin E3 ligase RNF113A promotes CXCR4 degradation, impairs downstream 
signaling, and affects cell motility. Depletion of RNF113A through shRNA preserves CXCR4 
protein level, extends CXCR4 protein half-life and enhances CXCR4 signaling. CXCR4 has been 
shown to be mono-ubiquitinated, specifically by ubiquitin E3 ligase ITCH, leading to its 
endosomal sorting and degradation (301, 371). However, poly-ubiquitination of CXCR4 has also 
been observed, and is suggested to play a role in immune cell aging (396, 397). We demonstrated 
RNF113A expression and CXCL12 treatment can increase high molecular weight ubiquitin signal 
of CXCR4 compared to control (Figure 57B). This suggests RNF113A facilitates the poly-
ubiquitination of CXCR4. 
The ubiquitin system is a critical mediator of the dynamics of cellular motility and 
migration (398). Specifically, RING E3 ligases, such as inhibitors of apoptosis (IAP), can both 
positively or negatively regulate cell migration through the ubiquitination of substrates including 
plasma membrane surface proteins or members of the signaling cascade (399). We observed that 
RNF113A overexpression attenuates CXCL12-CXCR4-dependent activation of Akt and ERK, 
kinases classically associated with cellular movement (Figure 60A). Conversely, silencing of 
RNF113A enhanced Akt and ERK activation (Figure 60B). RNF113A mediation of CXCR4 
degradation also has functional consequences. Cells with overexpressed RNF113A were less able 
to close the gap in a wound healing assay relative to empty vector plasmid (Figure 60C). However, 
among cells with RNF113A over-expression, the difference in gap closure between untreated and 
CXCL12-treatment trends toward insignificance (p = 0.0458). This suggests that RNF113A-
expressing cells are less sensitive to CXCL12-stimulated motility, possibly due to RNF113A-
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mediated degradation of the primary CXCL12 receptor, CXCR4. When RNF113A is silenced, 
which leads to the increased CXCR4 stability and abundance, cells exhibit a stronger response to 
CXCL12, with enhanced gap closure relative to control shRNA treatment (Figure 60D).  
GPCR and chemokine receptor signaling are heavily regulated by the stability of the 
receptor, specifically through post-translational modification. Phosphorylation by G-protein 
specific kinases has been known to be a main regulator through desensitization. However, 
ubiquitination is increasingly understood to be a potent regulator of stability and downstream 
function (400). Indeed, several ubiquitin E3 ligases are known to regulate the function and 
signaling of CXCR4.  
Substrates fated for ubiquitination are often characterized by specific targeting sequences 
that aid ubiquitin E3 ligases in identification and association. Specifically, protein binding motifs 
involving phosphorylation have proven critical for E3-substrate interaction (261, 393). Protein 
binding motifs have been shown to be critical in engaging CXCR4. Previous research has shown 
that ITCH binds CXCR4 with WW-motifs, which are binding regions with proline-rich affinity 
(394). We observed RNF113A to have a positively charged 10-residue region necessary for 
binding to CXCR4 (Figure 59A). Further, mutation of critical serine residues of CXCR4, known 
to be phosphorylated and thus negatively charged, led to decreased association with RNF113A 
(Figure 59H). These mechanistic studies suggest a complementary charge-dependent interaction 
facilitating the association between E3 ligase and substrate. Understanding of the mechanistic 
underpinnings of association will serve as the basis for future structure-based small molecule drug 
development. As a co-receptor for HIV-1, depletion of CXCR4 protein would be beneficial to 
prevent viral entry, similar to drug development efforts in antagonizing CCR5 (378). Enhancing 
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RNF113A-CXCR4 interaction or prolonging RNF113A half-life would function to decrease 
available co-receptor for viral entry, and potentially have therapeutic benefits for patients. 
RNF113A may be working in concert with other proteins or E3 ligases. Arrestin-2 has been 
shown to cooperate with ITCH in promoting ubiquitination of CXCR4, leading to its degradation 
(388, 401). Conversely, Holleman and Marchese described antagonism between the RING E3 
ligase Deltex-3L (DTX3L) and ITCH, as DTX3L inhibits ITCH ubiquitin ligase activity toward 
CXCR4 (389). Similarly, the downstream kinase CISK has been shown to inhibit ITCH activity 
in degrading CXCR4 (402). Interestingly, we observe that RNF113A protein signal also decays 
during cycloheximide chase (Figure 58A), suggesting RNF113A protein stability is subject to 
regulation. We have observed a similar multiple E3 ligase relationship in F-box only protein 3 
(FBXO3) regulating F-box/LRR-repeat protein 2 (FBXL2) leading to pleiotropic cellular and 
pathological consequences (403). Substrates have been shown to be regulated by a variety of 
ubiquitin E3 ligases depending on the specific spatiotemporal environment, and in response to 
discrete stimuli; a classic example being the ubiquitin-mediated regulation of p53 (404). It is 
possible that the regulation of CXCR4 by RNF113A works within a comparable regulatory 
framework. 
Aside from this study, the function of RNF113A remains unclear. Bioinformatics studies 
predict a RING domain in RNF113A (405). We observed that mutation of critical RING residues 
rescues substrate CXCR4 from degradation (Figure 57D). Genomic studies have shown that 
nonsense mutations within the catalytic RING domain of RNF113A occur in patients with the 
autosomal recessive disease Trichothiodystrophy (406). While trichothiodystrophy is a 
pathologically heterogenous disease, malfunction of DNA-repair mechanisms has been associated 
with patients (407). It could be that RNF113A is involved in regulation of these potentially disease-
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causing repair mechanisms. Further investigation is needed for determining the regulation of 
RNF113A on biologic processes. 
We believe this study is a stepping stone for further investigations into a novel regulator of 
CXCR4 stability and signaling. 
3.4.8 Materials and Methods 
 Materials 
Anti-CXCR4 antibody (UMB2) (ab124824) was from Abcam. Horseradish peroxidase-conjugated 
secondary antibodies (170-515/6) were from Bio-Rad. Antibodies against ERK1/2 (137F5; 4695), 
pERK1/2 (Thr202/Tyr204) (20G11; 4376), pAkt (Ser473) (D9E; 4060), and Akt (40D4; 2920) 
were from Cell Signaling Technologies. Anti-ubiquitin antibody (VU101) was from Life Sensors. 
Antibodies against RNF113A (V-25, sc-133965) were from Santa Cruz Biotechnology. Anti-actin 
antibody (A5441) was from Sigma Aldrich. Anti-V5 Tag (R960-25) was from Thermo Fisher 
Scientific. QuikChange II XL Site-Directed Mutagenesis Kit (200522) was from Aglient 
Technologies. Eagle's minimum essential medium (EMEM) (30-2003) and HeLa cells (CCL-2) 
were from ATCC. Thermal Cycler Life ECO (BYQ6078) was from BIOER Technology. 
Cytation5 Imager was from BioTek. Cycloheximide (BML-GR310) was from Enzo. Plasmids 
(pLKO.1) encoding shRNA against RNF113A were from GE Dharmacon. FBS (100-106) was 
from Gemini. DNA sequencing was performed at Genewiz. Phusion High-Fidelity DNA 
Polymerase (M0530) was from NEB. TnT T7 Quick Coupled Transcription/Translation System 
(L1170) was from Promega. Recombinant hCXCL12 (350-NS-010) was from R&D Systems. 
Agar (A5306) and XtremeGene HP (XTGHP-RO ROCHE) were from Sigma Aldrich. HisPur Ni-
NTA Magnetic Beads (88831), PureLink Quick Plasmid Miniprep Kit (K210010), Pierce Protein 
204 
A/G Magnetic Beads (88802), and pcDNA3.1D V5/HIS/TOPO kit (K490040) were from Thermo 
Fisher Scientific. 
 Cell culture 
HeLa cells were cultured in Eagle's minimum essential medium (ATCC) supplemented 
with 10% fetal bovine serum (EMEM-10). Cell line morphology was monitored via microscopy 
and immunoblotted for multiple markers. Mycoplasma contamination was checked using the 
MycoAlert Mycoplasma Detection Kit (Lonza, Switzerland). For plasmid overexpression in HeLa 
cells, plasmids were combined with XtremeGene HP kit following manufacturer’s protocol. After 
24 h, cells were treated with CXCL12 (6 nM) or cycloheximide (CHX; 50 µg/ml) for the indicated 
times. For RNF113A silencing studies in HeLa cells, scrambled shRNA control and RNF113A 
shRNA were transfected into cells for 48 h using XtremeGene HP kit following the manufacturer’s 
protocol. Exposed cells were collected and processed for immunoblotting. 
 Cloning and mutagenesis 
All wild-type (WT) and mutant CXCR4, RNF113A, and RING E3 ligase plasmid 
constructs were generated using PCR-based approaches using appropriate primers and were then 
subcloned into a pcDNA3.1D/V5-His vector (9, 34). Point mutants were generated using the 
QuikChange II XL kit (Aglient). All plasmid constructs were sequence-confirmed against NCBI 
reference sequences before experimentation, (e.g., NM_001008540 for CXCR4, NM_006978 for 
RNF113A). 
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 Western blotting 
Cell sample lysates were collected and digested in buffer A (150 mM NaCl, 50 mM Tris, 
1.0 mM EDTA, 2 mM dithiothreitol, 0.025% sodium azide, and 1 mM phenylmethylsulfonyl 
fluoride) on ice. Lysates were prepared by brief sonication at 4°C. Insoluble cellular debris was 
precipitated through centrifugation at 15,000 g for 10 min at 4°C. Lysate supernatant was 
normalized for protein concentration and diluted in denaturing loading buffer, with a final 1× 
formulation of: 50 mM Tris·HCl (pH 6.8), 2% SDS, 10% glycerol, and 100 mM DTT. Samples 
were resolved via SDS-PAGE prior to immunoblotting. Signal was detected via 
chemiluminescence on a Kodak Imaging Station. Densitometry was calculated via ImageJ 
(National Institutes of Health, Bethesda, MD). 
 HIS-pull down 
Full-length CXCR4-HIS-V5 plasmid was overexpressed in HeLa cells without and with 
coexpression of tagless RNF113A using the above protocol. Following 18 h of expression, cells 
were exposed to vehicle or CXCL12 (6 nM) for 1 h, before collection and lysis of cells. Clarified 
cell lysate was incubated with HisPur Ni-NTA agarose resin for 1 h at 25°C. Resin pull-downs 
were washed before elution at 70°C in 1× denaturing loading buffer and subsequent immunoblot 
analysis. 
 In vitro protein-binding assays 
CXCR4 protein was immunoprecipitated from 1 mg HeLa cell lysate using CXCR4 
antibody (rabbit) and coupled to protein A/G agarose resin. CXCR4 beads were then incubated 
with in vitro synthesized products (50 μl) expressing RNF113A-V5 deletion mutants. After 
washing, the proteins were eluted and processed for V5 immunoblotting. Similarly, RNF113A 
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protein was immunoprecipitated from HeLa cell lysate using RNF113A antibody (rabbit), and 
subjected to binding against V5-tagged CXCR4 mutants. 
 RNF113A shRNA knockdown 
pLKO.1 plasmids encoding nontargeting control (RHS6848) and shRNA against 
RNF113A were derived from the RNAi Consortium (TRC-Hs1.0, human) and purchased from GE 
Dharmacon. Mature antisense sequences are as follows: shRNA no. 1 (TRCN0000033729): 
TTTCCGGTCGAACCACAGTGC; shRNA no. 2 (TRCN0000033730): 
TAGCAATCAATTCTTTCGCTG; shRNA no. 3 (TRCN0000033731): 
TATCATTGGATTGTGGGTCAC; shRNA no. 4 (TRCN0000033732): 
AAAGATGGCTTGTGCATCGCG; and shRNA no. 5 (TRCN0000033733): 
ATTGAAGACGCCATTGGTCTG. Plasmids encoding shRNA were delivered to cells using 
transfection protocols described above. 
 Cellular migration assay 
HeLa cells were transfected with empty plasmid, RNF113A-V5, control shRNA, or 
shRNA against RNF113A as described above. Transfected cells were seeded in six-well plates to 
80–90% of confluence and starved for 24 h before scratching the monolayer with a pipette tip. 
CXCL12 (12 nM) was added to wounded monolayer immediately following injury and replaced 
every 24 h. Images were collected at 48 and 72 h post scratch. Images were collected with ×4 
objective using BioTek Cytation5 Imager. 
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 Statistical analysis 
Statistical comparisons were performed with means ± SE for continuous variables. All data 
were statistically analyzed by the indicated statistical tests with P < 0.05 indicative of statistical 
significance. All analyses were performed using GraphPad Prism 6. 
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4.0 Ubiquitination in Nutrient Sensing 
In the final aim of this dissertation, we conducted pilot studies into the role of ubiquitin E3 
ligase control of nutrient sensing mechanisms. Many of the previously described lung diseases 
disproportionately afflict the elderly. ARDS incidence and mortality is highest in the elderly (268). 
Likewise, individuals over 60 are the highest proportion of patients presenting with idiopathic 
pulmonary fibrosis (408, 409). As humanity enters an age where elders assume a hitherto unseen 
proportion of total persons, diseases such as ARDS, fibrosis, and other age-related co-morbidities 
will increase in prevalence (410). One route to intervene against these age-associated diseases is 
to investigate the mechanisms of aging itself; among these, nutrient sensing, and its dysfunction, 
has been implicated in longevity and health span. Understanding of the mechanisms controlling 
nutrient sensing may yield new protein relationships associated with health and disease, and 
present new targets for therapeutic intervention. In this pilot study, we investigated the E3 ligase 
RNF186 and its control of Sestrin-2, a protein that senses the amino acid leucine to regulate 
metabolic signaling through mTORC1. 
4.1 The RING-type E3 ligase RNF186 ubiquitinates Sestrin-2 and thereby controls nutrient 
sensing 
Adapted from: Lear et al., The RING-type E3 ligase RNF186 ubiquitinates Sestrin-2 and thereby 
controls nutrient sensing J. Biol. Chem. 2019 294: 16527-. doi:10.1074/jbc.AC119.010671, (411) 
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4.1.1 Introduction 
Nutrient sensing is a critical process controlling metabolism and growth function for cells 
and tissues (412). The primary signaling pathway controlling nutrient sensing is the mechanistic 
target of rapamycin complex 1 (mTORC1) pathway (413). During nutrient availability, mTORC1 
phosphorylates several key signaling proteins such as P70S6K, 4E-BP1, and ULK1, working to 
activate anabolic processes and inhibit processes such as autophagy (70). Specific amino acid 
sensors such as Sestrin-2 sense intracellular nutrient levels, and integrate this signal to the 
mTORC1 complex (414). 
 The nutrient sensing role of Sestrin-2 
Sestrin-2 (also known as Hi95) exerts inhibitory control over mTORC1 by associating with 
an mTORC1 activating protein complex called GATOR2 (415). This function is in a leucine-
dependent manner, such that when leucine is abundant, the Sestrin-2-GATOR2 interaction is 
impeded, allowing activation and anabolic mTORC1 activity (415, 416). Sestrin-2 loss-of-function 
and mutational studies demonstrate the sensor’s criticality for mTORC1 activity, as Sestrin-2 
depleted cells result in constitutively active mTORC1, even in the absence of nutrients such as 
leucine (415). Further Sestrin-2 has been shown to regulate autophagic flux in numerous cell types 
(417-419). Transcriptional control of Sestrin-2 has been well-characterized (420-422), however, 
the post-translational mechanisms of Sestrin-2 regulation remain unclear. Our group and others 
have noted distinct mechanisms of E3 ligase control of disease, such as lung innate immunity, 
fibrosis, and of mTORC1 activity (176, 261, 423). E3 ligases are also a growing field for 
therapeutic targeting and inhibition (424). We sought to determine if Sestrin-2 was subject to 
ubiquitin E3-ligase mediated degradation, and the effect of this control on mTORC1 activity. 
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 RNF186 as a new regulator of Sestrin-2 stability and activity 
Here we report the mechanistic study of Sestrin-2 ubiquitination and degradation by the 
RING E3 ligase RNF186. We observed Sestrin-2 has a short half-life in Beas-2b cells that is 
prolonged by inhibiting the proteasome or the ubiquitination cascade. We used unbiased high 
throughput screening of Sestrin-2-GFP expressing cells with a library of siRNA targeting ubiquitin 
proteins and E3 ligases to uncover the E3 ligase RNF186 as a regulator of Sestrin-2 stability. 
RNF186 silencing prolongs Sestrin-2 stability while RNF186 expression accelerated Sestrin-2 
degradation. RNF186 ubiquitinates and binds Sestrin-2 through specific domains. Silencing of 
RNF186 leads to decreased mTORC1 activity, potentially through increased Sestrin-2 protein 
abundance. This study adds a new mechanism for control of nutrient sensing through protein 
ubiquitination and suggests RNF186 may be potential target for inhibition to increase the level of 
the mTORC1 inhibitor Sestrin-2. 
4.1.2 The ubiquitin-proteasome system potently controls Sestrin-2 stability in airway cells 
We first investigated the stability of Sestrin-2 in human primary airway epithelial Beas-2B 
cells. Cycloheximide (CHX) time course revealed endogenous Sestrin-2 has a half-life around 4 
hours, which is prolonged with proteasomal inhibition by MG132 (Figure 61A). Treatment with 
the lysosomal inhibitor leupeptin did not increase Sestrin-2 protein stability. MG132 treatment 
also resulted in a time dependent increase in endogenous Sestrin-2 level (Figure 61B). While the 
proteasome is the endpoint for most protein degradation, the ubiquitination pathway is a major 
upstream mechanism controlling proteins fated for proteasomal degradation. Co-treatment of 
Beas-2B cells with CHX and the ubiquitin E1 inhibitor MLN7243 resulted in enhanced Sestrin-2 
stability, suggesting a role for ubiquitin-control of Sestrin-2 stability (Figure 61C) (425). 
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Expression of HA-tagged ubiquitin with CHX treatment led to Sestrin-2 degradation, which was 
also prevented with proteasomal inhibition (Figure 61D). Ubiquitin is often assembled in 
polymeric chains upon proteins to be degraded; this poly-ubiquitination is a canonical signal for 
degradation (94). Sestrin-2 pull-down in the presence of MG132 displayed extensive high 
molecular weight ubiquitin signal, characteristic of poly-ubiquitination (Figure 61E). These poly-
ubiquitin chains have the capacity to assemble different linkage types, forming a cellular code 
(426). We used the UbiCREST assay to unravel the specific poly-ubiquitin chain type assembled 
on Sestrin-2. UbiCREST utilizes the differential reactivity of de-ubiquitinase enzymes for  specific 
poly-ubiquitin-linkage types (427). We observed Sestrin-2 assembles predominately -K48 and -
K63 poly-ubiquitin chains as evidenced by the degradation of Sestrin-2 poly-ubiquitin signal upon 
treatment with deubiquitinases specific for these linkage-types (Figure 61F).  
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Figure 61 Sestrin-2 is ubiquitinated and degraded in the proteasome  
 
(A) Immunoblot analysis of Sestrin-2 protein from Beas-2b cells following CHX time course with MG132 or leupeptin 
co-treatment. Data and means ± SD of 3 independent experiments. (B) Sestrin-2 blotting from Beas-2b cells treated 
with vehicle, MG132, or leupeptin for indicated times. Data and means ± SD of 3 independent experiments. (C) 
Immunoblot analysis of Sestrin-2 protein from Beas-2b cells following CHX time course with the Ubiquitin E1 
inhibitor MLN7243 or leupeptin co-treatment. Data and means ± SD of 3 independent experiments. (D) HA-tagged 
ubiquitin was expressed prior to CHX time course with MG132 co-treatment and Sestrin-2 immunoblotting. Data and 
means ± SD of 3 independent experiments. (E) Sestrin-2-V5-HIS was expressed in Beas-2b cells prior to MG132 
treatment, HIS pulldown, and ubiquitin immunoblotting. (F) UbiCREST analysis of Sestrin-2 poly-ubiquitination 
pattern. Sestrin-2-V5-HIS was expressed in Beas-2b cells, treated with MG132, and pulled-down prior to digestion 
with different deubiquitinases and immunoblot analysis. *P ＜0.05, by F-test comparisons of nonlinear regression 
relative to controls (A-D). 
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4.1.3 The Ubiquitin E3 ligase RNF186 ubiquitinates and degrades Sestrin-2 
Ubiquitin E3 ligases are the critical substrate-recognition mechanism of the ubiquitination 
pathway. To understand the mechanism of Sestrin-2 degradation, we prepared a stable Sestrin-2-
GFP expressing cell line and utilized an RNAi library targeting proteins involved in ubiquitination 
(E1, E2, E3, etc) to screen for Sestrin-2 regulators. Sestrin-2-GFP cells were transfected with the 
siRNA library, and GFP fluorescence was measured after 72 hours and ranked by median absolute 
deviation Z-score. We observed several key regulators of Sestrin-2 stability (Figure 62A). 
Specifically, the ubiquitin E3 ligases RNF186 and PRFP19 resulted in potent Sestrin-2-GFP signal 
relative to ctrl siRNA (Figure 62B). Top hits from the screen were evaluated by immunoblotting, 
and RNF186 knockdown resulted in increased SESN2 protein signal (Figure 62C). Further, 
RNF186 expression resulted in dose dependent decrease in Sestrin-2 protein (Figure 62D). In 
contrast, mutation of a key residue within the RNF186 active site, His-60 to Trp (428), led to 
inability to decrease Sestrin-2 protein (Figure 62E). Beas-2B cells were treated with siRNA against 
RNF186 prior to CHX chase, and we observed that RNF186 knockdown resulted in prolonged 
Sestrin-2 stability relative to control siRNA (Figure 62F). Conversely, RNF186 overexpression 
led to accelerated Sestrin-2 degradation in CHX chase (Figure 62G). Finally, co-expression of 
RNF186 with ubiquitin and Sestrin-2 in an in vivo ubiquitination assay resulted in increased poly-
ubiquitination signal detected from Sestrin-2 pull-down, suggesting RNF186 facilitates the 
ubiquitination of Sestrin-2 (Figure 62H).  
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Figure 62 Ubiquitin RING E3 ligase RNF186 controls Sestrin-2 ubiquitination and degradation  
(A) Screening of an siRNA library targeting ubiquitin E3 ligases for effect on Sestrin-2-GFP signal. Fluorescence was 
measured by Cytation 5 automated microcopy. Sestrin-2-GFP signal was reported as median absolute deviation Z-
score. Top hits are ranked and displayed. (B) Representative Sestrin-2-GFP images from scramble siRNA and 
candidate E3 ligase siRNA from screen in (A). Scale bar indicates 100µm. (C) Immunoblot analysis of candidate E3 
ligases identified from screen in (A). (D) RNF186 was expressed dose-wise in Beas-2b prior to Sestrin-2 
immunoblotting. (E) Immunoblot analysis of Sestrin-2 following expression of RNF186 H60W mutant. (F) CHX 
chase of Sestrin-2 protein following siRNA knockdown of RNF186 in Beas-2b cells. Data and means ± SD of 3 
independent experiments. (G) CHX chase of Sestrin-2 protein following expression of RNF186 in Beas-2b cells. Data 
and means ± SD of 3 independent experiments. (H) Immunoblot analysis of Sestrin-2 ubiquitination following in vivo 
ubiquitination assay and pull-down of Sestrin-2 protein. *P ＜0.05, by F-test comparisons of nonlinear regression 
compared to controls (F, G).  
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4.1.4 RNF186 and Sestrin-2 bind each other through C-terminal motifs 
To further examine the mechanism of the RNF186/Sestrin-2 interaction, we conducted 
reductionist mapping experiments to find the critical protein motif for binding. We prepared 
RNF186 deletion mutants (Figure 63A), synthesized the protein fragments in vitro, and exposed 
them to immunoprecipitated Sestrin-2 in binding assays. We observed that the RNF186 ΔC27 
mutant lost binding with Sestrin-2, and upon further deletion mapping, we observe the C10-20 
region of RNF186 is critical for Sestrin-2 binding (Figure 63B-C). We also prepare deletion 
mutants of Sestrin-2 encompassing critical protein domains (Figure 63D). Sestrin-2 mutants lost 
binding with RNF186 with the ΔC173 mutant (Figure 63E). Further mapping studies show the key 
region for RNF186-engagement to exist between residue 308 and 380 of Sestrin-2 (Figure 63F).  
4.1.5 Lysine 13 is a critical ubiquitin-acceptor site for Sestrin-2 
Substrates are ubiquitinated through covalent isopeptide bond between ubiquitin’s C-
terminus and an acceptor amino acid on the substrate. The key substrate amino acid is often lysine 
(429). We sought to identify the critical ubiquitin-acceptor lysine site within Sestrin-2. Previous 
ubiquitin proteomics studies detected a ubiquitinated peptide corresponding to Sestrin-2 Lys13 
(430). To confirm this, we prepared Sestrin-2 point mutants, and co-expressed with RNF186 in 
Beas-2B cells. Sestrin-2 K13R mutant demonstrated resistance to RNF186 expression relative to 
wild-type (Figure 63G). Further, Sestrin-2 K13R mutant displayed a prolonged half-life in CHX 
time course (Figure 63H). As a negative control, mutation of non-ubiquitin-associated Sestrin-2 
lysine (K452R) did not confer protection from degradation (Figure 63I). 
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Figure 63 RNF186 and Sestrin-2 bind through discrete C-terminal Motifs  
 
(A) Schematic of RNF186 deletion mutant strategy and individual binding status with Sestrin-2. (B-C) Binding assay 
of in vitro synthesized RNF186 deletion mutants and Sestrin-2. (D) Sestrin-2 deletion mutant strategy and binding 
status with RNF186. (E-F) Immunoblot analysis of Sestrin-2 mutant binding with RNF186 protein. (G) Wild-type or 
K13R mutant Sestrin-2 was expressed in Beas-2b cells without or with expression of RNF186 prior to blotting. Data 
and means ± SD of 3 independent experiments. (H) Immunoblot analysis of Sestrin-2 wild-type or K13R expression 
prior to CHX time course. Data and means ± SD of 3 independent experiments. (I) Immunoblot analysis of Sestrin-2 
K452R mutant in CHX assay. NS, P > 0.05; *P ＜0.05; ***P < 0.001 by ANOVA, with Tukey’s test for multiple 
comparisons (G) or by F-test comparisons of nonlinear regression relative to control (H). 
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4.1.6 RNF186 affects Sestrin-2 regulation of mTORC1 
We next sought to explore the effect of the RNF186-Sestrin-2 axis on downstream 
mTORC1 signaling. As a leucine sensor, Sestrin-2 acts to inhibit mTORC1 activity by interacting 
with GATOR2, and preventing its downstream regulation of the Rag GTPases (415). The 
inhibitory effect of Sestrin-2 is most potent during leucine starvation. SESN2 silencing in Beas-2B 
cells led to increased mTORC1 activity as measured by phosphorylation of P70S6K (Thr389) 
Figure 64A-C). This effect persists even during cellular leucine starvation. Silencing of RNF186 
led to increased SESN2 protein relative to control (Figure 64D, E). Of note, RNF186 knockdown 
led to decreased mTORC1 activity relative to control (Figure 64). 
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Figure 64 RNF186 knockdown impairs leucine-dependent nutrient sensing  
(A) Immunoblot analysis of mTORC1 activity and autophagic flux from Beas-2b cells treated with control or SESN2 
siRNA prior to leucine starvation. Protein densitometry of (B) Sestrin-2 and (C) ratio of phosphorylated (Thr389) to 
total P70S6K was quantified. Data and means ± SD of 3-4 independent experiments. (D) Immunoblot analysis of 
mTORC1 activity and autophagic flux from Beas-2b cells treated with control or RNF186 siRNA prior to leucine 
starvation. Protein densitometry of (E) Sestrin-2 and (F) ratio of phosphorylated (Thr389) to total P70S6K was 
quantified. Data and means ± SD of 3-4 independent experiments. *P<0.05, **P < 0.01, ****P < 0.0001 by two-sided 
unpaired t-test (B, E) or by one-way ANOVA, with Tukey’s test for multiple comparisons (C, F).  
 
As a complementary assay, we utilized LC3-GFP-RFP reporter cells to measure the effect 
of RNF186 and SESN2 interaction. This autophagic tool exploited the instability of GFP at low 
pH to create a reporter sensitive to lysosomal maturation. The LC3 construct also has constitutively 
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cleaved RFP fusion protein is expressed in cells, serving as a loading control. The ratio of 
GFP/RFP is a surrogate for autophagic flux in a cell (431). As autophagy is an endpoint of 
mTORC1 regulation, we utilized this tool as a readout for mTORC1 activity. We knocked down 
SESN2 and RNF186 in Beas-2B cells that stability expresses LC3-GFP-RFP reporter prior to 
leucine starvation, fixation and automated microscopy. We observed control siRNA during leucine 
starvation resulted in 70% decrease in GFP/RFP ratio relative to baseline, consistent with previous 
studies into the effect of amino acid starvation on autophagic flux (Figure 65A, B) (431). SESN2 
knockdown resulted in a significantly higher GFP/RFP ratio, suggesting less autophagic flux 
(Figure 65A, C). Interestingly, RNF186 silencing decreased the GFP/RFP further, suggestive of 
increased autophagic flux (Figure 65A, D). These assays suggest the RNF186/Sestrin-2 axis plays 
a role in regulating cellular nutrient sensing and metabolic flux. 
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Figure 65 Sestrin-2 and RNF186 depletion affect starvation-mediated autophagic flux 
(A) Quantification of LC3B GFP to RFP ratio in cells starved of leucine. Data are normalized to Control siRNA 
baseline ratio. Data and means ± SD (n = 4-8). (B) Representative image of LC3B-GFP-RFP reporter cells transfected 
with scramble siRNA at baseline conditions. (C-E) Representative images of LC3B-GFP-RFP reporter cells starved 
of leucine and transfected with siRNA targeting (C) scramble, (D) SESN2, or (E) RNF186. ***P < 0.001; ****P < 
0.0001 by ANOVA, with Tukey’s test for multiple comparisons (A). Scale bar indicates 50µm. 
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4.1.7 Discussion 
E3 ligases are increasingly appreciated regulators of nutrient sensing and mTORC1 activity 
(423). A recent study has shown the GATOR1 subunit DEPDC5 to be potently regulated by the 
Cullin-3 substrate-receptor KLHL22 (81). Our data show that RNF186 plays a similar role in 
targeting Sestrin-2 for ubiquitination and degradation, which in turn affects mTORC1 activity and 
downstream autophagic flux. Dysfunction of nutrient sensing is recognized as a hallmark of aging; 
better understanding of the regulation of nutrient sensing will afford new potential targets for 
inhibition and intervention (68). 
RNF186 has been characterized as RING (Really new interesting gene)-type ubiquitin E3 
ligase (432). RING E3 ligases function through Zinc-finger domains that are critical for engaging 
the E2 ubiquitin conjugating enzyme (254). We observed that mutation of a critical residue within 
the RING-domain impaired RNF186 ability to degrade Sestrin-2 (Figure 62E), suggesting that the 
ubiquitin E3 ligase activity of RNF186 drives its effect on Sestrin-2 (428). We observed that 
RNF186 and Sestrin-2 binding was lost upon the deletion of a 72-residue region between amino 
acid 308 and 380 of the Sestrin-2 C-terminus (Figure 63F). Interestingly, this same region has been 
described as key for regulating mTORC1 activity, and for binding leucine (residues 374-377) (416, 
433). Future studies are needed to investigate the distinct mechanism of RNF186/Sestrin-2 
interaction, and if leucine plays a role. 
K48 poly-ubiquitination is the canonical signal for proteasomal degradation, and has been 
reported as a predominant linkage type among cellular poly-ubiquitin chains (434). Through 
UbiCREST assay, we observed Sestrin-2 poly-ubiquitination with K48-linkages, consistent with 
previous studies in neuronal cells (435). We also observed that Sestrin-2 contains poly-ubiquitin 
chains with K63 linkages. This linkage type has been implicated in several processes, notably 
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cellular trafficking (436). It remains unclear if Sestrin-2 ubiquitination plays a non-degradation 
role in its cellular localization. 
mTORC1 plays an important role in the lung epithelia and disease. Research has suggested 
mTORC1 activity plays a pathogenic role in epithelia during acute lung injury (437). Similarly, 
mTOR-driven signaling affects the pathophysiology of pulmonary fibrosis in fibroblasts (438). 
One study suggested Sestrin-2 inhibition to be protective in a mouse model of COPD (439). More 
research is needed to see if RNF186 and Sestrin-2 play a role in these lung diseases. 
In conclusion, we describe a new mechanism of ubiquitin E3-ligase mediated control of 
nutrient sensing through the interaction of RNF186 with Sestrin-2.  
4.1.8 Materials and Methods 
 Materials 
BEAS2-B (Cat# CRL-9609, RRID:CVCL_0168) were from ATCC. BioRad (Cat# 170-
6515 RRID:AB_11125142), Goat anti-Mouse HRP (Cat# 170-6516 RRID:AB_11125547), Rabbit 
anti-Goat HRP (Cat# 172-1034 RRID:AB_11125144 were from BioRad. UbiCREST assay kit 
was from BostonBiochem. Mouse Monoclonal anti-HA-Tag (clone 6E2) (Cat# 2367S 
RRID:AB_10691311), Rabbit anti-Phospho-p70 S6 Kinase (Thr389) (108D2) (Cat# 9234, 
RRID:AB_2269803), Rabbit anti-p70 S6 Kinase (49D7) (Cat# 2708, RRID:AB_390722), Rabbit 
anti-Sestrin-2 (D1B6) (Cat# 8487, RRID:AB_11178663), Mouse anti-Ubiquitin (P4D1) (Cat# 
3936, RRID:AB_331292), and Rabbit anti-LC3B (D11) XP (Cat# 3868, RRID:AB_2137707) 
were from Cell Signaling Technology. Cycloheximide (Cat# BML- GR310) was from 
Ubiquitinylation kit (Cat# BML-UW9920-0001) were from Enzo. Sequencing was conducted at 
Genewiz. DNA primers and dsiRNA were from IDT. pcDNA3.1D-V5-HIS-TOPO (Cat# 
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K490001), was from Invitrogen. TnT T7 Quick Coupled Transcription/Translation (Cat# L1170) 
was from Promega. Leupeptin (Cat# L2884) and Mouse Monoclonal anti-beta-Actin (clone AC-
15) (Cat# A5441 RRID:AB_476744) were from Sigma-Aldrich. Mouse Monoclonal anti-V5 Tag 
(Cat# R960-25 RRID:AB_2556564), Protein A/G Magnetic Beads (Cat# 88802), pcDNA3.1 
Directional TOPO Expression Kit (Cat# K490001), were from Thermo Fisher Scientific. pRK5-
HA-Ubiquitin-WT (Cat#17608, RRID:Addgene17608) Was a gift from Ted Dawson (440). Anti-
RNF186 antibody (Cat# ab86547, RRID:AB_2180433) was from Abcam. WesternBright Sirius 
HRP substrate (Cat# K-12043) was from Advansta. QuikChange II XL Site-Directed Mutagenesis 
Kit (Cat# 200521) was from Agilent Technologies. pLenti CMV GFP Puro (658-5) was a gift from 
Eric Campeau & Paul Kaufman (Addgene plasmid # 17448 ; http://n2t.net/addgene:17448; 
RRID:Addgene_17448). pMRX-IP-GFP-LC3-RFP was a gift from Noboru Mizushima (Addgene 
plasmid # 84573; http://n2t.net/addgene:84573; RRID:Addgene_84573)(431). pRK5-HA-Sestrin2 
was a gift from David Sabatini (Addgene plasmid # 72593 ; http://n2t.net/addgene:72593 ; 
RRID:Addgene_72593)(441). 
 Cell Culture 
Beas-2b cells were from ATCC and cultured in HITES media supplemented with 10% 
FBS. Cells were treated with cycloheximide (100μg/mL), MG132 (20μM), leupeptin (20μM), and 
MLN7243 (10μM) for indicated times. Cells were transfected with Nucleofector 2b (Amaxa) or 
XtremeGene siRNA reagent (Roche). Cells were starved by two washes, then incubation with 
EBSS supplemented with amino acids minus leucine (Gibco). 
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 UbiCREST Assay 
Ubiquitination Linkage-type analysis was measured by UbiCREST assay(427)  
(BostonBiochem). Briefly, Sestrin-2 was expressed in Beas-2b, treated with MG132 (20μM, 4 
hours), and lysed prior to HIS-pull down with HisPur Resin (ThermoFisher). Following 
UbiCREST digestion, resin eluate was assayed by immunoblotting. 
 Ubiquitination siRNA Screen  
Stably expressing Beas-2b Sestrin-2-GFP cells in 384-well glass-bottom plates were 
transfected with MISSION esiRNA targeting ubiquitination proteins (E1, E2, E3 ligases etc) 
(Sigma-Aldrich) using XtremeGene siRNA transfection reagent (Roche). Knockdown proceeded 
for 72 hours prior to washing, fixation, and fluorescent imaging using BioTek Cytation5. 
 LC3 Fluorescent Reporter Assay 
LC3 reporter cells were transfected with dsiRNA against scramble, SESN2, or RNF186 and 
seeded to 96-well glass-bottle plates for 60 hours before starvation in EBSS + amino acids minus 
leucine for 18 hours. Cells were fixed in 4% paraformaldehyde and imaged using ImageXpress 
Micro XLS. Fluorescence was quantified and GFP:RFP ratio was calculated with CellProfiler 
(231). 
 In vitro protein binding assays 
Protein binding assays were conducted as previously described (261). Briefly, Sestrin-2 or 
RNF186 protein was immunoprecipitated from 1mg of Beas-2b cell lysate using 1:100 antibody 
dilution. Protein was precipitated in IP buffer (50 mM Tris HCl pH 7.6, 150 mM NaCl, 0.25 % v/v 
Triton-X-100) for four hours at +4C, then coupled to protein A/G agarose resin for an additional 
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two hours. Binding mutants were in vitro synthesized using TnT expression kits and allowed to 
bind overnight. Resin was washed and protein was eluted in 1x Laemmli buffer at 88°C for five 
minutes prior to immunoblotting analysis. 
 Statistics 
All statistical tests were calculating using Graphpad Prism 8. P < 0.05 was used to indicate 
significance. Densitometry was calculated using ImageJ (NIH). 
4.1.9 Acknowledgements 
We thank Alison C. McKelvey and Sarah R. Dunn for their assistance in cloning the initial 
RNF186 plasmid construct. 
4.1.10 Conflict of interest 
The authors acknowledge no conflicts of interest with the contents of this article 
226 
5.0 Concluding Remarks 
5.1 Ubiquitin E3 Ligase Mediated Lung Disease and Public Health in an Aging World 
These data show that Ubiquitin E3 ligases play intricate and important roles in lung disease 
and progression, including fibrosis, inflammation, and nutrient sensing disorder. These new 
mechanistic understandings are needed more than ever as humanity enters a more aged world. 
Public health initiatives, medical advances, and numerous other factors have led to the phenomena 
of an increasingly aged human population. This is pointedly shown in that the proportion of 
humans over 65 now outnumbers those under 5; it is estimated this inflection point is occurring in 
this decade (442). The public health consequences of an aging population are numerous, but lung 
diseases are a key effect. Several lung diseases are disproportionately represented among the 
elderly. Inflammatory lung diseases show sharp increases in incidence among older patients; Acute 
Lung Injury incidence peaks among those aged 75-84 (268). Further, fibrotic lung disease afflict 
the elderly; patients aged 60 to 70 make up the largest percentage of those presenting with 
Idiopathic pulmonary fibrosis (409, 443). As a key hallmark of aging, nutrient sensing 
dysregulation will continue to be an underlying biological mechanism for aging-related diseases 
(68). Studies into the ubiquitin-proteasome based control of key regulator proteins in lung disease, 
including the research in this thesis, not only expand understanding of the networks of ubiquitin-
based control, but provide new targets for future therapeutic development. These studies show that 
targeting Ubiquitin E3 ligases has experimental efficacy, which may translate to therapeutic 
efficacy in future studies.  
227 
5.2 Future Directions for E3 ligase-based intervention 
As ubiquitin E3 ligases are increasingly recognized as avenues for therapeutic intervention, 
new technologies are under development to target their activity. Researchers have utilized 
established E3 ligase-binding chemicals to pharmacologically develop proteolysis targeting 
chimeras or PROTAC chemicals (444, 445). These small molecules are comprised of an E3 ligase 
ligand connected to a substrate-specific ligand by a linker region in the attempt to bring E3 ligases 
near substrates to facilitate substrate degradation (446). PROTAC utilizes a number of E3 ligases 
for targeted degradation; the two primary E3 ligases are the VHL E3 ligase, and the CRL4 subunit 
Cereblon which binds to thalidomide-based chemicals (447, 448). These E3 ligase chemicals form 
the basis of a combinatorial chemical which can be exchanged for whatever ligand binds the 
desired substrate.  Research has shown PROTAC is extremely potent in targeted degradation of 
substrate proteins such as STAT3 and Bromodomains, which potential application to 
inflammation, cancer and other diseases (449-451). Further, recent research has shown efficacy in 
animal models, which will further aid in the evaluation of PROTAC as a potential therapeutic 
strategy (452). Currently, clinical studies are underway to determine the efficacy of PROTAC for 
use in human patients with cancer (NCT03888612). 
5.3 Conclusion 
These studies demonstrate that Ubiquitin E3 ligases are biologically relevant in lung 
diseases through their targeted ligase activity against critical cell signaling substrates, leading to 
substrate degradation. We explored E3 ligase-mediated control of fibrotic signaling in interstitial 
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lung disease, including idiopathic pulmonary fibrosis and systemic sclerosis (Aim 1). We 
documented the biologic effect of E3 ligases in various stages and aspects of lung inflammation 
through epithelial cell recognition of pathogen signals, transduction of inflammatory signaling, 
modulation of signaling by exogenous host cytokines, and the regulation of motility signaling 
(Aim 2). Finally, we explored mechanisms related to aging itself through nutrient sensing in lung 
epithelial cells and mechanisms of control by E3 ligases (Aim 3). Collectively these studies support 
a model in which ubiquitin E3 ligases are central to the pathogenesis and perpetuation of disease 
in the lung (Figure 66). 
 
Figure 66 Ubiquitin E3 ligases at the center of lung disease signaling 
Schematic model of dissertation studies. Ubiquitin E3 ligases play a central role in regulation of numerous 
pathologic signaling mechanisms in the lung, including fibrotic signaling in TGF-β-driven interstitial lung disease 
(Aim 1), inflammatory signaling related to bactieral infection and lung injury (Aim 2), and in controlling nutrient 
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sensing apparatus for metabolic control (Aim 3). Ubiquitin E3 ligases also present an opportunity for therapuetic 
internvetion through small molecule targeting to inhibit E3 ligases.  
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